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ABSTRACT 
Background. The natural course of rheumatoid arthritis (RA) leads through joint 
inflammation to progressive joint damage and lost functional ability, elevated 
incidence of work disability and even increased mortality. Effective treatment with 
disease modifying antirheumatic drugs (DMARDs) has been shown to prevent or 
delay this progression. Thus, an early and aggressive treatment of RA is 
recommended internationally. In Finland, mainly due to beneficial 2- and 5-year 
results of a national multicenter study, the Finnish Rheumatoid Arthritis 
Combination Therapy Trial (FIN-RACo), a combination of 3 DMARDs and a small 
dose glucocorticoid (GC) is recommended as the initial treatment in active RA. In 
this study we aimed to elucidate the long-term effects and safety of such aggressive 
initial treatment by analysing the 11-year follow-up results of the FIN-RACo Trial. 
We also wanted to clarify how DMARDs are currently used in early RA in Finland 
and whether the possible change in treatments may have affected the incidence of 
work disability (WD) in early RA. 
Methods. In the FIN-RACo study 199 patients with early active RA were 
randomized to treatment with a combination of methotrexate (MTX), sulfasalazine 
(SASP), and hydroxychloroquine (HCQ) with prednisolone (FIN-RACo group) or 
treatment with a single DMARD (initially, SASP) with or without prednisolone 
(SINGLE group). The treatment in both groups aimed at remission. After 2 years, 
the treatment strategy became unrestricted. At 11 years, function was assessed with 
the Health Assessment Questionnaire (HAQ), and remission with the American 
College of Rheumatology (ACR) criteria (I). The radiographs of hands and feet, as 
well as of large joints were assessed and scored according to the Larsen method (II). 
In the second part of the study, data for all new Finnish RA patients was collected 
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from a nationwide register maintained by the Social Insurance Institution (SII) from 
1.1.2000 to 31.12.2007. Patient cohorts were analyzed in 2-year time periods (2000-
01, 2002-03, 2004-05, 2006-07) and DMARDs purchased by them during the first 
year after the diagnosis were registered (III). For the patients available to labour 
force at the time of the diagnosis the incidence of continuous WD up to 31 Dec 
2008 was clarified (IV). 
Results. At 11 years, 138 patients were assessed (68 in the FIN-RACo group and 
70 in the SINGLE group). The mean ± SD HAQ scores were 0.34 ± 0.54 in the FIN-
RACo group and 0.38 ± 0.58 in the SINGLE group (p = 0.88). ACR remission was 
achieved by 37% (95% CI: 26 to 49) of the FIN-RACo group and by 19% (95% CI: 
11 to 29) (p = 0.017) of the SINGLE group (I). The radiographs of hands and feet 
were available in 65 patients in each group at baseline and at 11 years. The mean 
change from baseline to 11 years in Larsen score was 17 (95 % CI: 12 to 26) in the 
FIN-RACo group and 27 (95 % CI: 22 to 33) in the SINGLE group (p = 0.037). 
Respectively 87% (95% CI: 74 to 94) and 72% (95% CI: 58 to 84) of the patients in 
the FIN-RACo and the SINGLE groups had no erosive changes in large joints at 11 
years (II). From the SII database 14 878 (68.0% female, 62.6% RF-positive) 
patients with a new diagnosis of RA between 2000-07 were identified. In the first 
cohort single DMARD treatment (56.1%) was the most commonly used strategy 
during the first 3 months and SASP (63.0%) the most commonly used DMARD 
during the first year. In the last cohorts the respective treatments were combination 
DMARDs (55.3%) and methotrexate (69.0%). The change in treatment strategies 
and in DMARDs used was highly significant (p <0.001 for linearity) (III). From the 
same database, 7 831 (71% female, 61% RF-positive) not pensioned patients were 
11 
identified. During the first 2 years the incidence of RA related continuous WD was 
8.9 %, 9.4 %, 7.2 %, and 4.8 % (p < 0.001 for linearity) (IV).   
Conclusions. Targeting remission with tight clinical controls results in good 
functional, clinical and radiographic outcomes in most RA patients. However, 
compared to initial single-DMARD therapy, initial combination DMARDs results in 
higher rates of patients achieving strict ACR remission and in lower radiographic 
progression even in the long term. During this millennium in Finland, increasingly 
active treatments have been adopted in the treatment of early RA and the incidence 
of continuous work disability has declined. 
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TIIVISTELMÄ 
Varhaisen nivelreuman hoitostrategia ja pitkäaikaistulokset - FIN-REKO-
tutkimuksen opetukset ja nykyinen suomalainen lääkehoitokäytäntö 
 
Tausta. Nivelreuman luonnollinen kulku johtaa tulehduksen kautta nivelten 
tuhoutumiseen, toiminta- ja työkyvyn alenemiseen ja lisääntyneeseen 
kuolleisuuteen. Antireumaattisten lääkkeiden on todettu estävän, tai ainakin 
hidastavan tätä taudinkulkua, ja niinpä varhainen ja aggressiivinen hoito 
antireumaattisilla lääkkeillä on nykyään kansainvälisesti suositeltu hoitostrategia 
nivelreumassa. Suomessa, suurelta osin kansallisen monikeskustutkimuksen, FIN-
REKO:n (Finnish Rheumatoid Arthritis Combination Therapy Trial, FIN-RACo) 
suotuisten 2- ja 5-vuotistulosten ansiosta, aktiivisessa nivelreumassa aloitushoidoksi 
suositellaan kolmen antireumaattisen lääkkeen ja pieniannoksisen kortisonin 
yhdistelmähoitoa. Nykyisessä tutkimuksessa halusimme tutkia tämän aggressiivisen 
aloitushoidon pitkäaikaisvaikutuksia ja turvallisuutta analysoimalla FIN-REKO-
tutkimuksen 11 vuoden seurantatulokset. Lisäksi pyrimme kartoittamaan kuinka 
antireumaattisia lääkkeitä käytetään Suomessa varhaisessa nivelreumassa, ja onko 
mahdollisesti aikaisempaa aktiivisemmilla hoitokäytännöillä voitu vähentää pysyvää 
työkyvyttömyyttä.  
Menetelmät. FIN-REKO-tutkimuksessa 199 varhaista nivelreumaa sairastavaa 
potilasta satunnaistettiin saamaan joko metotreksaatin (MTX), sulfasalatsiinin 
(SASP), hydroksiklorokiinin  (HCQ) sekä prednisolonin yhdistelmähoitoa (FIN-
REKO-ryhmä) tai yksittäistä antireumaattia (aloittaen SASP:lla) joko prednisolonin 
kanssa tai ilman sitä (SINGLE-ryhmä). Hoito molemmissa ryhmissä tähtäsi 
remissioon. Kahden vuoden jälkeen hoidot olivat vapaat. Yhdentoista vuoden 
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jälkeen toimintakykyä kartoitettiin erillisellä kyselykaavakkeella [Health 
Assessment Questionnaire (HAQ)] ja remissiota American College of 
Rheumatology (ACR) kriteereillä (I). Käsien, jalkojen ja suurten nivelten 
röntgenkuvat analysoitiin Larsenin menetelmällä (II). Tutkimuksen toisessa osassa 
kerättiin Kansaneläkelaitoksen (Kela) rekisteritiedoista kaikki uuden 
nivelreumadiagnoosin 1.1.2000 - 31.12.2007 saaneet potilaat. Potilastiedot 
analysoitiin kaksivuotiskohorteittain (2000-01, 2002-03, 2004-05, 2006-07) ja 
potilaiden ensimmäisen vuoden aikana ostamat antireumaatit rekisteröitiin (III). 
Lisäksi analysoitiin diagnoosihetkellä työkykyisten potilaiden jatkuvan 
työkyvyttömyyden ilmaantuvuus vuoden 2008 loppuun mennessä (IV). 
Tulokset. FIN-REKO-tutkimuksen 11 vuoden käynnille osallistui 138 potilasta 
(68 FIN-REKO- ja 70 SINGLE-ryhmissä). HAQ keskiarvo ± SD oli 0.34 ± 0.54 
FIN-REKO- ja 0.38 ± 0.58 SINGLE-ryhmissä (p = 0.88). ACR remissiossa oli 37% 
(95% CI: 26, 49) FIN-REKO potilaista ja 19% (95% CI 11, 29) (p = 0.017) 
SINGLE potilaista (I). Käsien ja jalkojen röntgenkuvat oli otettu 65 potilaasta 
kummassakin ryhmässä tutkimuksen alussa ja 11 vuoden kohdalla. Larsen scoren 
keskimääräinen muutos tällä välillä oli 17 (95 % CI: 12, 26) FIN-REKO- ja 27 (95 
% CI: 22, 33) SINGLE-ryhmissä (p = 0.037). Isot nivelet olivat säilyneet 
normaaleina 87%:lla (95% CI: 74, 94) FIN-REKO- ja 72%:lla (95% CI: 58, 84) 
SINGLE-ryhmien potilaista 11 vuoden kohdalla (II). Kela:n rekisteristä saatiin 
14 878 nivelreumaan vuosina 2000-07 sairastuneen potilaan tiedot (68.0% naisia, 
62.6% RF-positiivisia). Varhaisimmassa kohortissa ensimmäisen kolmen 
kuukauden aikana reumalääkkeen  yksittäishoito oli yleisin hoitostrategia (56.1%) ja 
SASP yleisimmin käytetty antireumaatti ensimmäisen vuoden aikana (63.0%). 
Viimeisessä kohortissa vastaavat hoidot olivat antireumaattien yhdistelmähoito 
14 
(55.3%) ja MTX (69.0%). Muutos hoitostrategioissa ja antireumaattien käytössä oli 
tilastollisesti hyvin merkitsevä  (p <0.001 lineaarisuudelle) (III). Samasta 
rekisteristä kerättiin 7831 (71% naisia, 61% RF-positiivisia) diagnoosihetkellä 
työkykyistä potilasta. Kohorteissa kahden vuoden aikana nivelreumasta johtuvan, 
jatkuvan työkyvyttömyyden ilmaantuvuudet olivat  8.9 %, 9.4 %, 7.2 %, and 4.8 % 
(p < 0.001 lineaarisuudelle) (IV).   
Yhteenveto. Aktiivinen, remissioon pyrkivä hoitostrategia tuottaa hyvän kliinisen 
ja radiologisen tuloksen useimmilla potilailla. Kuitenkin alkuvaiheessa kolmen 
lääkkeen yhdistelmähoitoa saaneilla potilailla on vielä pitkäaikaisseurannassakin 
enemmän remissioita ja vähemmän radiologista etenemistä kuin alkuvaiheessa 
yksittäishoitoa saaneilla. Tällä vuosituhannella varhaisen nivelreuman hoito on 
Suomessa muuttunut entistäkin aktiivisemmaksi. Samaan aikaan varhaisesta 
nivelreumasta johtuvan pitkäaikaisen työkyvyttömyyden ilmaantuvuus on alentunut.   
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INTRODUCTION 
Up till the mid 1980s a misapprehension of the allegedly benign nature of the 
natural course of rheumatoid arthritis (RA) led widely to a conservative treatment 
strategy based on non-steroidal anti-inflammatory drugs (NSAIDs) and bed rest, as 
well as to avoidance of at that time available, often toxic or ineffective disease 
modifying antirheumatic drugs (DMARDs) (Sokka et al. 2008). Through increasing 
evidence, however, the true nature of RA as a disabling disease was unravelled and 
the urge for more aggressive treatment strategies grew evident (Wilske and Healey 
1989). Thus, during the 1990s, earlier and continuous (when needed, sequential) use 
of different DMARDs became increasingly common (Fries 1990). Still, while a 
great improvement to earlier treatments, real life proved this “sawtooth” strategy 
ineffective in many patients, and clinicians turned to creative use of different 
DMARD combinations even though the evidence of their use was at that point 
sparse (Borigini and Paulus 1995).  
As the treatment of RA had traditionally been active in Finland (Sievers et al. 
1963, Isomäki and Martio 1976, Luukkainen et al. 1977), the Finnish 
rheumatologists were aware of the dilemma of these mediocre treatment results and, 
as early as in 1993, initiated the Finnish Rheumatoid Arthritis Combination Therapy 
Trial (FIN-RACo) comparing initial combination DMARD strategy to initial single 
DMARD strategy in early RA (Möttönen et al. 1999). So far the results have 
favoured the initial combination strategy without any increase in adverse effects; at 
2 years the remission rate was higher and radiographic progression lower (Möttönen 
et al. 1999) in the combination group compared to the single group, and especially 
the patients with a delay to treatment benefited from the combination treatment 
(Möttönen et al. 2002). And despite the release of the treatments after 2 years, at 5 
19 
years the combination group patients had less radiographic damage in small joints 
(Korpela et al. 2004) as well as in cervical spine (Kauppi et al. 2009), and better 
preserved working ability (Puolakka et al. 2004) than the single group patients.  
The results of FIN-RACo Trial as well as of other studies have led to the 
contemporary consensus of treating RA actively, and aiming at remission or low 
disease activity (Current Care Guideline 2009, Smolen et al. 2010a, Smolen et al. 
2010b). As these recommendations, however, are based on rather short follow-up 
trials (Gaujoux-Viala et al. 2010) and while RA is a chronic disease requiring 
lifelong treatment, there is a demand for studies elucidating the long term efficacy 
and safety of different treatment strategies. Also, earlier cohort studies have shown, 
that despite the current recommendations, in real world the treatment of RA may be 
suboptimal (Edwards et al. 2005, Carli et al. 2006, Neovius et al. 2011a). Therefore, 
before giving new recommendations it would be essential to clarify how the old 
ones are followed. 
In the present study, first the long-term effects and safety of an initial 
combination-DMARD treatment compared to a single-DMARD treatment in early 
RA from the 11-year data of the FIN-RACo Trial were studied. In the second part of 
this study the aim was to clarify from a register-based data the DMARD strategies 
prescribed to all Finnish new RA patients during the present millennium, as well as 
the incidence of work disability in those patients.  
20 
REVIEW OF THE LITERATURE 
1. Rheumatoid arthritis 
1.1 Definition of rheumatoid arthritis 
The concept of rheumatoid arthritis (RA) comprises a variety of clinical 
phenotypes, all of which share the predisposition of chronic, systemic auto-
inflammation presenting mainly in synovial joints and leading to joint destruction. 
In clinic, rheumatologists base their diagnosis of RA on patient history, as well as 
on clinical, radiological and laboratory findings. Also, mainly for scientific 
purposes, various classification criteria of RA have been produced. The original aim 
of these criteria has been to differentiate RA from other rheumatic diseases with 
high specificity and sensitivity in clinical trials. During the past decades, the most 
often applied criteria have been The American College of Rheumatology (ACR; 
formerly The American Rheumatism Association) 1987 revised criteria for the 
classification of rheumatoid arthritis (Table 1) (Arnett et al. 1988). 
 
Table 1. The American College of Rheumatology (ACR; formerly The American 
Rheumatism Association) 1987 revised criteria for the classification of rheumatoid 
arthritis (Arnett et al. 1988)  
 
 
Present for over 6 weeks 
1. Morning stiffness in joints lasting at least 1 hour + 
2. Arthritis of 3 or more joints observed by a physician + 
3. Arthritis of the proximal interphalangeal (PIP), 
    metacarpophalangeal (MCP), or wrist joints  
+ 
4. Symmetric arthritis + 
5. Rheumatoid nodules  
6. The presence of rheumatoid factor  
7. Radiographic erosions and/or periarticular osteopenia in 
    hand and/or wrist joints 
 
 
According to these criteria the disease can be classified as RA if 4 of the above 7 
criteria are fulfilled. 
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The ACR 1987 criteria are particularly valid for differentiating established RA 
from other rheumatic diseases. However, as they underline the findings in hand 
joints and emphasize such late features of RA as rheumatoid nodules and 
radiographic changes, they have been criticized for not recognizing early RA. As 
increasing evidence has proven the early and active treatment of RA critical for 
improved outcomes (Cush 2007), new criteria were urged for. Therefore, in 2010, 
ACR and the European League Against Rheumatism (EULAR) formulated a new 
set of criteria to be used in newly presenting patients with at least one swollen joint 
that may not be better explained by some other disease (Aletaha et al. 2010).  
 
Table 2. The parameters and scoring system used in 2010 ACR/EULAR 
classification criteria for newly presenting arthritis (Aletaha et al. 2010)  
 
A. Joint involvement  
      1 large joint 0 
      2-10 large joints 1 
      1-3 small joints (with or without involvement of large joints) 2 
      4-10 small joints (with or without involvement of large joints) 3 
      >10 joints (at least 1 small joint) 5 
B. Serology (at least 1 test result is needed for classification)  
      Negative RF and negative ACPA 0 
      Low-positive RF or low-positive ACPA 2 
      High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least 1 test result is needed for classification)  
      Normal CRP and normal ESR  0 
      Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms  
     <6 weeks 0 
     ≥6 weeks 1 
 
Score ≥6 represents definite RA in a patient with at least one swollen joint that may not be explained 
by another disease. 
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These criteria assess and score the number and size of swollen joints, serology, 
acute phase reactants and symptom duration; a score ≥6 represents definite RA 
(Table 2). Patients with typical erosive radiographic findings may also be diagnosed 
as having RA, even if they do not fulfil these criteria. Still, whatever the 
contemporary classification criteria, the physicians make, and should make, their 
diagnosis as well as treatment decisions on clinical grounds. 
1.2 Aetiology of rheumatoid arthritis 
The aetiology of rheumatoid arthritis remains unclear. Presumably a genetic 
predisposition together with an unknown, even varying, triggering environmental 
factor induces the outset of this chronic, progressive autoimmune disease. It also 
appears evident that RA consists of several subtypes of disease with partly specific, 
partly shared predisposing and triggering factors.  
Studies in monozytogic twins have shown that genetic factors explain 
approximately half of the variation of RA prevalence between different populations. 
Thus far the best-described genetic factor associated with increased susceptibility to, 
and severity of, RA, is a so-called shared epitope (SE). It consists of a specific 
amino acid sequence (glutamine-leucine-arginine-alanine-alanine) found in certain 
HLA-DRB1 alleles (*0101, *0102, *0401, *0404, *0405, *0408, *1001, *1402) in 
the MHC class II molecules on the surface of antigen presenting cells (APCs) and 
activated T-cells. The mechanism through which the SE predisposes the individual 
to RA is, however, still unknown. Besides SE, the HLA-DR4 allele has been found 
to be more common in RA patients than in general population. Other genetic factors 
predisposing to RA have been discovered amongst various single nucleotide 
polymorphisms (SNPs), some of which are also connected to an increased risk of 
other autoimmune diseases (Kvien et al. 2009).  
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Nevertheless, none of the abovementioned genetic factors alone causes RA; an 
external factor is needed to generate the disease start. Therefore, quite self-
evidently, different infections have served as usual suspects for triggering RA; yet, 
hitherto, in extensive research none has been found guilty. Conversely, cigarette 
smoking has been confirmed to predispose to the development of RA (Heliövaara et 
al. 1993, Klareskog et al. 2006, Verstappen et al. 2011) and is also associated with 
more severe disease and worse responsiveness to traditional and biological disease 
modifying anti-rheumatic drugs (DMARDs) (Hyrich et al. 2006, Saevarsdottir et al. 
2011). Recently, periodontal disease has been linked to etiopathogenesis of RA 
(Detert et al. 2010). Other environmental risk factors for RA proven in some cohorts 
have been coffee consumption, high body mass index (BMI), as well as 
occupational exposure to mineral oils and to anthracite, asbestos and silica dust. Sex 
hormones have also been conjectured to RA, as the starting age of menarche, the use 
of oral contraceptives, pregnancies, and menopause have all, in different ways, been 
connected to the risk and severity of RA (Kvien et al. 2009). 
1.3 Pathogenesis of rheumatoid arthritis 
Knowledge of the pathogenetic process behind RA is still fragmented. 
Nevertheless, the essential phenomenon of RA is the inflammation of the synovial 
joints. Normally, inflammation is the body’s defence mechanism against external 
attackers, where inflammatory cells recognize foreign antigens and strive to destroy 
their source. In auto-inflammatory diseases, such as RA, the inflammatory process, 
however, is directed against the body’s own tissues. This requires a breakdown of 
the immunological tolerance, which normally prevents the inflammatory cells from 
recognizing self-antigens (Schulze-Koops et al. 2009).  
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The cells involved in auto-inflammation of RA represent both innate and humoral 
immunology. Dendritic cells (DCs) represent antigens to naïve T cells, which, if co-
stimulation occurs, then differentiate into effector T cells. They produce different 
cytokines, some of which activate B cells into secreting autoantibodies, such as 
rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). This in 
turn leads to immune complex formation and complement activation. Other 
cytokines enhance the endothelial permeability contributing to recruitment of T cells 
as well as other effector cells such as neutrophils and macrophages. This activates 
the production of further proinflammatory cytokines and chemokines and as well as 
the osteoclastogenesis, all leading to tissue destruction. The origin of this cascade is 
thus far unknown, and as the antigen initiating the process leading to clinical RA 
most probably differs between individuals, and as it may precede the clinical 
manifestation of RA by years, it might never be solved (Firestein 2005).  
1.3.1 Autoantibodies in rheumatoid arthritis 
In the 1940s and 1950s, the discovery of rheumatoid factor (RF) generated the 
idea of RA being an autoimmune disease. RF is an autoantibody targeting the Fc 
part of human IgG, and found in the serum of many RA patients (60-70 %); less 
often in normal population (5 %). RF is mainly presenting as IgM and forms 
immune complexes, which activate the complement. This increases the capillary 
permeability and stimulates the synthesis of chemotactic factors, which, in turn, are 
thought to enrol inflammatory cells to joints. However, as on one hand, RF is found 
in healthy individuals and in other autoimmune as well as in infectious diseases, 
and, as on the other hand, not all RA patients are seropositive for RF, it alone cannot 
be held responsible for the whole pathogenetic cascade in RA. Still, on average, RF 
positive disease is more aggressive, and leads to earlier joint damage and extra-
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articular manifestations, than RF negative one (Bukhari et al. 2002, Taylor et al. 
2011).  
A more specific autoantibody found in the sera of 50-70 % of RA patients, but 
seldom in healthy individuals, is the one targeting citrullinated peptides. 
Citrullination of arginine residues to non-naturally occurring citrulline emerges 
through deamination, which is catalyzed by enzymes called peptidyl-arginyl-
deiminases (PADs). This reaction requires the presence of calcium and is induced 
by inflammation, especially when significant cell death is present. Citrullination can 
occur in any inflammatory state, but the formation of anti-citrullinated protein 
antigens (ACPA) appears to be specific for RA and depend on the host’s genotype, 
especially on the presence of shared epitope (Taylor et al. 2011). How ACPA act in 
the pathogenesis of RA is unknown, but ACPA-positive RA leads to radiographic 
progression more often than ACPA-negative one (Bukhari et al. 2007, Syversen et 
al. 2008).  
1.3.2 Proinflammatory cytokines in rheumatoid arthritis 
Leukocytes, especially T cells, macrophages, and stromal cells all secrete 
cytokines. The balance between proinflammatory and anti-inflammatory cytokines 
as well as the expression of their corresponding receptors defines the degree of 
inflammation. Numerous different cytokines exist and their distribution varies in 
different types of arthitidem, but the current understanding of the therapeutic effects 
of certain anti-cytokine therapies emphasizes the importance of tumour necrosis 
factor α (TNF-α), interleukin-6 (IL-6), and IL-1 in maintaining chronic 
inflammation and leading to tissue destruction in RA (Karmakar et al. 2010).  
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1.4 Epidemiology of rheumatoid arthritis 
Worldwide, the prevalence of RA varies between 0.3-1.1 % with the lowest 
figures in South-European and developing countries and the highest in the US, 
especially amongst some Native American tribes (Kvien et al. 2009). In Finland, 0.8 
% of the population suffers from this disease which has a yearly incidence of 34/100 
000 (Kaipiainen-Seppänen 2000). RA is more prevalent in females than in males 
(3:1) and its incidence rises with increasing age, plateauing after the age of 60. In 
the last decades, a decreasing trend in the incidence of RA was found (Doran et al. 
2002, Kaipiainen-Seppänen and Kautiainen 2006); however this variation appears 
cyclic as the latest findings show again an increase in the incidence of RA (Gabriel 
and Michaud 2009). 
1.5 Natural course of rheumatoid arthritis 
Locally, auto-inflammation is expressed most often in the small and middle-sized 
joints, especially the proximal interphalangeal (PIP), metacarpophalangeal (MCP) 
and wrist joints in the hand as well as the metatarsopahalangeal (MTP) and ankle 
joints in the feet. Inflammatory cells invade the synovium causing first hyperplasia 
and later formation of invasive and destructive tissue (“pannus”). The clinical signs 
of this phenomenon are swelling, stiffness and tenderness of the affected joints. 
When not treated, the disease progresses and spreads to other, even large, joints. 
Other local manifestations of the disease include inflammation of the tendon sheaths 
and bursae. The rate of progression varies amongst individuals and may have 
several phenotypes (Graudal 2004). Spontaneous remission, healing of the disease, 
however, is rare and would even question the authenticity of the diagnosis.  
If allowed to continue, the inflammation causes progressive destruction of the 
cartilage and adjacent bony structures; changes detectable by radiographies (Abu-
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Shakra et al. 1998). In the beginning of the disease, acute inflammation, and later, 
the destruction of the joints both lead to augmented disability (Kirwan 2001) 
threatening the patients’ function in daily practices, as well as working ability 
(Pincus et al. 1984).  
Extra-articular manifestations of chronic inflammation in RA include 
rheumatoid, subcutaneous, nodules, secondary Sjögren’s syndrome, pulmonary 
nodules or interstitial fibrosis, pleuritis, pericarditis, episcleritis and scleritis, Felty’s 
syndrome, as well as vasculitis, at times manifested as mononeuritis multiplex. As 
in many systemic autoimmune diseases the chronic activation of autoreactive B cells 
increases the risk of lymphoma, being twofold in RA compared to general 
population (Kaiser 2008). Chronic, systemic inflammation causes elevation of acute 
phase proteins such as serum amyloid A, which through accumulation predisposes 
the patient to amyloidosis; most commonly manifesting as proteinuria, and later, 
renal failure (Kvien et al. 2009). The most frequent and thus the most important 
complication of chronic inflammation is, nevertheless, the cardiovascular disease. 
Systemic inflammation as such appears to accelerate atherosclerosis, even 
overpowering the traditional risk factors, which, however, also contribute to the 
total risk of cardiovascular diseases in RA (Kitas and Gabriel 2011). Today, the 
increased mortality found in RA patients is mainly explained by cardiovascular 
diseases (Sihvonen et al. 2004). 
Besides the comorbidities related to the disease itself, the treatments used in RA 
pose distinct problems, most of which are transitory. Nevertheless, 
immunosuppressive medications increase the risk of serious infections, and 
glucocorticoids additionally predispose the patients to osteoporosis, hypertension, 
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diabetes mellitus, and cataract. However, all of these are features of high-dose 
glucocorticoid treatment and rare when small doses are used (Da Silva et al. 2006).  
2. Outcome measures in rheumatoid arthritis 
2.1 Clinical outcomes  
2.1.1 The core set 
Quantifying the disease activity of RA is important when evaluating the efficacy 
of a given treatment for a single patient in daily clinical practice, but in clinical 
studies it becomes mandatory. Not only is it essential to quantify the results of a 
study to convince the readers; to enable comparisons between different data sets, it 
is necessary to use similar methods internationally. For this purpose, a core of 
different estimates has become established (Tugwell and Boers 1993).  
2.1.1.1 Joint assessment 
In clinical examination the joints are assessed with respect to swelling, 
tenderness in palpation and in motion, and with respect to limitation of motion or 
deformity. Specific joint counts are used for swollen joints, where the number of 
joints assessed may vary from 28 to 66; and for tender joints, from 28 to 68 joints 
(Table 3). In most joint counts both swelling and tenderness of each joint are scored 
on a 0-1 scale; however, in the Ritchie articular index part of the joints are assessed 
in units (the PIP, MCP, MTP, temporomandibular, sternoclavicular and 
acromioclavicular joints), and the tenderness is graded on a 0-3 score (Ritchie et al. 
1968).  
2.1.1.2 Visual Analogue Scales 
Three different Visual Analogue Scales (VAS) from 0 to 100 millimetres have 
been developed to measure the patient’s evaluation of general health, as well as of 
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pain, and the physician’s estimation of global disease activity. These scales are easy 
and fast to use and give valuable information of the disease course of an individual 
patient, even though, as subjective measures, might not be that reliable when 
comparing different patients. 
 
Table 3. Joints assessed in different joint counts (Pincus and Sokka 2006). 
Joint 66/68 
joints 
Ritchie 
index 
44 joints 42 joints 28 joints 
Atlantoaxial  +    
Temporomandibular + +    
Sternoclavicular + + +   
Acromioclavicular + + +   
Shoulder + + + + + 
Elbow + + + + + 
Wrist + + + + + 
Metacarpophalangeal (1-5) + + + + + 
Proximal interphalangeal (1-5) + + + + + 
Distal interphalangeal (1-5) +     
Hip (tenderness only) + +  +  
Knee + + + + + 
Talocrural + + + +  
Subtalar  +    
Midtarsal + +    
Metatarsophalangeal (1-5) + + + +  
Proximal interphalangeal (1-5) +     
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2.1.1.3 Acute phase reactants 
The current systemic inflammation may be assessed by measuring the acute 
phase reactants; the erythrocyte sedimentation rate (ESR) with the Westergren 
method or the C-reactive protein (CRP) with nephelometry. They are non-specific 
markers of inflammation, but correlate well with disease activity and progression. 
However, their sensitivity is not optimal as normal values are often found, even in 
the presence of high disease activity (Sokka and Pincus 2009).  
2.1.2 Disease activity score (DAS) 
Despite their importance in assessing the RA disease activity, the single core 
estimates may give too fragmented and even conflicting a picture of the disease 
activity. Therefore, especially for studies comparing the efficacy of different 
treatment outcomes, various composite indices have been created (van der Heijde 
and Östergard 2009). 
Today, the most common estimates of disease activity, especially in studies 
comparing the efficacy of certain medical agents, are the disease activity scores 
assessing 28 joints (DAS28) or 44 joints (DAS), which are counted from the 
formulas:  
DAS28 = 0.56 * √(tender28) + 0.28 * √(swollen28) + 0.70 * ln(ESR) + 0.014 * 
(GH) (Prevoo et al. 1995). 
DAS = 0.55938 * √(RAI) + 0.06465 * √(swollen44) + 0.330 * ln(ESR) + 
0.00722 * (GH) (van der Heijde et al. 1990) 
In these formulas “tender28” and “swollen28” represent the number of tender and 
swollen joints out of the 28 joint assessments, “GH” the patient’s global assessment 
of disease activity on VAS of 100mm, “RAI” the Ritchie Articular Index (53 joints 
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in 26 units, graded for tenderness), and “swollen44” the number of swollen joints in 
the 44 joint assessment.  
2.1.3 Remission 
In general, remission means the state of absence of disease activity in patients 
with a chronic illness, with the possibility of returning disease activity. In RA, 
remission predicts preserving the functional capacity as well as retarding the 
radiographic progression (van Tuyl et al. 2010a). However, various definitions still 
exist for such an essential outcome measure (Mäkinen et al. 2005a). In clinical 
practice, the valid definition is no active joints (in particular no swollen joints), 
normal acute phase reactants, and no radiographic progression (Mäkinen et al. 
2005a). In the present era of the modern imaging possibilities some authors have 
gone even further by suggesting that remission should not allow any inflammatory 
activity in power doppler or in magnetic resonance imaging (Brown et al. 2008).  
In clinical studies the definition of remission has to be unambiguous. Numerical 
limits of disease activity are commonly used; DAS28 below 2.6 or DAS below 1.6 
are considered to represent the state of remission (Prevoo et al. 1995). Their 
limitation for clinical practice is the fact that they still do allow some disease 
activity (Mäkinen et al. 2005b).   
More stringent criteria for remission are the ones developed in 1982 by the ARA 
(nowadays ACR) (Table 4) (Pinals et al. 1981). They include six requirements, five 
of which should be fulfilled for the patient to be in remission. However, the use of 
these criteria is not stable; in some studies the requirement of no fatigue may be 
omitted and the number of requisite criteria may vary. In 2011 ACR and EULAR 
published new criteria for defining remission in clinical trials (Table 5) (Felson et al. 
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2011). These criteria are thought to work in clinical studies, but in clinical practice 
they still allow some disease activity. 
 
Table 4. The ACR criteria for remission in RA (Pinals et al. 1981) 
Five or more of the following requirements must be fulfilled for at least two consecutive months 
1. Duration of morning stiffness not exceeding 15 minutes 
2. No fatigue 
3. No joint pain (by history) 
4. No tenderness or pain in motion 
5. No soft tissue swelling in joints or tendon sheaths 
6. ESR (Westergren method) < 30mm/hour for a female or <20mm/hour for a male 
 
 
Table 5. The 2011 ACR and EULAR criteria for remission in RA (Felson et al. 
2011) 
 
To be in remission the patient must at any time point fulfil either of the two following definitions: 
       Boolean-based definition  
       The patient must have all of the following: 
 Tender joint count ≤ 1 (including also the feet and ankles in addition to the 28 joint count) 
 Swollen joint count ≤ 1 (including also the feet and ankles in addition to the 28 joint count) 
 CRP ≤ 1mg/dl 
 Patient global assessment ≤ 1 (on a 0-10 scale) 
       Index-based definition 
 Simplified Disease Activity Index (SDAI) score ≤ 3.3  
(SDAI is counted as the simple sum of the TJC (using 28 joints), SJC (using 28 joints), 
patient global assessment (0-10 scale), physician global assessment (0-10 scale), and CRP 
level (mg/dl). 
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2.1.4 Minimal disease activity 
As, especially in established RA, the state of remission may be difficult to 
achieve, other, near-remission clinical outcome measures have been developed. Of 
these, minimal disease activity (MDA) is defined to be present if the patient has no 
swollen joints, no tender joints and an ESR ≤ 10 mm/hour or if she or he fulfills at 
least 5 of the following 7 criteria: swollen joint count ≤ 1 (0-28), tender joint count 
≤ 1 (0-28), HAQ ≤ 0.5 (0-3), VAS for pain ≤ 20 (0-100), patient’s global assessment 
of disease activity ≤ 20 (0-100), physician’s global assessment of disease activity ≤ 
15 (0-100), ESR ≤ 20 mm/hour (Wells et al. 2005). 
2.1.5 Functional ability 
A disease causing joint swelling, stiffness, pain, and damage leads inevitably to 
decreased function. In RA the functional capacity is most often assessed by the 
Health Assessment Questionnaire (HAQ), which includes 20 questions assessing 8 
different areas of function: dressing, arising, eating, walking, hygiene, reaching, 
gripping, and performing tasks (Fries et al. 1980). The answers to each question are 
scored from 0 to 3; the score is 0 if the activity can be performed without difficulty, 
1 if the patient has some difficulty, 2 if the patient has much difficulty or needs help 
or devises, and 3 if the patient is unable to perform that activity. The mean value of 
the highest scores of each 8 subdimensions is counted. The HAQ score of 0 
represents normal function, of 0.13-1 mild to moderate disability, 1-2 severe 
disability and 2-3 very severe disability (Bruce and Fries 2003). The Finnish version 
of HAQ has been used since the 1990s (Hakala et al. 1994). The HAQ score has 
been claimed to be the most important single predictive measure of consequent 
disability and even mortality in RA (Farragher et al. 2007). However, in a large 
German study by Ziegler et al. (2010) the authors noted that even though all the 
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physician derived outcomes improved between 1997 and 2007, the patient derived 
ones, including functional ability, did not. 
 
Table 6. The questions included in the Health Assessment Questionnaire (HAQ) 
 
 Without any 
difficulty   
(0) 
With some 
difficulty 
(1) 
With much 
difficulty  
(2) 
Unable 
to do     
(3) 
DRESSING AND GROOMING. Are you able to:     
1. Dress yourself, including tying shoelaces and 
doing buttons? 
    
2. Shampoo your hair?     
ARISING. Are you able to:     
3. Stand up from a straight chair?     
4. Get in and out of bed?     
EATING. Are you able to:     
5. Cut your meat?     
6. Lift a full cup or glass to your mouth?     
7. Open a new milk carton?     
WALKING. Are you able to:     
8. Walk outdoors on a flat ground?     
9. Climb up five steps?     
HYGIENE. Are you able to:     
10. Wash and dry your body?     
11. Take a tub bath?     
12. Get on and off the toilet?     
REACH. Are you able to:     
13. Reach and get down a 5-pound object (such as a 
bag of sugar) from just above your head? 
    
14. Bend down to pick up clothing from the floor?     
GRIP. Are you able to:     
15. Open car doors?     
16. Open jars which have previously been opened?     
17. Turn faucets on and off?     
ACTIVITIES. Are you able to:     
18. Run errands and shop?     
19. Get in and out of a car?     
20. Do chores such as vacuuming or yard work?     
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2.1.6 Response measures 
In clinical practice the target of the treatment is remission or low disease activity. 
However, traditional antirheumatic treatments alone seldom succeed in inducing 
this, and yet they differ from placebo. For clinical studies two valid tools for 
interpretation of group results during follow-up have been developed, the ACR 
improvement criteria (Felson et al. 1993) (Table 7) and the EULAR response 
criteria (van Gestel et al. 1996) (Table 8). The ACR-N describes a continuous 
percentage the improvement or worsening of a single patient in analogy of the 
ACR20, ACR50 and ACR70 responses (Bathon et al. 2000). 
 
Table 7. The ACR improvement criteria (Felson et al. 1993) 
20 / 50 / 70 % improvement in 5 out of the following 7 core set variables, first 2 required, none allowed to 
worsen 
 Tender joint count 
 Swollen joint count 
 Acute phase reactant 
 Patient’s assessment of pain 
 Patient’s global assessment of disease activity 
 Observer’s global assessment of disease activity 
 Patient’s assessment of physical disability 
 
 
Table 8. The EULAR response criteria depending on the DAS/DAS28-value 
achieved at endpoint and the magnitude of change from baseline (van Gestel et al. 
1996) 
 
DAS at endpoint DAS28 at endpoint Improvement in DAS or DAS28 from baseline 
  > 1.2 > 0.6 and ≤ 1.2 ≤ 0.6 
≤ 2.4 ≤ 3.2 Good   
>2.4 and ≤ 3.7 > 3.2 and ≤ 5.1  Moderate  
> 3.7 > 5.1   None 
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2.2 Radiographic progression 
2.2.1 Small joints of hands and feet 
As RA affects first and mainly the small joints, leading to narrowing of the joint 
spaces and erosive damage to the adjacent bony structures, the radiographs of hands 
and feet are used to evaluate the degree of joint destruction. In clinical practice, 
when setting the diagnosis and evaluating the efficacy of treatment, the treating 
rheumatologist and, if needed, the radiologist estimate the presence of RA related 
findings and their progression over time. However, in clinical studies more exact 
evaluations are needed. The two most important methods for this are the Larsen 
(Larsen et al. 1977) and the Sharp / van der Heijde (van der Heijde 2000) methods.    
The Larsen scoring method is based on a set of reference radiographs (Larsen et 
al. 1977). The MCP I-V and PIP II-V joints as well as IP I joints of the hands, 
wrists, and IP I and MTP II-V joints of the feet are assessed. Each joint is graded 
with a scale form 0 to 5; where 0 stands for normal appearance, 1 for slight 
abnormality, 2 for definite early abnormality, 3 for medium destructive abnormality, 
4 for severe destructive abnormality, and 5 for mutilating abnormality. After 
multiplying the wrist scores by 5, all individual joint scores are summed up, giving 
thus the maximal total score of 200. 
The Sharp / van der Heijde method assesses and grades separately the possible 
erosions as well as joint space narrowings in hand, wrist and feet joints (van der 
Heijde 2000). In the hands the maximal total score for erosions is 160 and for 
narrowing 120, in the feet the respective figures are 120 and 48; thus the maximal 
total score is 448.  
There are some differences between these two main scoring methods. The 
Sharp/van der Heijde method has been found to be more sensitive to change than the 
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Larsen score, thus it is able to detect small changes earlier (Bruynesteyn et al. 2002, 
Guillemin et al. 2005). On the other hand, the Larsen method tends to be more 
specific than the Sharp/van der Heijde method (Bruynesteyn et al. 2002). Also, in 
Larsen score the intraobserver reliability is somewhat better than that of the 
Sharp/van der Heijde method (Sharp et al. 2004, Guillemin et al. 2005).  
2.2.2 Large joints and total joint replacements 
Even though RA initially affects mainly the small joints of hands and feet, it 
often spreads to large joints, and in rare cases may start from them. The involvement 
of large joints disturbs greatly the patient’s functional ability (Drossaers-Bakker et 
al. 2000) and may require operative treatment, especially total joint replacements 
(Wolfe and Zwillich 1998), causing substantial difficulties and costs both for the 
patient and for the society. In clinical practice the symptomatic large joints are 
radiographed and treated accordingly, but in published RA follow-up studies the 
radiographic assessment of large joints is rare. In one study radiographic damage 
was found in large joints in 50 % of the patients after 6 years of RA (Kuper et al. 
1997) and in another in 54 % of the patients after 12 years of RA (Drossaers-Bakker 
et al. 2000). Thus far the only validated method for evaluating the radiographic 
progression in large joints is the Larsen method (Larsen et al. 1977).  
2.3 Working ability 
Understandably, the cumulative disability, caused by continuous inflammation 
and consequent damage of the joints, leads to increased work disability. Therefore, 
one important aim of the treatment of RA is to decrease, or to postpone, work 
disability. However, as, in addition to disability, working ability depends on 
numerous other factors, such as the patients’ age, psychosocial factors, education 
and working environment, as well as the socioeconomic and legislative settings of 
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the surrounding society, interpretation of these studies is challenging. Also, the 
heterogeneous nature (sick leave, temporary or permanent work disability, 
employment) and varying definitions (official register data, patient’s own 
announcement) of work disability complicate the matter. Even though the best 
information on temporal trends of work disability in RA would be achieved by 
studying longitudinal, population based materials in a fixed setting (Verstappen et 
al. 2004), many studies are cross-sectional or carried out in small cohorts.  
 
Table 9. Earlier Finnish studies on work disability in RA 
First author 
and year 
Type of the 
study 
Number 
of 
patients 
Disease 
duration 
Work disability 
rate 
Risk factors for work 
disability 
Mäkisara and 
Mäkisara 
1982 
Cross-sectional 405 5 years 
10 years 
15 years 
40 % 
50 % 
67 % 
Age, strenuous work, 
low education, no 
vocational training 
Nissilä et al. 
1983 
Longitudinal 107 3 years 32 %  
Kaarela et al. 
1987 
Longitudinal 103 8 years 43 % Age, strenuous work, 
severe RA 
Jäntti et al. 
1999 
Longitudinal 103 20 years 80 %  
Sokka et al. 
1999a 
Longitudinal 86 2 years 
10 years 
23 % 
38% 
Physically demanding 
job, age, number of 
swollen joints 
 
2.3.1 European studies 
In the previous European studies of patients with early RA, 20-50 % of the 
patients had become work disabled 2 years after the diagnosis (Doeglas et al. 1995, 
Albers et al. 1999, Sokka et al. 1999a, Barrett et al. 2000), 40-50 % by 10 years 
(Mäkisara and Mäkisara 1982, Sokka et al. 1999a, Barrett et al. 2000), and 80 % by 
20 years after the diagnosis (Jäntti et al. 1999). Similar figures are found in the 
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earlier Finnish studies on RA and work disability presented in Table 7. However, in 
more recent studies from Germany (Ziegler et al. 2010) and Sweden (Neovius et al. 
2011b), the work disability caused by RA appears to be declining.  
2.3.2 North-American studies 
Presumably due to differences in social policy, in American studies the early 
work disability is lower than in European studies; 5-15 % after 2 years of RA, but 
increasing to 30-50 % after 10 years (Yelin 1992, Wolfe and Hawley 1998). 
However, in a more recent study, Allaire et al. (2008a) assessed data from a large 
US national databank between 2002-05. In the 4385 RA patients who had been 
employed at disease onset and who at assessment had a mean disease duration of 14 
years, the prevalence of arthritis-attributed work cessation was 13.6 % in subjects 
with 1-3 years of disease duration, increasing to 19.0 %, 28.9 %, 28.3%, 38.2 % and 
42.2 % after a disease duration of 4-6, 9-11, 14-16, 19-21 and ≥25 years, 
respectively. Also, 39 % of the patients who had stopped working at some time, 
returned later to work at least temporarily. Thus, RA still does cause a notable 
menace to the patients’ working ability, but the contemporary risk may be lower 
than that in the previous decades.  
2.3.3 Comparisons between different countries 
The intercontinental difference was confirmed by Chung at al (2006), who 
compared a Finnish cohort of 364 working aged and working RA patients to an US 
cohort of 269 similar patients. They found the probability to continue working 1, 2, 
3 and 4 years after the RA diagnosis to be 92 %, 86 %, 84 % and 80 % in Finland 
and 92 %, 89 %, 89 % and 84 % in the US, respectively, thus higher than in 
previous studies. Interestingly, however, the adjusted incidence of work disability 
was 2.6-fold higher in Finland than in the US, even though the Finnish RA patients 
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had better functional capacity and global status as well as less pain than the US 
patients.  
In the Quantitative Standard Monitoring of Patients with Rheumatoid Arthritis 
(QUEST-RA) trial, the authors collected cross-sectional data of 8039 RA patients 
from 32 countries worldwide (Sokka et al. 2010). In this study, 37 % of the patients 
who had been working at the time of the first symptoms of RA reported subsequent 
work disability due to RA. When the 1756 patients with the disease onset during this 
millennium were analysed separately, the authors found the probabilities to continue 
working to be 80 % after 2 years of RA and 68 % after 5 years, similarly in high 
gross domestic product (GDP) (>24K US dollars [USD] per capita) and low-GDP 
(<11K USD per capita) countries. Patients who stopped working had worse clinical 
status than the ones who continued to work, in both the high- and the low-GDP 
countries, with the HAQ-score being the one most important identifier of work 
disability. Most interestingly, the patients who had become work disabled in the 
high-GDP countries had significantly better HAQ and DAS28 scores than the 
patients who continued to work in the low-GDP countries, again stressing the 
importance of different social security systems’ explanatory role.  
2.3.4 Work disability in RA compared to general population 
Table 10 presents the details of the studies that have compared the prevalence of 
work disability in RA patients and in general population. As the table shows, the 
number and inclusion criteria of RA patients, the disease duration, the definition of 
work disability, the method of data collection, and the definition of general  
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Table 10. Studies comparing work disability in RA patients and general population 
 
 
 
N.A. = not available 
 
 
 
 
Author 
 
Year of data 
collection  
 
Country 
 
Method 
 
Number (definition) of 
patients 
 
Disease duration 
(mean) 
 
 
General population 
 
Definition of work 
disability 
 
Results 
 
Mitchell et 
al. 1988 
 
1978 
 
US 
 
Interview within the 
Social Security Survey of 
Disability and Work. 
Results extrapolated to the 
total population 
 
5 652 
(Persons reporting both 
arthritis diagnosis and 
polyarthritis symptoms) 
 
N.A. 
 
Persons reporting 
neither arthritis 
diagnosis nor arthritis 
symptoms 
 
Interview:  
Degree of disability (not  
– moderately – severely 
disabled) 
Work status (working – 
not working) 
 
Polyarthritis patients vs. general 
population  
Disabled: 78 % vs. 10 % 
Working: 
males: 56 % vs. 89 %  
females: 31 % vs. 62 %  
 
Yelin 1992 1970-87 US Data from National Health 
Interview Surveys.  
Results extrapolated to the 
total population 
 
N.A. 
(Self reported arthritis) 
N.A. Persons without arthritis Persons out of labour 
force, self-report 
Labour force participation 
approximately 20 % lower in males 
and 25 % in females with arthritis 
than in those without it 
 
Mau et al. 
1996 
1982-87 Germany 6-year prospective follow-
up of a single institute 
cohort 
73 
(RA patients, diagnosis 
≤ 12months) 
7 years Members of the 
compulsory German 
social security insurance 
(result given only in the 
Discussion, data source 
official statistics) 
Persons with total 
cessation of employment 
due to RA receiving a 
social security pension 
37 % of the patients permanently 
work disabled due to RA after 7 
years of disease duration, steepest 
decrease within the first 3 years. 
In general population the annual 
incidence of permanent work 
disability 0.6 % 
 
Mau  et al. 
2005 
1993-2001 Germany 
 
Cross-sectional analysis of 
the National Database of 
the German Collaborative 
Arthritis Centres 
 
26 071 
(20-59 year-old RA 
patients) 
42 % ≤ 5 years 
26 % 6-10 years 
32 % > 10 years 
Population data from an 
annual interview survey 
of 1 % of German 
households from 
Federal Statistical 
Office 
 
Self-administered patient 
questionnaires on current 
employment status 
Standardized employment ratio 
0.78 in all RA patients compared to 
general population (0.81 in males 
and 0.76 in females), worse with 
long disease duration and in former 
East Germany 
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Table 10. Continues 
 
 
N.A. = not available 
 
Author 
 
Year of data 
collection  
 
Country 
 
Method 
 
Number (definition) of 
patients 
 
Disease duration 
(mean) 
 
 
General population 
 
Definition of work 
disability 
 
Results 
 
Albers et 
al. 2001 
 
1991-92 
 
Netherlands 
 
 
Retrospective/ prospective 
interview on the patients’ 
socio-economic situation 
before and after the 
diagnosis of RA 
 
76  
(RA patients who at the 
time of the diagnosis 
were working-aged and 
working) 
 
2.8 years 
 
Dutch population (data 
source not given) 
 
Interview questions on “to 
what extent occurs 
(partial) work disability?” 
and official registers 
 
51 % of the RA patients became (at 
least partially) work disabled. 
Relative risk compared to Dutch 
population: 
females 14.5  
males 4.1 
 
van 
Jaarsveld  
et al. 1998 
1996 Netherlands Since 1990 all one-
institute early RA patients 
randomised to 2 treatment 
arms, in 1996 interviewed. 
All working aged 
respondents included. 
  
211 
(Working aged RA 
patients, data on 
employment at the time 
of the diagnosis not 
given) 
  
< 6 years Dutch population 
(national statistics 
available and used in 
age groups 25-44 and 
45-64 years) 
Interview questions on 
work disability in general 
and due to RA, hours 
worked per week 
61 % of the patients not working 
compared to 38 % of the Dutch 
population (of 45-64 year-old 
males 63 % and 32 %, 
respectively).  
Chorus et 
al. 2000 
1996 Netherlands Random sample of 16-59 
year-old RA patients from 
a Dutch Standardised 
Diagnosis Register of 
Rheumatic Diseases (a 
rated sampling to include 
sufficient number of male 
and younger patients) 
1056 
(RA patients, 62 % of 
the initial cohort) 
12 years Dutch population 
(official national 
statistics) 
Interview questions on 
work situation at the time 
of the diagnosis and 
currently (Having a paid 
job equalled labour force 
participation) 
Standardised labour force 
participation 61.2 % in RA patients 
(disease duration < 6 years) vs. 
65.5 % in general population, in 
longer disease duration decreased 
participation in RA patients.  At 
the time of the diagnosis 58.3 % of 
the patients working, 35.2 % of 
them later stopped due to RA. 
 
Barrett et 
al. 2000 
1989-92 
1994-97 
UK Postal interview of 2 
primary–care based 
inception cohorts (Norfolk 
Arthritis Register) 
Cohort 1: 160  
Cohort 2: 134 
(Economically active 
early RA patients) 
8 years 
4 years 
Age, gender and 
employment status 
matched controls for the 
first group 
Interview questions 
changes in employment 
status since 1989 (hours at 
work, job title, nature of 
job, reasons for stopping 
work, educational 
attainment) 
 
Cohort 1: work disability rates 14 
% 1 y, 26% 2 y, 33 % 5 y, 39 % 10 
years after RA diagnosis. Work 
disability 32 times more likely than 
in matched controls. 
Cohort 2:  work disability rates 23 
% 1 y, 33% 2 years after RA 
diagnosis 
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population in these studies are very heterogeneous and thus not necessarily 
comparable. However, all of them show that RA patients have a decreased ability to 
work compared to the general population (Mitchell et al. 1988, Yelin 1992, Mau et 
al. 1996, van Jaarsveld et al. 1998, Albers et al. 1999, Barrett et al. 2000, Chorus et 
al. 2000, Mau et al. 2005). 
2.4 Mortality 
During the previous decades the mortality of RA patients has been increased 
compared to general population or matched controls with the standardized mortality 
ratio (SMR) varying between 1.28 and 2.98 (Doran et al. 2002, Gabriel and 
Michaud 2009) and the main causes of death being the cardiovascular diseases 
(Goodson et al. 2005); extra-articular manifestations have been the most significant 
single risk factor for increased mortality (Gabriel et al. 2003). More recent findings 
have, however, suggested that the mortality gap between RA patients and population  
may be narrowing (Sokka et al. 1999b, Kroot et al. 2000, Puolakka et al. 2010, 
Kapetanovic et al. 2011). Especially the increasing use of methotrexate appears to 
be protective from premature mortality, underlining the role of inflammation and 
it’s control in the total outcome of the RA patient (Choi et al. 2002, van Nies et al. 
2010, Westlake et al. 2010, Mikuls et al. 2011). 
 
3. Drug treatment of early rheumatoid arthritis 
As the aetiology and pathogenesis of RA remain unclear, its treatment has long 
been based on clinical experience of efficacious agents, rather than on true 
understanding of the pathogenetic mechanisms of the disease. Recently, with the 
increasing knowledge of the effect of cytokines and inflammatory cells in the 
pathogenetic cascade of RA, new biological drugs have been developed. At the 
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same time, the mechanisms of action of the older DMARDs have been at least partly 
revealed.      
3.1 Disease modifying anti-rheumatic drugs (DMARDs) 
3.1.1 Methotrexate 
Methotrexate (MTX) was originally developed as an anticancer therapy. Therein 
it inhibits the purine and pyrimidine synthesis via folate antagonism, leading to 
inhibition of cellular proliferation. In addition to this, in RA, methotrexate appears 
to have several anti-inflammatory properties; even though the exact mechanisms of 
the most crucial ones may still remain unclear (Chan and Cronstein 2010).  
Due to its good efficacy and favourable safety profile, leading to good treatment 
continuity, methotrexate has become the anchor drug in RA (Pincus et al. 2003). 
The results achieved by methotrexate are comparable across different studies. In one 
study comparing methotrexate, adalimumab and the combination of the two in early 
RA, by the end of the first year, methotrexate monotherapy had led to an ACR20, 
ACR50 and ACR70 response in 63%, 46%, and 28 % of the patients, respectively, 
and up to 21% of the patients achieved DAS28 remission (Breedveld et al. 2006). 
Methotrexate is recommended to be started with a small weekly dose and 
stepwise escalated to up to 20-30 mg per week with a regular monitoring of liver 
enzymes and complete blood count. Folate supplementation is advocated for 
reducing toxicity (Visser et al. 2009). Intramuscular or subcutaneous administration 
increases efficacy and reduces toxicity (Visser and van der Heijde 2009).  
3.1.2 Sulfasalazine  
In addition to being a frequently used medication of inflammatory bowel 
diseases, sulfasalazine (SASP) is a well-established DMARD, whose mechanism of 
action remains, however, unclear (Plosker and Croom 2005). It has been proven 
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effective in placebo controlled studies (Hannonen et al. 1993, Suarez-Almazor et al. 
2000a), and proven to be as effective as methotrexate (Haagsma et al. 1997, 
Dougados et al. 1999), leflunomide (Smolen et al. 1999), intramuscular gold 
(Williams et al. 1988), or hydroxychloroquine (Faarvang et al. 1993) in head to head 
comparisons. The most common side effects of sulphasalazine are gastrointestinal 
disturbances, headache and elevated liver enzymes; neutropenia being an 
uncommon but serious complication. 
3.1.3 Hydroxychloroquine 
Hydroxychloroquine (HCQ) was primarily an anti-malarial drug, but is currently 
mainly used as a DMARD in RA and in various collagenosis.  Its antirheumatic 
efficacy is moderate, but safety profile favourable, with the most common side 
effects being mild gastrointestinal disturbance, solar rash, nightmares, and rarely 
retinopathy (Suarez-Almazor et al. 2000b). In active RA it is currently seldom used 
as monotherapy but rather as a part of different DMARD combinations.  
3.1.4 Other DMARDs 
3.1.4.1 Azathioprine 
Azathioprine has some antirheumatic potential (Jeurissen et al. 1991). Nowadays 
in clinical practice it is most often used in the presence of mild renal failure or 
possible disease features of collagenoses. Side effects such as elevated liver values 
or nausea are common. In the FIN-RACo trial azathioprine was used as a substitute 
for MTX. 
3.1.4.2 Aurothiomalate 
Gold compounds are the first true DMARDs and have been used in the treatment 
of RA since decades (Kean and Kean 2008). The effect of intramuscular gold may 
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be good and a substantial portion of patients achieves even remission, however, side 
effects, such as rash and proteinuria, cytopenias and elevated liver enzymes are not 
rare, and unfortunately constrain the use of aurothiomalate.  
3.1.4.3 Auranofin 
The oral gold compound, auranofin has significantly weaker anti-rheumatic 
effect, yet similar but weaker side effects than aurothiomalate and today has a minor 
role in the treatment of RA (Kean and Kean 2008). In the FIN-RACo trial auranofin 
was used as a substitute for HCQ. 
3.1.4.4 Cyclosporine 
Cyclosporine (CyA) is a calcineurin inhibitor and primarily used as an 
immunosuppressant after organ transplantations. However, it has also been used as a 
DMARD with a moderate beneficial effect on clinical activity of RA. It is not 
recommended for first line use in monotherapy, and in most recent studies it is 
included as a part of a combination treatment (Kitahara and Kawai 2007). The 
typical side effects of cyclosporine are impairment of renal function and 
hypertension. 
3.1.4.5 Leflunomide 
Leflunomide came to market in the late 1990s for the treatment of RA (Behrens 
et al. 2011). It has a similar efficacy to sulfasalazine (Smolen et al. 1999) and 
methotrexate (Cohen et al. 2001). Its most common side effects are liver enzyme 
elevations and diarrhoea. 
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3.2 Glucocorticoids  
Glucocorticoids (GCs) have extensive anti-inflammatory and immunosuppressive 
effects (Spies et al. 2010) and they are widely used in RA; the majority of the 
patients use them at some point, and approximately 60 % more or less continually. 
GCs retard the radiological progression in early RA (Kirwan et al. 2007) and as they 
relieve inflammatory symptoms more rapidly than traditional DMARDs, GCs are 
often used as bridging therapy (Gorter et al. 2010).  However, their long-term use is 
restrained by cumulative side effects such as osteoporosis, diabetes, hypertension, 
skin atrophy, infections, and cataract.  
With local, intra-articular administration of the GCs the symptom relief is fast 
(Habib et al. 2010) and lasts for one month, on the average. Also, the structural 
destruction appears to halt (Hetland et al. 2008) and the side effects are less 
common than with systemically administered GCs. 
3.3 Biological treatments 
3.3.1 TNF-α-inhibitors 
With increasing understanding of the pathogenetic mechanisms behind RA, more 
tailored treatments, such as TNF-α-inhibitors, have been developed (Firestein 2005). 
The first TNF-α-inhibitor to come to clinical use in 1999 was infliximab, which is a 
chimeric (mouse-human), monoclonal antibody against TNF-α (Maini et al. 1999). 
After that, etanercept, a soluble TNF-α-receptor was introduced (Weinblatt et al. 
1999). Adalimumab, a totally human monoclonal antibody against TNF-α was the 
next one to come to market (Keystone et al. 2004) and under recent years 
certolizumab-pegol (Smolen et al. 2009) and golimumab (Keystone et al. 2009) 
have been introduced as well. All of these TNF-α-inhibitors have quite similar 
therapeutic effects, decreasing the disease activity and retarding the radiographic 
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progression in many patients (Singh et al. 2009). They are more efficient when used 
in combination with MTX, possibly due to MTX’s reducing effect on the 
immunogenicity of these therapeutic proteins (Bendtzen et al. 2006). When 
biologics are used in monotherapy, their efficacy in MTX-naïve patients equals that 
of MTX monotherapy. Their efficacy toward other manifestations of autoimmunity 
differs slightly, as does their safety profile (Singh et al. 2009). In general, TNF-
inhibition impairs the function of the host defence system, and thus increases the 
incidence of infections, including opportunistic ones (Singh et al. 2011a, Woodrick 
and Ruderman 2011). The TNF-α-inhibitors are administered either subcutaneously 
(adalimumab, certolizumab pegol, golimumab, etanercept) or intravenously 
(golimumab, infliximab) at different intervals according to their half-life. 
TNF-α-inhibitors were first tested in refractory, especially MTX resistant RA, 
and therefore, in clinical practice, often used in long-standing RA. Under recent 
years with increasing evidence of the importance of early induction of remission in 
RA, TNF-α-inhibitors have been studied in early, MTX-naïve RA (Genovese et al. 
2002, St Clair et al. 2004, Breedveld et al. 2006) and in clinical practice their 
introduction has spread to earlier disease. 
3.3.2 Others  
In addition to TNF-α-inhibitors other biological therapies in RA have come to 
clinical use. Anakinra is an IL-1 receptor antagonist indicated for treatment of RA 
(Cohen et al. 2002), but appears less effective than other biologics (Singh et al. 
2009). Rituximab is a B-cell depleting agent (anti-CD20), and is especially effective 
in RF- or ACPA-positive RA and is mainly used in patients failing or having contra-
indications to TNF-α-inhibitors (Buch et al. 2011). Abatacept suppresses the 
rheumatoid inflammation by inhibiting the co-stimulation of T-cells (Kremer et al. 
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2005). Tocilizumab inhibits IL-6, an important proinflammatory cytokine, and 
improves the clinical outcomes in RA combined to MTX (Singh et al. 2011b), but 
also as monotherapy (Nishimoto et al. 2009).  
3.4 Treatment strategies 
3.4.1 Pyramid strategy 
In the 1960s through 1970s, as therapeutic modalities, as well as proper 
understanding of the course of RA, were lacking, a so-called pyramid treatment 
strategy was adopted (Kamin and Multz 1969, Bluestone 1970). Aspirin or other 
nonsteroidal anti-inflammatory drugs (NSAIDs) were administered regularly; 
glucocorticoids were used as local, intra-articluar injections, systemic 
glucocorticoids were reserved for rare cases and for short use. Disease modifying 
anti-rheumatic drugs (DMARDs); mainly intramuscular gold and antimalarial 
compounds; were administered only if other treatments failed, and even then, for 
short terms. Other treatment modalities included bed-rest, physiotherapy and 
rehabilitation, splinting, synovectomies, and orthopaedic surgery. 
3.4.2 Saw tooth strategy 
In the 1980s and 1990s, as the false presumption of the good prognosis of RA 
gave way to more realistic ideas, a more active treatment policy started to prevail 
(Wilske and Healey 1989). DMARDs were changed to each other sequentially in a 
so-called saw-tooth method, if the clinical response was not satisfactory or due to 
side effects (Fries 1990, Sokka et al. 2000).  
3.4.3 Combination strategies 
The results of earliest studies utilising combinations of different DMARDs were 
not encouraging. Side effects were common and the increase in efficacy marginal 
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(Felson et al. 1994).  However, with more effective and less toxic agents, new 
studies assessing the efficacy and safety of different DMARD combinations have 
been carried out. They can be divided into two main categories. In step-up studies 
the treatment is started with a single DMARD, but in case of inefficacy intensified 
by adding another DMARD(s) to the original one. One version of step-up strategy is 
a treatment response steered strategy. A step-down treatment strategy includes 
starting multiple DMARDs at the same time, and continuing, or even increasing 
them until a predetermined time or treatment goal is reached, after which tapering or 
even stopping one DMARD at a time may be attempted.  
3.4.4 Combination treatment trials 
Several studies have been carried out comparing treatment with a combination of 
DMARDs to a treatment with single DMARDs, as well as with using different 
strategies. Some of these studies are presented in Table 11 (O'Dell et al. 1996, 
Calguneri et al. 1999, Dougados et al. 1999, Marchesoni et al. 2003, Capell et al. 
2007, Saunders et al. 2008) and others below in greater detail. 
3.4.4.1 COBRA 
In the COBRA study 155 patients with early RA were randomized to receive 
either initial sulfasalazine monotherapy or a combination of sulfasalazine, high dose 
prednisolone (starting from 60 mg daily and tapered down and stopped during the 
first 28 weeks) and methotrexate (tapered and stopped after 40 weeks) (Boers et al. 
1997). A pooled index assessing the clinical disease activity was better in the 
combination group than in the monotherapy group at 28 weeks, but the difference 
disappeared after prednisolone was stopped. However, the radiographic progression 
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Table 11. Studies on combination DMARD treatment 
 
 
Author and year 
 
Number and 
characteristics of 
patients 
 
 
Disease 
duration 
 
Follow-up 
 
Treatments 
 
Outcome measures 
  
Favours  
initial 
combi 
 
O’Dell et al. 1996  
 
n=103 
Poor response to at least 
one earlier DMARD 
 
10 years 
 
2 years 
 
 
MTX+SASP+HCQ   
SASP+HCQ  
MTX 
 
50% improvement:  
77%  
40%  
33% 
  
 
+ 
 
Calguneri et al. 1999 
 
 
n=180 
Active RA (but SJC 5), 
not on DMARDs 
 
2.3 years 
 
2 years 
 
 
MTX+SASP+HCQ  
MTX+SASP / MTX+HCQ  
MTX / SASP /HCQ 
 
ACR remissions:      
60%  
45%  
32% 
 
Radiographic non-progression: 
69% 
64% 
25% 
 
 
+ 
 
Dougados et al. 1999 
 
n=205 
Active, DMARD-naïve 
RA 
 
< 1 year 
 
1 year 
 
 
SASP 
MTX 
SASP+MTX 
 
Change in DAS: 
-1.15 
-0.87 
-1.26 
 
EULAR good response: 
34% 
38% 
38% 
 
 
Marchesoni et al. 
2003 
 
n=61 
Active, DMARD-naïve 
RA 
 
0.9 years 
 
12 months 
 
 
MTX+CsA 
MTX 
 
Damage score change (0-12mo): 
1.9 
7.5 
 
ACR20/50/70: 
53%/50%/47% 
61%/42%/19% 
 
 
+ 
 
Capell et al. 2007 
 
n=165 
SASP (6 months) failure 
(DAS>2.4), willing to 
participate 
 
1 year 
 
18 months 
 
 
MTX+SASP 
SASP 
MTX 
 
ACR 20% response (6-18mo): 
29% 
18% 
15% 
 
Remission: 
10% 
5% 
3% 
 
 
+ 
 
Saunders et al. 2008 
 
n=96 
Active, DMARD-naïve 
RA 
 
11.5 months 
 
12 months 
 
 
SASP>SASP+MTX>SASP+MTX+HCQ 
SASP+MTX+HCQ 
Both groups: targeted (DAS28<3.2) 
treatment, monthly visits, ia. GCs 
 
 
Change in DAS28 (0-12mo): 
-4.0 
-3.3 
 
DAS28 remission 
45% 
33% 
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was slower in the combination group at 1 year, at 5 years (Landewe et al. 2002), and 
possibly even after 11 years (van Tuyl et al. 2010b) than in the monotherapy group. 
In a short pilot study van Tuyl and colleagues (2008) treated 21 patients with early, 
active RA with “intensified COBRA strategy” (predisolone starting from 60mg 
daily, tapered down, but continued throughout the follow-up with 7.5mg daily; 
MTX 10mg/week; SASP 2g/day; HCQ 400mg/day) and found that 90 % of the 
patients were in DAS28 remission at 40 weeks. 
3.4.4.2 FIN-RACo 
In the FIN-RACo trial 199 early, DMARD-naïve, RA patients were randomized 
to receive for the first 2 years either a triple DMARD combination starting with 
sulfasalazine, methotrexate, hydroxychloroquine, and low dose prednisolone, or a 
single DMARD starting with sulfasalazine with or without low dose prednisolone 
(Möttönen et al. 1999). The aim of treatment in both groups was to achieve 
remission, and to maintain it. The treatments were intensified according to a 
predefined protocol and intraarticular GCs were injected to inflamed joints. In case 
of intolerance, the DMARDs could be switched to others. After 2 years, strict ACR 
remission was more common in the combination group than in the single group 
(37% vs. 18%), and radiographic progression slower. The combination group 
patients also sustained the achieved remission more often than the single group 
patients (Mäkinen et al. 2007). In patients with very early disease (< 4 months), 
even single treatment gave satisfactory results, but if the disease duration was 
longer, combination DMARD strategy was superior (Möttönen et al. 2002). After 2 
years the treatments were unrestricted. At 5 years the difference between remissions 
rates was not significant, but the combination group patients had less radiographic 
damage than the single group patients (Korpela et al. 2004), which was especially 
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explained by the slower radiographic progression in the ACPA-negative patients 
(Mustila et al. 2011). There were also less radiographic changes in the cervical spine 
in the combination group than in the single group at 2 (Neva et al. 2000) and at 5 
years (Kauppi et al. 2009). At 5 years the working capacity was preserved more 
often in the combination than the single group patients (Puolakka et al. 2004), and 
especially in those patients who had been in remission at 6 months (Puolakka et al. 
2005a).   
3.4.4.3 BeSt 
In the BeSt study a total of 508 patients with early, DMARD-naïve (prior 
antimalarials allowed) RA were randomized to four different treatment strategies 
(Goekoop-Ruiterman et al. 2005). The first treatment group received sequential 
DMARD monotherapy, the second one step-up combination therapy; in both initial 
monotherapy groups the treatment was started with MTX 15-30mg weekly. The 
third group received initially the COBRA regimen (Boers et al. 1997), where 
prednisolone was tapered from 60mg/day to 7.5mg/day within 7 weeks and in case 
of persistent low disease activity (DAS44 < 2.4) stopped after 28 weeks and MTX 
was tapered to zero after 40 weeks. The fourth group initiated the treatment with a 
combination of MTX and infliximab; the latter could be tapered down and stopped 
after 6 months of low disease activity (DAS44 < 2.4). On the other hand, according 
to a predefined protocol, with control visits every 3 months, the treatments in all 
groups were intensified if the treatment response was insufficient (DAS44 > 2.4). 
During one year of follow-up, the patients in either original combination group 
reached earlier functional improvement and had less radiographic damage than the 
patients of the initial monotherapy groups. Low disease activity (DAS44 < 2.4) was 
less common in the sequential monotherapy group (53%) than in either of the 
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combination groups (71% and 74%). The percentage of patients who had received 
intraarticular GCs during the first year was higher in the monotherapy groups than 
in the combination groups (22% and 26% vs. 8% and 13%). However, after 5 years 
follow up, 48% of the patients were in remission (DAS < 1.6) irrespective of the 
original randomization group, and 14% were in drug-free remission (Klarenbeek et 
al. 2011). Additionally, all the clinical outcomes and the rate of radiographic 
progression were similar between the groups from one year onward, but as the two 
initial combination group patients had had less radiographic damage during the first 
year, their cumulative damage by 5 years was smaller than that of the monotherapy 
patients. At 5 years, 21%, 5%, 11%, and 19% of the patients in the respective 
groups were using infliximab.  
3.4.4.4 TICORA 
TICORA was the first study designed especially to differentiate between 
different treatment strategies (Grigor et al. 2004). There 111 combination-DMARD-
naïve patients with RA for less than 5 years were randomized to receive either 
routine care with control visits every 3 months and treatment adjustments according 
to the treating physician’s judgement; or intensive care, with monthly visits and 
DAS-steered therapy so, that in case of persisting disease activity (DAS > 2.4) first 
sulphasalazine monotherapy was changed to a combination of sulphasalazine, MTX 
and hydroxychloroquine, then the doses were increased and prednisolone added, 
later the DMARDs could be switched to others. According to the protocol, 
intraarticular GCs were injected to inflamed joints in the intensive group; in the 
routine group these were allowed but far less commonly given. During the 18 
months follow-up, the patients in the intensive group were using more combination 
treatments (67% vs. 11%), and had received more intraarticular GCs than the 
55 
routine group patients. By the end of the follow-up the intensive group patients had 
lower disease activity, more DAS-remissions (65% vs. 16%), and less radiographic 
progression than the routine group patients.  
3.4.4.5 CIMESTRA 
In the CIMESTRA trial a total of 160 patients with early RA were randomized 
into two step-up groups: combination group (MTX plus CyA) and monotherapy 
group (MTX plus placebo-CyA) during the first year (Hetland et al. 2006). Both 
groups were treated actively by injecting intraarticlar GC injections to all inflamed 
joints and by increasing the dosage of MTX up to 20mg/week. If swollen joints 
persisted despite these treatment modifications, CyA or placebo-CyA was 
introduced. During the second year of the study, CyA or placebo-CyA was tapered 
to zero and HCQ was added to all patients in order to enable the withdrawal of 
MTX from patients in sustained remission after 3 years. If an ACR20 response was 
not achieved, first MTX was changed to parenteral dosing, further SASP was added 
to form triple therapy, and thereafter a TNF-α-inhibitor was introduced. At 2 years 
more patients in the combination group had reached an ACR20 and ACR50 
response than in the monotherapy group, however, there were no differences in the 
ACR70 (59% vs. 54%) or DAS-remission (51% vs. 50%) rates or in the 
radiographic progression. Similar excellent results were gathered after 5 years, when 
78% of the patients were in DAS-remission, 56% in ACR-remission, 17% in drug-
free remission and 47% had no radiographic progression from baseline (Hetland et 
al. 2010). The 5-year results did not differ between the original randomization 
groups, but baseline bone marrow oedema in wrist MRI, the presence of ACPA, as 
well as the total Sharp-van der Heijde score predicted the radiographic progression 
at 5 years. 
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3.4.4.6 CARDERA 
In a British multicenter study, the CARDERA, a total of 1391 patients with 
active RA of less than 2 years duration were screened, and 467 randomized to 
double-blindly receive either MTX, MTX and CsA, MTX and prednisolone, or a 
combination of all three, and followed up for 2 years (Choy et al. 2008). The 
primary outcome measure was radiographic progression. In the MTX group 29% of 
the patients developed new erosions, while 17%, 16%, and 13% did so in the 
MTX+CsA, MTX+prednisolone, and the triple group, respectively. Similar additive 
efficacy of the triple therapy was noted in the mean change of the total Larsen score, 
as well as the mean change in HAQ. 
3.4.4.7 CAMERA 
In the CAMERA study a total of 299 early RA patients were randomized to 
intensive care with monthly visits or to routine care with visits every 3 months 
(Verstappen et al. 2007). The initial treatment in both groups was MTX 
7.5mg/week, and this was increased and further altered to parenteral administration 
and addition of CyA or switch to other DMARDs in case of insufficient treatment 
response. In the intensive care group the clinical outcome measures were entered 
into a computer decision program which analyzed whether the predefined response 
criteria (> 20 % improvement compared to the previous visit and > 50% 
improvement from baseline) were met and whether the treatment needed to be 
intensified or not. Opposite to TICORA, to CIMESTRA, and to FIN-RACo the 
intraarticular and systemic glucocorticoids were deliberately avoided. The main 
outcome of this study was reaching at least one 3-month period of remission, and 
that succeeded for 50% of the intensive care patients and for 37% of the routine care 
patients. All clinical variables appeared similar by the end of 2 years, but during this 
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follow-up the areas under curve were lower in the intensive care group. After 5 
years the groups did not differ, the mean DAS28 values being 2.68 and 2.75 (Bakker 
et al. 2011). Good response according to EULAR criteria at 6 months predicted a 
good outcome at 5 years, irrespective of the original treatment allocation. Changing 
MTX to parenteral dosing increased the efficacy of the treatment whereas adding 
CyA did not (Bakker et al. 2010). 
3.4.4.8 Swefot 
In a Swedish multicenter study, 487 patients with early, DMARD-naïve RA were 
first all treated with MTX monotherapy, then assessed at 3-4 months, when the 258 
patients tolerating MTX, but not having reached low disease activity (DAS28<3.2) 
were included in the Swefot study and randomized to receive either an addition of 
SASP and HCQ or that of infliximab to MTX (van Vollenhoven et al. 2009). At 12 
months, the primary outcome, EULAR good response, was reached by 25% of the 
MTX+SASP+HCQ treated patients, and by 39% of the MTX+infliximab treated 
patients. Of the 147 patients not included in the Swefot study and having reached 
low disease activity with initial MTX, DAS28 remission was reached by 60% after 
1 year, and by 72% after 2 years (Rezaei et al. 2011). However, regardless of the 
clinical outcome, 61% of the patients still progressed radiologically, at baseline 52% 
of the patients had had radiographic damage, while at 2 years 80% did so. Still, the 
progression of damage was moderate.  
 
 
 
 
58 
4. Treatment recommendations 
4.1 Finnish Current Care guideline 
According to the national Finnish guideline, early and aggressive application of 
DMARDs is essential for a positive treatment result in RA (Current Care Guideline 
2009). Remission during the first year of treatment predicts permanent remission, 
milder joint damage and better functional ability. Methotrexate is recommended as 
the first DMARD, but as the authors of the Finnish guideline consider combination 
therapies to be more effective than single therapies, they recommend a combination 
of methotrexate, sulfasalazine, hydroxychloroquine and prednisolone to be initially 
used in active RA. For patients with an unsatisfactory response to DMARDs 
(including methotrexate and DMARD combinations), TNF blockers, or further, in 
non-responders, other biologics, should be used. 
4.2 Other recommendations 
Several national recommendations for the use of DMARDs exist. Of these, at 
least the United Kingdom (NICE 2009), the American (Saag et al. 2008), and the 
Canadian (Bykerk et al. 2011) versions deem initial combination treatment in active 
RA with poor prognostic factors (positive RF or ACPA, high disease activity or 
early radiographic changes) possible. However, the EULAR (Smolen et al. 2010a) 
recommendations suggest initial MTX monotherapy to all patients without 
contraindications, and if that fails and the patient has poor prognostic factors, adding 
a biologic. According to the EULAR recommendations, combining or switching 
traditional DMARDs is only the second option after MTX failure and reserved for 
patients without poor prognostic factors. Additionally, a so-called Treat to Target 
initiative has been published underlining the importance of aiming at sustained 
remission or low disease activity (Smolen et al. 2010b).  
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5. Realisation of medical treatment in early RA in clinical 
practice 
5.1 Specialist opinions 
Different methods can be utilized to assess the use of DMARDs. Interviewing 
rheumatologists is an accessible option. However, interviewed physicians may 
report more idealistic treatment strategies than the ones they actually use, and, 
moreover, in such studies the respond rate is seldom high.  
In 1998, before the era of biologics, Maetzel et al. (1998) sent a survey about 
treatment strategies in RA to all members of the Canadian Rheumatology 
Association and to a 10 % sample of the members of the American College of 
Rheumatology, 214 (81.3 %) and 214 (66.9 %) of whom responded and were still 
practicing rheumatologists, respectively. The authors queried the first and second 
treatment choices in hypothetical patient cases representing: aggressive DMARD-
naïve RA (26 actively inflamed joints and 3 erosions), moderate DMARD-naïve RA 
(6 actively inflamed joints, no erosions), and aggressive RA failing MTX. The 
majority of Canadian rheumatologists preferred MTX (68.7 %) as the first DMARD 
and im. gold (50.0 %) as the second one in aggressive RA. If MTX failed, more than 
half of the rheumatologists would still have continued with a single DMARD, most 
often SASP (34.6 %), 16.4 % would have combined HCQ and 3.3 % HCQ and 
SASP to MTX. The US rheumatologists appeared somewhat more active; in 
aggressive RA 78.5 % of them chose MTX as the first option, 11.2 % would have 
combined HCQ and 4.7 % both HCQ to MTX already as the first treatment. In 
aggressive RA failing MTX, triple therapy was the most common option (21.5 %), 
otherwise the choices spread widely. In moderate RA 90.2 % chose a single agent, 
equally commonly MTX (38.8 %) and HCQ (39.3 %).  
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Mikuls and O’Dell (2000) carried out an interview study of 200 US 
rheumatologists in 1999 and compared the responses to those from similar 
questionnaires in 1995 and 1997. MTX was the most commonly used initial 
DMARD; in 1999, 64 % of the US rheumatologists chose it as first-line therapy (in 
1995 50 %, and in 1997 53 % did the same). HCQ, SASP and injectable gold were 
other possible first-line DMARDs. Combination treatment was deemed as suitable 
initial therapy by 47 % of the rheumatologists. 
Jobanputra et al. (2004) reported the results of a postal interview about the 
treatment of early RA to 460 UK rheumatologists, 331 of whom responded. As the 
first treatment, 46.5 % of them preferred MTX, 43.5 % SASP, and 5 % either of 
these two. Depending on the first choice, the most common option for the second 
DMARD was switching MTX to SASP or vice versa, or combining them to each 
other and, in some cases, adding HCQ. If these treatments would have failed, 
leflunomide was valued over intramuscular gold, and after them, anti-TNF agents.  
Maravic and colleagues (2004) sent a questionnaire about the diagnosis and 
treatment of RA to French rheumatologists, 917 (37 %) of whom answered. As 
initial treatment, only 74% would have prescribed DMARDs, most often MTX (46 
%). 
Through a postal questionnaire sent to Dutch rheumatologists (response rate 50 
%), van Tuyl and colleagues (2007) noted that even though the physicians admitted 
the evidence-based efficacy of the Cobra combination treatment, they found the 
combination too complex to be used in clinical practice and worried about the 
possible side effects of high dose prednisolone. 
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5.2 Cohort studies  
5.2.1 Clinical cohorts 
Kvalvik and co-workers (2001) reviewed retrospectively the treatment data of a 
cohort of 147 patients who had had their first visit to a Norwegian tertiary 
rheumatology centre in 1977 due to RA, up to 1992 or the patients’ death. They 
found that at the time of the diagnosis, in 1977, DMARDs were given to 62% of the 
patients, mainly to those with a short symptom duration and severe RA. During 
follow-up, 54 % of the patients received DMARDs, which were administered only 
for a median of 29 months. 
As a subgroup of a larger Austrian single-institute material, Aletaha and Smolen 
(2002) present the data of the initial treatment in 222 early RA patients treated 
between 1971 and 1999. The authors report that throughout this long observation 
time, antimalarials, SASP, MTX, parental gold, oral gold and combination 
DMARDs were given to 34.7 %, 28.4 %, 16.2 %, 11.3 %, 6.8 % and 1.8 %, 
respectively. Gold compounds and antimalarials were the leading DMARDs in the 
beginning, SASP and MTX replaced them towards the end of the of the study 
period. 
Saraux et al. (2002) present data of 98 early RA patients from 8 French 
rheumatology departments in Brittany between 1995-97.  Injectable gold (32 %) and 
HCQ (34 %) were the most common initial DMARDs; 14 % of the patients were not 
prescribed any DMARDs at their first visit with RA. After 2-4 years follow-up, at 
their last visit within the study, 23 %, 23 %, 21 %, and 18 % of the patients were on 
MTX, injectable gold, HCQ or no DMARDS, respectively. Only 3 % of the patients 
received DMARD combination treatment. 
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Sokka and Pincus (2002) reviewed retrospectively the initial treatment of 232 
early RA patients diagnosed after 1998 in a private US clinic. Single MTX was the 
first DMARD in 81.5 % and HCQ in 6.5 % of the patients; 7.3 % were not 
prescribed DMARDs initially. All the patients were evaluated in clinic in 2001, and 
at that time, after a mean disease duration of 21 months, 56.0 % of the patients were 
on single MTX, 15.5 % were using combinations of traditional DMARDs and 9.4 % 
combinations including biological agents; 9.1 % were not on DMARDs. At the 
study visit, 59.9 % of the patients were taking prednisone with the median dose of 
5mg; 87.0 % of the patients had used prednisone for over two weeks at some time 
during their RA treatment. 
5.2.2 Population-based cohorts  
5.2.2.1 Early RA 
Carli and colleagues (2006) analysed data from a national Swedish Rheumatoid 
Arthritis Register, including 2584 early RA patients from 19 Swedish hospitals 
diagnosed between 1997-2001. During the study period the use of DMARDs 
increased, which was mainly explained by the increased use of methotrexate; in 
1997 approximately 20 % of the patients received it, while in 2001 55 % did so. The 
use of other DMARDs remained quite stable, but the proportion of patients without 
DMARDs decreased from 32.2% to 14.9%. Approximately 40 % of the patients 
were using oral GCs with a median dose of 7.5-10 mg. Active treatments were more 
often used by doctors practicing in university and county hospitals than by those 
from district hospitals. 
The Norfolk Arthritis Register (NOAR) in the UK assesses the long-term follow-
up data of adult patients presenting with inflammatory polyarthritis, thus not 
necessarily RA. From this register, two cohorts of patients were assessed; the first 
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one included in 1990-94 and the latter one in 2000-2004. In the first cohort 44.6% of 
the patients were ever treated with DMARDs [median (IQR) treatment time 0 (0-47) 
months, MTX 20.3 %] during the first 5 years of follow-up, in the latter cohort 71.9 
% of the patients received DMARDs [51 (0-60) months, MTX 55.2 %] (Scire et al. 
2011). 
5.2.2.2 Established RA 
Berard and co-workers (2000) published data of 10 262 New Jersey RA patients 
registered in different beneficiaries between 1992-1995. When the prescription data 
of these patients during 1995 was analysed, only 13% of them were prescribed any 
DMARDs; 57 % were using NSAIDs and 23 % oral glucocorticoids. 
Edwards et al. (2005) present the data from 34 364 RA patients registered in the 
UK national database between 1987-2002. Only 50% of the patients were prescribed 
any DMARD during the study period, most often SASP (46.3%) or MTX (31.4%), 
the use of the latter having increased 17-fold during the study period, while the use 
of intramuscular gold had decreased. 
In an observational study of 5 864 RA beneficiary program patients, 65 years or 
older, from US, Pennsylvania, treated for RA between 1995 and 2004, Schmajuk 
and colleagues (2007)  found that the use of DMARDs increased during follow-up; 
in 1996 24% and in 2003 43% of the patients received DMARDs (41% and 70% of 
those with at least 1 rheumatologist visit). Older patients were less likely to receive 
DMARDs than the younger ones. 
In Germany, a national database (the National Database of the German 
Collaborative Arthritis Centres) has been established in 1993 to monitor the 
treatment and outcomes of patients with arthritis (Zink et al. 2001). In the most 
recent publication on this database including data from 38 723 RA patients with a 
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mean disease duration of approximately 10 years, Ziegler et al. (2010) reported that 
from 1997 to 2007 the proportion of patients using combination DMARDs increased 
from 7.5 % to 22.8 %, that of patients on a single DMARD decreased from 74.3 % 
to 61.8 %. Throughout the follow-up, the percentage of patients with no DMARDs 
varied between 12.7 % and 19.2 % without a clear trend, but the proportion of 
patients using only GCs increased from 4.9 % to 8.1 %. The use of MTX remained 
stable at a level of 52.2-57.5 %. In 2007, 16.2 % of the patients received biologics. 
During the same follow-up, the mean DAS28 decreased from 4.5 to 3.4 and the 
proportion of patients in DAS28 remission (<2.6) more than doubled from 13.7 % to 
29.3 %, reflecting the better results achieved by the increasingly aggressive 
treatment policy.  
Neovius and co-workers (2011a) published a study on the prevalence of RA in 
Sweden, as well as on the penetration of anti-rheumatic treatment in that population, 
based on data from 58 102 patients alive in 2008. They found that in 2001-2007, 62 
% of the patients received DMARDs, 49 % GCs and 15 % biologics.  
 
6. The effect of medical treatment on work disability in RA 
6.1 Conventional DMARDs 
In 1991, in a Scandinavian multi-centre study Borg et al. (1991) proved, that 
early RA patients treated double-blindly with auranofin (n=42) for 24 months had at 
the end of the study a higher probability of continuing to work than those treated 
with placebo (n=41), with 57 % and 37 % of the patients in auranofin and placebo 
groups having unchanged working ability and 31 % and 39 % retiring prematurely, 
respectively. In this study, risk factors for early retirement were blue-collar jobs, 
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higher age and increased disability, but even when these were taken into account, 
the initial treatment with auranofin had a protective effect.  
Within the FIN-RACo trial, Puolakka and others (2004) compared the incidence 
of sick leaves and work disability during 5 years follow-up in the 162 early RA 
patients who had been available to work force at baseline. They found that the 
patients initially treated with the FIN-RACo strategy had an annual median of 12 
days of sick leave while the respective figure in the patients treated with the 
SINGLE strategy was 30 days. The proportion of patients receiving a permanent 
disability pension by 5 years was 20 % and 29 % in the FIN-RACo and in the 
SINGLE groups, respectively. However, the sex, age and baseline unemployment 
status adjusted hazard ratio was not statistically significant [1.25 (95 % CI: 0.65 to 
2.41)]. In a following study the authors evaluated the relation of the clinical 
outcome at 6 months and the subsequent work disability at 5 years and showed that 
regardless of the initial treatment strategy, none of the patients achieving remission 
at 6 months became work disabled during 5 years (Puolakka et al. 2005a). Of the 
patients having an ACR50, ACR20 or less than ACR20 response at 6 months, 23 %, 
21 %, and 56 %, respectively, became permanently work disabled by 5 years. In a 
monetary analysis of the FIN-RACo material better improvement of disease activity 
was associated with less cost (Puolakka et al. 2006). 
In the 2-year cost-utility analysis of the BeSt study the authors present amongst 
other outcome measures the mean worked hours per week. During both the first and 
the second year these hours were higher in the initial combination groups than in the 
sequential monotherapy or the step-up combination therapy groups, 12-14 
hours/week and 8-11 hours/week, respectively (van den Hout et al. 2009). In this 
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respect, the initial combination treatment with either prednisolone or infliximab did 
not differ from each other. 
6.2 Biologics 
Despite the excellent clinical results achieved by biological DMARDs, their 
effect on working ability is still unclear and possibly depends on the timing of the 
treatment. 
6.2.1 Established RA 
In 1999, Yelin with colleagues (2003) carried out a telephone interview of 194 
RA patients who were using etanercept as a part of a clinical study and of 185 RA 
patients belonging to an observational study cohort and not using etanercept. These 
patients had been employed at the time of the diagnosis of RA, which in the 
etanercept users had took place a mean 14 years and in the non-users 17 years 
earlier. At the time of the study, 71 % of the etanercept users and 55 % of the non-
users were employed and the authors found the difference significant even when 
adjusted for RA duration and severity, demographics, other health status, occupation 
and industry. 
Within the large aforementioned US cohort (Allaire et al. 2008a), the same 
authors compared the risk of work disability between two subgroups; 1986 anti-
TNF-treated patients and 1900 never-anti-TNF-treated patients, all of whom had 
been employed at disease onset and completed the required follow-up (Wolfe et al. 
2007a). The authors noted that anti-TNF therapy in fact increased the risk of both 
self-reported and Social Security compensated work disability; when all covariates 
(demographics, comorbidities, disease severity, treatments) were included in the 
model, the difference remained statistically significant for self reported but not for 
Social Security compensated work disability. Further, from the same observational 
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US cohort, Allaire and co-workers (2008b) studied longitudinally the efficacy of 
TNF-inhibitors on work disability during 18 months of follow-up, and did not find 
any protective effect in a cohort of 953 RA patients. However, in a subanalysis, 
disease duration played a role so that patients with shorter (< 11 years) disease 
course benefited of TNF-inhibitors (OR 0.5 [0.2-0.9]) while patients with longer 
disease duration (> 11 years) did not (OR 1.6 [0.9-3.6]).   
Halpern et al. (2009) followed up for 24 months 158 multinational RA patients 
receiving adalimumab as a part of an extension study of six prior clinical studies and 
180 Norwegian register-based RA patients receiving traditional DMARD treatment, 
who would have fulfilled the inclusion criteria for the abovementioned adalimumab 
studies. All of these patients had been employed at baseline, while the authors report 
that at one year 117/158 (74 %) and 62/180 (34 %), and at two years 108/158 (68 
%) and 36/180 (20 %) of the adalimumab and of the DMARD treated patients, 
respectively, would have continued working. However, these results are in great 
contrast with a figure from the same article, according to which the corresponding 
percentages were approximately 90 % and 75 % at one year, and 87 % and 67 % at 
two years. Whatever the figures the authors base their analysis on, they conclude 
that the patients receiving adalimumab had a decreased the risk of becoming work 
disabled (HR 0.36) and worked approximately seven months longer than non-anti-
TNF treated patients. 
Augustsson and co-authors (2010) describe a Swedish cohort of 594 patients 
treated with TNF-inhibitors and followed up for five years. At the beginning of the 
treatment the patients had a mean disease duration of 9.4 years and were all 
available to labour force. During follow-up, the weekly working hours increased by 
up to a mean of seven hours, especially in patients being able to continue treatment 
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with the same TNF-inhibitor. No figures on the incidence of permanent work 
disability were given and the study included no control group. However, it could 
well be hypothesized that in patients with severe enough RA to claim treatment with 
biologics, the natural prognosis of working ability without treatment would rather be 
deterioration than improvement. 
Verstappen et al. (2010) present the British Society for Rheumatology Biologics 
Register data of 3291 RA patients treated with infliximab, etanercept or adalimumab 
and of 379 RA patients with active disease and treated with DMARDs between 
2001-2005. The mean RA duration was 13 years in the anti-TNF-treated patients 
and 8 years in the DMARD-treated cohort. The working status of the patients was 
elucidated at baseline when already 49 % of the anti-TNF-treated patients and 36 % 
of the DMARD-treated patients were work disabled. After three years of treatment 
the incidence of new work disability was 9 % and 5 % in the anti-TNF- and 
DMARD-treated RA cohorts, respectively. The anti-TNF-treated patients who had 
reaching remission by six months after the induction of treatment had a reduced risk 
of consequent work disability; in others anti-TNF treatment did not appear to 
prevent loss of work ability. Elevated HAQ and manual job were risk factors for 
new work disability. 
6.2.2 Early RA 
In a clinical study setting, Smolen et al. (2006) analysed employment and 
employability data of 500 patients with a RA duration of less than 3 years and 
randomized to receive either infliximab or placebo infusions together with MTX and 
followed up for 54 weeks. The actual employment rate did not differ between the 
groups, the net employment loss was 1.3 % in the placebo group and 0.5 % in the 
infliximab group.  However, fewer patients lost workdays and higher proportion 
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maintained their subjective employability in the infliximab group than in the 
placebo group.  
Bejarano et al. (2008) randomised in 2003-04 a total of 148 employed, MTX-
naïve, early RA patients to receive treatment with either MTX or with MTX plus 
adalimumab and followed them up for 56 weeks The primary end point was actual 
or imminent work loss after 16 weeks, which did not differ statistically significantly 
between the groups. However, presumably due to the early treatment failure in the 
MTX group, during the total follow-up, fewer patients in the MTX plus adalimumab 
group experienced actual or imminent job loss than in the MTX group, 19 % and 40 
%, respectively.  Imminent job loss was defined as a failure to achieve an ACR20 
response and either deteriorating or persistently high scores in a specific 
questionnaire predicting a high risk of work disability; actual job loss was rare in 
either group (data not shown in the article). 
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AIMS OF THE STUDY 
 
1. To compare the long-term effects of initial combination DMARD strategy 
starting with methotrexate, sulfasalazine, hydroxychloroquine, and low dose 
prednisolone to single DMARD strategy starting with sulfasalazine, with or 
without prednisolone on clinical outcomes in patients with early RA. 
 
2. To compare the long-term effects of initial combination DMARD strategy 
starting with methotrexate, sulfasalazine, hydroxychloroquine, and low dose 
prednisolone to single DMARD strategy starting with sulfasalazine, with or 
without prednisolone on radiographic damage in patients with early RA. 
 
3. To study the initial treatment of early RA in the whole Finnish population 
and to estimate how it adheres to the contemporary recommendations.  
 
4. To study how work disability in early RA patients has changed during this 
millennium in Finland. 
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MATERIALS AND METHODS 
7. The FIN-RACo 11-year follow-up studies (I and II) 
7.1 Patients 
Between April 1993 and May 1995, in a multicenter setting, 199 DMARD-naïve 
patients with a recent onset RA (symptom duration <2 years; median 6 months) 
were admitted to this open, parallel-group and randomized study comparing the 
efficacy and tolerability of two treatment strategies (4). The patients could be 
included in the study if they fulfilled the American College of Rheumatology (ACR; 
formerly, the American Rheumatism Association) 1987 revised criteria for RA (13), 
were aged 18–65 years, had a duration of symptoms of less than 2 years, and had an 
active disease, with at least three swollen joints and at least 3 of the following 4 
features: either an erythrocyte sedimentation rate (ESR) ≥28 mm/hour or a C-
reactive protein (CRP) level >19 mg/l, morning stiffness ≥29 minutes in duration, 
>5 swollen joints, and >10 tender joints.  
7.2 Study design  
7.2.1 Study design during the first 2 years 
The FIN-RACo strategy included an initial combination of three DMARDs and 
was started with methotrexate 7.5 mg/week, sulfasalazine 500 mg twice daily, and 
hydroxychloroquine 300 mg/day, with prednisolone 5 mg/day, but the dosages 
could be adjusted to achieve remission. The highest dosages allowed were 15 
mg/week for methotrexate, 2 gm/day for sulfasalazine, and 10 mg/day for 
prednisolone. If, for any reason, any of these drugs had to be discontinued, it was 
replaced with a different DMARD so that constantly a combination of three 
DMARDs was used. The SINGLE strategy was initiated according to the 
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“sawtooth” strategy, using sulfasalazine (2 g/day) as the first drug for all patients. 
The dosage could be increased to 3 g/day, and the simultaneous use of prednisolone 
up to 10 mg/day was allowed. If the clinical response was insufficient or if an 
adverse event occurred, sulfasalazine was replaced with methotrexate, and if 
needed, further with a different single DMARD. In all patients the treatment was 
targeted toward remission and thus intra-articular glucocorticoid injections into 
inflamed joints were allowed and even exhorted for.  
7.2.2 Study design after 2 years 
After 2 years, the use of DMARDs became unrestricted. However, in both groups 
the treatment was still aimed at maintaining or achieving remission. Therefore, 
regardless of the original randomization group, patients who had an insufficient 
response could be treated liberally with increased dosages of DMARDs and with 
DMARD combinations as tolerated and clinically indicated. Once available to 
market, biological DMARDs could be used. On the other hand, if a patient was in 
long-term remission, the protocol required drug dosages to be reduced and 
eventually tapered off, beginning with prednisolone. If it could be discontinued 
without losing remission, one DMARD per year could gradually be tapered down. If 
RA was reactivated, the last medication and dosage at which remission was 
maintained was reinstituted. As a consequence, depending on the clinical situation, 
the drug therapies of the study patients could vary from no DMARDs or 
prednisolone to a combination of DMARDs as well as to biological agents.  
7.3 Clinical assessments 
The treating rheumatologist performed all clinical assessments. During the first 2 
years the study visits occurred every 1-3 months, between 2-5 years every 6 months 
and after that once a year. All patients who had participated in the 5-year follow-up 
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survey were invited to participate in the 11-year follow-up visit even if they had not 
participated otherwise after 5 years and, on the other hand, only patients who had 
participated at 5 years were included in the 11-year analysis.  
Outcome measures included the patient’s self-report of physical functioning and 
assessment of RA clinical activity, including all the measures required to determine 
the frequency of remissions. The medications used by the patients were recorded at 
each study visit. DMARD strategies used between year 2 and year 11 were carefully 
elucidated based on the patient’s self report and his or her medical records. Serious 
adverse events, including death, any life-threatening event, malignant disorders, and 
any event that necessitated hospital admission, among the patients participating in 
the 11-year follow-up were recorded. The vital status of all patients who had entered 
the study was inquired from the Local Register Office. Death certificates for all 
deceased patients were obtained from the office of Statistics Finland. Comorbidities 
and their duration were inquired from the patient as well as from the medical 
records. Functional capacity was assessed with the Health Assessment 
Questionnaire (HAQ) (Fries et al. 1980). Clinical activity of RA was assessed with 
the Disease Activity Score 28-joint assessment (DAS28) (Prevoo et al. 1995).  
Modified Minimal Disease Activity (MDA) was assessed to be present, if the 
patient had no swollen joints, no tender joints, and an ESR ≤10 mm/hour or fulfilled 
of at least 5 of the following 7 criteria: swollen joint count ≤1 (range 0–52), tender 
joint count ≤1 (range 0–52), HAQ score ≤0.5 (range 0–3), visual analog scale (VAS; 
0–100-mm scale) score for pain ≤20, for the patient’s global assessment of disease 
activity ≤20, and for the physician’s global assessment of disease activity ≤15, and 
an ESR ≤20 mm/hour. In this study a 52-joint count of tender and swollen joints 
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was used, instead of the 28-joint count used in the original analysis (Wolfe et al. 
2007b), which made these modified criteria more stringent. 
Also the definition of remission used in this study was very strict; it included the 
fulfilment of all the other 5 ACR criteria (Pinals et al. 1981), when fatigue and 
duration of remission criteria were excluded. Thus, a patient in remission could not 
have any tender or painful joints, no swollen joints or tendon sheaths, no elevation 
of the ESR (normal <30 mm/hour in women and <20 mm/hour in men), nor a 
duration of morning stiffness of >15 minutes. Remission according to the DAS28 
was defined as score of <2.6. 
7.4 Radiological assessment 
The hands and feet of all patients were radiographed at baseline, at 2, 5 and at 11 
years. Radiographs of hip, knee, elbow and shoulder joints of the patients were 
taken at 11 years in 13 study centers; in 2 study centers only clinically symptomatic 
large joints were radiographed. Total joint replacements were assessed from the 
radiographs as well as from the patients’ medical records. The same experienced 
radiologist (LL), who was blinded to the clinical data but aware of the order of the 
radiographs, assessed the radiographs and scored the radiographs of hands and feet 
according to the method of Larsen et al. (Larsen et al. 1977) with the range from 0 
to 200. The large joints were also scored according to the method of Larsen (Larsen 
et al. 1977) and a score of ≥ 2 was considered indicating erosive disease. 
7.5 Ethical considerations 
The study was performed according to the principles of the Declaration of 
Helsinki. The protocol was approved by the national health authorities and ethics 
committees of all 18 participating hospitals. All patients gave written informed 
consent.  
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7.6 Statistical methods 
Results are presented as the mean ± standard deviation (SD), the median with the 
interquartile range (IQR), or counts with percentages. The 95% confidence intervals 
(95% CIs) are given for the most important outcomes. Statistical comparison 
between groups was performed with the t-test, permutation test, chi-square test, or 
Fisher’s exact test, as appropriate. Repeated measures for continuous and binary 
outcomes were analyzed using generalized estimating equation (GEE) models with 
the exchangeable correlation structure. GEE models do not require complete data 
and can be fit even when individuals do not have observations at all time points. The 
Cox proportional hazards model was used to estimate the adjusted risk of death 
between groups. The underlying proportional hazards assumption was tested by 
computing the Schoenfeld residuals for each of the covariates in the final model and 
plotting them against the length of survival. The standardized mortality ratio (i.e., 
the ratio of observed to expected deaths) was calculated using the subject-years 
method with 95% CIs, assuming a Poisson distribution. Probabilities of survival in 
an age- and sex-matched sample of the general population were calculated from data 
from the Official Statistics of Finland. 
The 95 per cent confidence intervals (95 % CI) for Larsen score are obtained by 
bias-corrected bootstrapping due to the skewed distribution.  The difference in crude 
change in Larsen score between the groups was tested by a permutation test. A 
random coefficient model with bootstrapped standard errors was adapted to analyze 
the progression of Larsen score during 11 years and to compare the groups in time. 
An ordered logistic regression analysis was used to estimate the prediction of 
achieving radiologic progression. The adjusted risk ratio (RR) between the groups 
for having no erosive changes in large joints was estimated by a generalized linear 
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model (log link) with presence of erosion in hands or feet at baseline as covariate. A 
time-to-event analysis based on the product limit estimate of the cumulative 
“survival” function (Kaplan- Meier) was used in order to describe the time to event. 
A log-rank test was used to identify any survival difference between the groups.  
8. The Finnish early RA register studies (III and IV) 
8.1 Background 
In Finland, the entire population is covered by general sickness insurance, and all 
permanent residents are issued a personal health insurance card. The Social 
Insurance Institution (SII) generally reimburses the costs of medicines prescribed by 
a doctor and intended for the treatment of an illness. The basic reimbursement rate is 
42% of the price of the medicine, but patients with certain severe and chronic 
diseases are entitled to a special reimbursement of medications if their condition 
meets predefined criteria. Thus, the patients with chronic inflammatory rheumatic 
disorders can be granted the special reimbursement of 72% for antirheumatic drugs. 
To establish entitlement, the patient must submit to the SII a medical certificate 
issued by a specialist or based on examinations performed by a specialist-level 
health care unit. The medical certificate must include information on proper 
diagnostic procedures, an ICD-10 diagnosis, and a treatment plan according to a 
good clinical practice. An insurance physician of SII reviews the certificates before 
the special reimbursement can be granted. The administrative process usually takes 
a couple of weeks. Practically all Finnish patients with antirheumatic medications 
receive the reimbursement decision as it is economically in the patients’ interest and 
if the reimbursement decision does not exist, the pharmacists generally encourages 
the patient to request it. At one transaction up to three months’ supply of medicines 
can be reimbursed.  
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Finland has two, complementary, statutory pension systems; the national 
pensions and earnings-related pensions. National pensions, awarded and paid by the 
SII, offer a basic income for persons who are entitled only to a very small earnings-
related pension or to none at all. Earnings-related pension rights accumulate through 
employment and self-employment. There are several earnings-related pension 
providers all of whom belong to the Finnish Centre for Pensions.  
If unable to work, 16-67 year-old persons with long-term illnesses will first be 
paid a sickness allowance for up to 150 working days. After that, 16-64 year old 
persons who have lived in Finland for at least 3 years and who have an illness, 
injury or defect that prevents them from earning a reasonable living, stated by a 
doctor’s certificate, can apply either for a temporary rehabilitation allowance or a 
permanent disability pension. Permanent disability pensions are usually granted, at 
the earliest, after one year of sick leave or rehabilitation allowance. Persons over 60 
years may get a disability pension on somewhat easier terms. In case of application 
for both a national pension and an earnings-related pension on account of disability 
for work, SII and the responsible pension provider consult each other before issuing 
a decision. The SII and the Finnish Centre for Pensions maintain a register on sick 
leaves, rehabilitation allowances and permanent disability pension. 
8.2 Patient cohort 
The SII maintains a nationwide register of all medicine reimbursement decisions. 
From that register the data were gathered from 1.1.2000 to 31.12.2007, including 
information on sex, date of birth, and the date of reimbursement decision (index 
day) of patients who, for the first time in their life, had been granted a special 
reimbursement of medications for rheumatoid factor (RF) -positive (ICD-10 
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diagnosis M05) or RF-negative RA (M06). According to the index day the patients 
were divided into 2-year cohorts (2000-01, 2002-03, 2004-05, 2006-07).  
For the work disability analysis, similar data were separately collected for 18-64 
year-old patients who were available for labour force at the index day. 
8.3 Medications 
The SII maintains a prescription register on the drugs purchased from pharmacies 
and reimbursed according to the basic or the special rate. In this register, drugs are 
classified according to the Anatomical Therapeutic Chemical (ATC) classification 
(WHO 2009). The register includes the date of purchase and the amount of the drug. 
From this register, we collected data on the antirheumatic drugs purchased by the 4 
patient cohorts for 31 days before the index day (to include medication possibly 
purchased before the reimbursement decision) and for 31 days, for 91 days, and for 
one year after the index day. Since prednisolone 5 mg tablets were not reimbursed in 
Finland between 1.1.2006 and 30.11.2007 the purchase of glucocorticoids was 
assessed only between years 2000 and 2005. Also, the intravenous drugs given and 
reimbursed by hospitals and outpatient clinics are not registered by the SII. 
Consequently, our study does not include infliximab or other infusion-based 
biological therapies. In addition to the distinct first-month and first-year DMARDs 
used by the patient cohorts, we investigated the early drug treatment strategies up to 
3 months from the index day - no DMARD, single conventional DMARD, 
combination of conventional DMARDs, or treatment including TNF-inhibitors – 
and the change in strategy over time.  
For the patients available to work force at the index day we collected data on the 
antirheumatic drugs purchased by the 4 patient cohorts from 31 days before (to 
include medication possibly purchased before the reimbursement decision) up to 91 
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days after the index day. We studied the early drug treatment strategies up to 3 
months from the index day: no DMARD, single non-methotrexate (MTX) DMARD, 
single MTX, combination of DMARDs not including MTX, or combination of 
DMARDs including MTX. The initiation of adalimumab or etanercept during the 
first 3 months as well as during any time throughout the follow-up was elucidated. 
8.4 Work disability 
From the registers of the SII and of the Finnish Centre for Pensions data were 
collected for the patients in each cohort (2000-01, 2002-03, 2004-05, 2006-07) 
available to work force at the index day. The annual work disability (WD) days 
were analyzed, including all periods of sickness allowance, temporary rehabilitation 
allowance, partial disability pensions (the number of the days divided by 2), and of 
permanent disability pension from 31 days before the index day up to the end of 
follow-up, 31 Dec 2008. However, sick leaves shorter than or equal to 10 days are 
not compensated by the SII, and could thus not be assessed. The mean annual WD 
days per patient years for any reason were counted for each cohort. In this analysis 
also the patients already on partial pensions on index date were included, and the 
number of their WD days was divided by 2. During the same period permanent 
disability pensions, as well as long-term rehabilitation allowances still continuing at 
the end of our follow-up, were elucidated, including WD pensions for any reason 
and those exclusively due to RA. The follow up of the patients ended when they 
retired because of another reasons than RA, became 65 years old, or died, whichever 
the first. From the same institutes the incidence data of premature work disability 
pensions of all 18-64 year-old Finnish citizens were received. 
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8.5 Ethical considerations 
There was no legal requirement for approval by an ethics committee, since only 
unidentifiable register data were used and patients were not contacted. 
8.6 Statistical methods 
When analyzing the medications used, the statistical comparisons between 
groups were made by using analysis of variance (ANOVA) and chi-square test. 
Statistical significance for hypotheses of linearity was evaluated by Cochran-
Armitage test. In the work disability analysis the results are expressed as means with 
standard deviation (SD) and as medians with interquartile range (IQR). Statistical 
significance for hypotheses of linearity was evaluated by analysis of variance 
(ANOVA), Cochran-Armitage test. The 95% confidence intervals for annual WD 
days were obtained by bias-corrected bootstrapping and the linearity across year-
cohorts was tested by bootstrap type analysis of covariance with an appropriate 
contrast. The cumulative incidence of continuous WD was estimated and illustrated 
by Kaplan-Meier method. In order to adjust for confounding factors, the differences 
between the groups and the hypothesis of linearity were tested by using Cox’s 
regression models with a contrast, when appropriate.  Cox’s multivariate regression 
model was also used to analyse factors associated to continuous WD. The 
underlying proportional hazards assumption was tested by computing the 
Schoenfeld residuals for each of the covariates in the final model and plotting them 
against the length of survival.  The patients with RA and the population at risk were 
stratified by gender and age (in 5 year categories), and incidence rates with 95% 
confidence intervals (CI) were calculated. The ratio between observed and expected 
numbers, Standardized Incidence Ratio (SIR), was calculated with 95% confidence 
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intervals, assuming a Poisson distribution; significance for hypotheses of linearity 
was evaluated by Poisson regression models. 
 
82 
SUMMARY OF THE RESULTS 
9. Long term outcomes of the FIN-RACo strategy 
9.1 General results 
9.1.1 Demographics and baseline clinical characteristics 
Figure 1 presents a flow chart of the study patients. One-hundred ninety-nine 
patients were originally randomized to the study and 195 of these started the 
treatment, 97 in the FIN-RACo group and 98 in the SINGLE group. Two patients in 
both groups withdrew consent before receiving the first dosage of study medication. 
The 2-year follow-up was completed by 178 patients and the 5-year follow-up by 
160 patients. After the 5-year visit, 6 patients in the FIN-RACo group and 7 in the 
SINGLE group had either changed residence, were reluctant to continue the follow-
up, or had been enrolled at a center that did not participate in the study after 5 years 
(Figure 1) and therefore did not participate at the 11-year visit. During the entire 11-
year follow-up period, 6 patients in the FIN-RACo group and 9 in the SINGLE 
group had died. Thus, a total of 138 patients were assessed at the 11-year visit, 68 in 
the FIN-RACo group and 70 in the SINGLE group (I). Radiographs of hands and 
feet were available at baseline and at 11 years in 65 cases in each group (II).  
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195 early RA patients
97 combi 98 single
87 combi 91 single
Baseline
2 years
5 years
11 years
n = 78      n = 82      
n = 68      n = 70      
10 lost to follow-up
3 consent withdrawn
4 protocol violation
1 interfering illness
1 lost to follow-up
1 loss of efficacy
7 lost to follow-up
5 consent withdrawn
1 death after 2years
2 protocol violation
8 lost to follow-up
4 remission
3 refused
1 death after 9 years
1 moved
1 death
7 lost to follow-up
5 remission
1 adverse event
1 refused
1 death after 6 years
2 deaths
6 lost to follow-up
4 deaths
7 lost to follow-up
5 deaths
 
Figure 1. Flow-chart of the patients participating in the FIN-RACo study during 11 
years (I) 
 
The baseline demographic and clinical characteristics of the patients did not 
differ significantly between the groups (Table 12). The participants and the dropouts 
in both study arms had similar clinical and demographic data at baseline and at 2 
years, as well as did the dropouts of both study groups (data not shown). 
Nevertheless, a trend towards a higher mean (range) Larsen score at baseline was 
found in the SINGLE group compared to the FIN-RACo group: 5 (0-30) vs. 3 (0-25) 
(p = 0.069). Furthermore, the dropout cases in the FIN-RACo group had a higher 
mean ± SD Larsen score at baseline than the completers: 6 ± 9 vs. 3 ± 6 (p = 0.037). 
In the SINGLE group the baseline Larsen scores did not differ between the dropouts 
and the completers: 3 ± 5 vs. 5 ± 7 (P = 0.22). 
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Table 12. Baseline demographics and clinical characteristics of the original FIN-
RACo and SINGLE patients participating at the 11-year follow-up (I) 
 
Characteristic Randomization group for the 2 
initial years 
 P 
 
 
FIN-RACo 
(n = 68) 
SINGLE 
(n = 70) 
  
Demographic Data at Baseline     
   Age (years), mean ±  SD years 46 ± 9 47 ± 11  0.41 
   Female, no. (%) 42 (62) 48 (69)  0.40 
   Rheumatoid factor present (% ) 49 (72) 46 (66)  0.42 
   Duration of disease (months), median (IQR) 6 (4–9) 7 (4–12)  0.23 
Measures of Disease Activity at Baseline     
   Number of swollen joints, median (IQR) 13 (9–16) 13 (10–16)  0.84 
   Number of tender joints, median (IQR) 16 (12–22) 16 (13–24)  0.76 
   Erythrocyte sedimentation rate (mm/h), median (IQR) 27 (16–48) 33 (22–54)  0.087 
   Patient’s global assessment (VAS, mm), median (IQR) 48 (29–65) 47 (30–61)  0.84 
   Pain (VAS, mm), median (IQR) 47 (27–63) 48 (26–61)  0.64 
   Physician’s global assessment (VAS, mm), median (IQR) 38 (31–54) 43 (30–59)  0.81 
   DAS28, mean ± SD 5.39 ± 0.86 5.65 ± 1.13  0.13 
   Physical function (HAQ, range 0-3) , mean ± SD 0.82 ± 0.53 0.90 ± 0.63  0.43 
SD = standard deviation; IQR= Interquartile range; VAS = visual analog scale; DAS28 = disease 
activity score assessing 28 joints; HAQ = health assessment questionnare  
 
9.1.2 Treatment strategies after 2 years 
The treatment strategies became unrestricted after 2 years, but were still targeting 
remission. At 11 years, methotrexate was the most commonly used DMARD, 
followed by hydroxychloroquine and sulfasalazine (Table 13). At the 11-year visit, 
various combinations of synthetic DMARDs were used by 32 (47%) of the FIN-
RACo group and 32 (46%) of the SINGLE group patients. Fifteen (22%) and 23 
(33%) of the patients in the FIN-RACo therapy and SINGLE groups were using a 
single DMARD, respectively, and 13 (19%) and 10 (14%) patients no DMARDs at 
all, respectively. 
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Table 13. Antirheumatic medications used by the original FIN-RACo and SINGLE 
groups at the 11-year visit. 
 
Medications at the 11-year visit, n (%) Randomization group for the first 2 years 
 FIN-RACo 
(n = 68) 
SINGLE 
(n = 70) 
   Methotrexate 39 (57) 42 (60) 
   Hydroxychloroquine 36 (53) 26 (37) 
   Sulfasalazine 29 (43) 23 (33) 
   Leflunomide 2 (3) 7 (10) 
   Cyclosporine 1 (2) 5 (7) 
   Aurothiomalate 2 (3) 4 (6) 
   Auranofin 1 (2) 2 (3) 
   Podofyllotoxin (CPH 82) 1 (2) 2 (3) 
   Azathioprine 0 (0) 1 (1) 
   TNF-inhibitors 8 (12) 4 (6) 
   Rituximab 0 (0) 1 (1) 
   Prednisolone 22 (32) 33 (47) 
 
A biological agent was used by 8 (12%) of the patients in the original FIN-RACo 
group (in 3 patients with a DMARD-combination of and in 5 with a single 
DMARD). In the original SINGLE group, 5 (7%) of the patients were using a 
biological agent (in 2 patients with a DMARD-combination of and in 3 with a single 
DMARD). At some time between the 2-year and the 11-year visits, a combination-
DMARD strategy had been used by 62 (91%) of the patients in the original FIN-
RACo group and by 56 (80%) of the patients in the original SINGLE group (p = 
0.062). The respective figures for single-DMARD strategy were 39 (59%) of those 
in the original FIN-RACo group and 56 (80%) of those in the original SINGLE 
group.  
Twenty-two (33%) of the patients in the FIN-RACo group and 27 (39%) of those 
in the SINGLE group had been able to discontinue all DMARDs, at least 
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temporarily, during the follow-up period from year 2 to year 11. The median 
percentage of time receiving the combination-DMARD strategy between year 2 and 
year 11 was 79% (IQR 43–100) in the original FIN-RACo group and 54% (IQR 3–
94) in the original SINGLE group (p = 0.0043). The respective median percentages 
for receiving the single-DMARD strategy were 5% (IQR 0–30) and 35% (IQR 3–
67) (p < 0.001), and the respective median percentages for receiving the no-
DMARD strategy were 0% (IQR 0–6) and 0% (IQR 0–8) (p not significant).  
 
9.2 Clinical outcomes (I) 
9.2.1 ACR Remissions  
At 11 years the strict ACR remission criteria were met by 37% (95% CI: 26 to 
49) of the FIN-RACo group and by 19% (95% CI: 11 to 29) of the SINGLE group 
(p = 0.017) (Figure 2) with a significant age-, sex-, and baseline DAS28–adjusted 
treatment effect over time (P = 0.0015). When analysing the ACR remission rates at 
2, 5, and 11 years, 13% of the patients in the FIN-RACo group were in remission at 
all 3 time points, 54% at 1–2 time points, and 32% at no time points. In the SINGLE 
group, these percentages were 3%, 37%, and 60%, respectively. The difference 
between the groups was significant (p = 0.006, adjusted for age, sex, and baseline 
DAS28).  
Of the 68 patients in the FIN-RACo group participating at 11 years, 18 (26.4 %) 
had reached remission at 6 months, and of those 13 (72.2 %) were in remission also 
at 11 years. In the SINGLE group the respective proportions were 7 out of 70 (10.0 
%) and 2 out of 7 (28.6 %) (Figure 3). Thus, remission at 6 months predicted 
remission at 11 years in the FIN-RACo group [RR 3.08 (95 % CI: 1.85–5.14) 
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(p<0.001, adjusted for age and rheumatoid factor presence)], but not in the SINGLE 
group [RR 1.88 (95 % CI: 0.52–6.73) (p = 0.34)].   
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Figure 2. The percentage of patients in strict ACR-remission at the 2, 5, and 11 year 
visits. The values are presented as means with 95% confidence intervals (I). 
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Figure 3. The proportions of patients in remission at 6 months and at 11 years in the 
two original randomization groups. 
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9.2.2 Disease activity according to the modified MDA and the DAS28 
The clinical characteristics of the patients at the 11-year follow-up visit are 
shown in Table 14. Clinical disease activity was similarly low in both treatment 
groups, only the physician’s global assessment of disease activity favoured the FIN-
RACo group. Yet, at 11 years the modified MDA criteria were met more often by 
the patients in the original FIN-RACo group [63% (95% CI: 51 to 77)] than by those 
in the original SINGLE group [43% (95% CI: 32 to 55)] (p = 0.016).  
 
Table 14. Measures of disease activity at the 11-year visit in the patients 
participating in the FIN-RACo study (I) 
 
 Randomization group for the 2 
initial years 
 P 
Measures of Disease Activity at 11 years FIN-RACo 
(n = 68) 
SINGLE 
(n = 70) 
  
     
   DAS28, mean (SD)  2.48 ± 1.22 2.73 ± 1.23  0.23 
   Erythrocyte sedimentation rate (mm/h), median (IQR) 10 (6–21) 13 (6–20)  0.61 
   Number of swollen joints, median (IQR) 0 (0–3) 2 (0–4)  0.10 
   Number of tender joints, median (IQR) 1 (0–5) 2 (0–5)  0.25 
   Patient’s global assessment (VAS, mm), median      (IQR) 16 (3–35) 19 (5–36)  0.26 
   Pain (VAS, mm), median (IQR) 15 (3–30) 16 (5–34)  0.35 
   Physician’s global assessment (VAS, mm), median (IQR) 5 (1–14) 12 (3–19)  0.016 
   Physical function (HAQ, range 0-3), mean ± SD 0.34 ± 0.54 0.38 ± 0.58  0.88 
DAS28 = disease activity score assessing 28 joints; HAQ = health assessment questionnare; IQR= 
Interquartile range; SD = standard deviation; VAS = visual analog scale; 
 
At 2 years, the prevalence of the modified MDA had been 70 % (95% CI: 58 to 
81%) in the FIN-RACo group and 50 % (95% CI: 38 to 62%) in the SINGLE group. 
Had the modified MDA been present at 2 years, it was also present at 11 years in 74 
% (95 % CI: 60 to 86 %) of the FIN-RACo and in 51 % (95 % CI: 34 to 69 %) of 
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the SINGLE patients (p = 0.024, adjusted for age, sex, and baseline DAS28). Had 
MDA not been present at 2 years, the respective numbers were 35 % (95 % CI: 15 
to 59 %) and 34 % (95 % CI: 19 to 52 %) (p = 0.81) (Figure 4). In the FIN-RACo 
group the only predictive factor for MDA present at 11 years was MDA present at 2 
years (p = 0.028), but not age, sex, RF, baseline DAS or duration of combination 
DMARD treatment after 2 years. None of these factors was statistically significant 
in the SINGLE group.  
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Figure 4. Number of patients in different original randomization groups reaching 
modified minimal disease activity at the 2 and 11-year visits 
 
The mean DAS28 scores are shown in Figure 5. The treatment effect over time 
showed a significant advantage for the original FIN-RACo group as compared to the 
single group (p = 0.0022). At 2, 5, and 11 years, the mean DAS28 score in patients 
of the original FIN-RACo group was below the reported DAS28 remission limit 
(<2.6), while in those of the original SINGLE group the mean DAS28 scores 
remained in the area of low disease activity. DAS28 remission at 11 years was 
reached by 57% (95% CI: 45 to 69) of the FIN-RACo group and by 49% (95%: CI 
37 to 60) of the SINGLE group (p = 0.30).  
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Figure 5. The mean DAS28 scores at different time points in the two original 
randomization groups. The values are presented as means with 95% confidence 
intervals (I) 
 
9.2.3 Functional ability 
The HAQ scores decreased from baseline to 2 years statistically significantly in 
both treatment groups (P < 0.001), with a mean decrease of –0.56 (95% CI: –0.70 to 
–0.42) in the FIN-RACo group and –0.61 (95% CI: –0.74 to –0.47) in the SINGLE 
group. The decrease was similar in both groups, thus the age-, sex-, and baseline 
DAS28–adjusted treatment effect over time was not significant (p = 0.90) (Figure 
6). At 11 years, 56% of the patients of the FIN-RACo group and 43% of the 
SINGLE group had a HAQ score of 0 and HAQ scores >1 were present in only 10% 
and 9% of the patients, respectively (Figure 7). 
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Figure 6. HAQ scores at different time points in the two original randomization 
groups. The values are presented as means with 95% confidence intervals (I) 
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Figure 7. HAQ scores in different treatment groups at the 11-year visit (I) 
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9.3 Radiographic outcomes (II) 
9.3.1 Small joints of hands and feet 
The mean Larsen scores of hands and feet at baseline, and at 2, 5 and 11 years in 
both groups are shown in Figure 8. The crude mean change in Larsen score from 
baseline to 11 years was 17 (95% CI: 12 to 26) in the FIN-RACo group and 27 
(95% CI: 22 to 33) in the SINGLE group (p = 0.037). When using all time points (0, 
2, 5 and 11 years) and adjusting for Larsen score at baseline, the progression of 
Larsen score differed statistically significantly between the groups (p = 0.021, for 
time-by-group interaction-effect) with the FIN-RACo group having on average 
lower progression (p < 0.001, for group-effect).  
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Figure 8. A. Mean Larsen score at different time points according to the original 
randomization group. B. The mean changes in Larsen score during years 0-2, 2-5 
and 5-11 according to the initial treatment groups. The values are presented as 
means with 95% confidence intervals (II) 
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In a multivariate ordered logistic regression analysis the progression of joint 
damage in the small joints of hands and feet at 11 years was predicted by RF-
positivity at baseline and by initial SINGLE strategy (Table 15). 
 
Table 15. Multivariate ordered regression analysis of factors for radiographic 
damage in small joints after 11 years of RA (II) 
 
Variable at baseline Odds ratio (95% CI) P-value 
Female sex 1.74 (0.84 to 3.60) 0.13 
Age, years 0.99 (0.96 to 1.02) 0.60 
Disease duration before diagnosis, months 1.02 (0.94 to 1.10) 0.68 
Rheumatoid factor positivity 3.17 (1.45 to 6.92) 0.004 
Erythrocyte sedimentation rate 1.01 (0.99 to 1.02) 0.33 
Larsen score 0.99 (0.94 to 1.05) 0.77 
Initial randomization group  0.016 
       FIN-RACo 1.00 (reference)  
       SINGLE 2.39 (1.78 to 4.84)  
 
In RA patients being in remission at 1 year the crude mean change from baseline 
to 11 years in Larsen score was 10 (95% CI: 6 to 16) as compared to 25 (95% CI: 21 
to 31) in RA patients not being in remission at 1 year (p = 0.001) (Figure 9). When 
using all time points (0, 2, 5 and 11 years) and adjusting for Larsen score at 
baseline, the progression of Larsen score differed statistically significantly between 
the patients in remission and not in remission at 1 year (p < 0.001, for time-by-
group interaction-effect) with the patients in remission at 1 year having on average 
lower progression (p < 0.001, for group-effect). 
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Figure 9. The mean Larsen score at different time points in patients in remission or 
not in remission at one year regardless of the original randomization group. The 
values are presented as means with 95% confidence intervals (II) 
 
 
9.3.2 Large joints 
At 11 years, 52 patients in the FIN-RACo and 54 in SINGLE groups had all their 
large joints radiographed. Respectively, 87% (95% CI: 74 to 94) and 72% (95% CI: 
58 to 84) of these patients had no erosive changes in their large joints at 11 years 
[RR 1.22 (95% CI: 0.99 to 1.50)]. Damage to any large joint was present in 13% of 
the FIN-RACo and 28% of the SINGLE patients; the number of damaged large 
joints (Larsen score ≥ 2) did not differ between the groups (Table 16). 
9.3.2.1 Need for joint replacement therapy 
Four patients in the FIN-RACo and 5 in the SINGLE group had altogether 12 
total joint replacements (6 knees and 6 hips). The occurrence of total joint 
replacements did not differ between the FIN-RACo and the SINGLE treatment 
groups: 6% (95% CI: 2 to 16) vs. 8% (95% CI: 3 to 18) (p = 0.73) during the follow 
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up. Moreover, two total joint replacements had been performed due to primary 
osteoarthrosis of the knee and one due to hip fracture.  
 
Table 16. Radiographic damage in different large joints in the two original treatment groups 
at the 11-year visit (II) 
 
                             Original randomization group 
 FIN-RACo N = 52  SINGLE N = 54  
Radiographed joint Unilateral 
damage 
Bilateral damage  Unilateral 
damage 
Bilateral damage 
Shoulder 0 (0 %) 2 (4 %)  4 (7 %) 7 (13 %) 
Elbow 1 (2 %) 0 (0 %)  1 (2 %) 1 (2 %) 
Hip 3 (6 %) 2 (4 %)  4 (7 %) 1 (2 %) 
Knee 3 (6 %) 1 (2 %)  2 (4 %) 0 (0 %) 
 
9.4 Other results 
9.4.1 The effect of treatment strategies between 2-11 years to consequent 
outcomes 
At 11 years, there was a trend for a more frequent use of oral prednisolone in the 
SINGLE group compared to the FIN-RACo group (p = 0.076) (Table 13). However, 
it was not related to the good clinical outcomes; in the SINGLE group 15 % of the 
patients in remission and 54 % of the patients not in remission were using 
prednisolone; in the FIN-RACo the respective percentages were group 28 % and 35 
%. 
The RA patients in the original FIN-RACo group had used a combination-
DMARD strategy between 2 and 11 years more frequently than the patients in the 
original SINGLE group. This, however, had no impact on the frequency of those 
meeting the modified MDA criteria at 11 years. Those patients of the original FIN-
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RACo group who met the modified MDA criteria at 11 years and those who did not, 
had, after 2 years, received the combination-DMARD strategy for a median of 54 
months (95% CI: 46 to 62) and 108 months (95% CI: 101 to 115), respectively (p < 
0.001). For patients in the original SINGLE group, the median times were 51 
months (95% CI: 11 to 91) and 61 months (95% CI: 26 to 96) (p = 0.71), 
respectively.  
The same phenomenon could be seen regarding the radiographic results. In both 
groups, the patients in the tertile of the lowest radiological progression in hands and 
feet from years 2 to 11 (change in Larsen score 0-1) had received significantly 
shorter periods of combination-DMARD treatments between years 2 to 11 than the 
patients with intermediate (change in Larsen score 2-17) or high (change in Larsen 
score ≥18) progression rates (p = 0.001 for linearity in both treatment groups) 
(Figure 10). A similar trend was found for biological treatments in the entire study 
population; 14 patients (11 %) had received TNF-inhibitors, of these 1 had low, 5 
intermediate and 8 high radiographic progression between years 2 to 11. 
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Figure 10. Percentage of treatment time using combination DMARD strategy 
between year 2 and year 11 in patients of the original randomization groups divided 
into tertiles according to change in Larsen score of hands and feet from year 2 to 
year 11. Values are median and interquartile range. (II) 
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9.4.2 Serious adverse events  
The number of serious adverse events between years 5 to 11 did not differ 
between the patients in the original FIN-RACo group and those in the original 
SINGLE group, neither did the number of all malignancies during the 11 years 
(Table 17). 
 
Table 17. Serious adverse events between 5-11 years in the two original 
randomization groups 
 
Adverse event Original randomization group  P-value 
 
FIN-RACo 
(n=68) 
SINGLE 
(n=70) 
  
Infections 2 4  0.68 
           Chronic leg ulcer 1 0   
           Pneumonia 0 2   
           Pyelonephritis 1 1   
           Septic arthritis 0 1   
Cardiovascular 5 4  0.74 
           Acute myocardial infarct / unstable AP 1 2   
           Heart insufficiency  2 1   
           Cerebral stroke 2 1   
Malignancies  6 4  0.52 
           Acute myeloid leukemia 0 1†   
           Breast cancer 1 0   
           Colon cancer 0 2†   
           Lung cancer 1† 0   
           Lymphoma 1 0   
           Multiple myeloma 1 0   
           Pancreas cancer 1 0   
           Skin basalioma 1 0   
           Ventricular cancer 0 1   
Other (hospitalization) 3 2  0.69 
           ALT elevation 0 1   
           Recent diabetes mellitus 1 0   
           Pleuritis and pericarditis 1 0   
           Urticaria and lung reaction 0 1   
           Ventricular ulcer 1 0   
† =  death due to SAE; AP = angina pectoris; ALT = Alanine aminotransferase 
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9.4.3 Comorbidities 
The occurrence of comorbidities, such as hypertension, osteoporosis, 
cardiovascular diseases, or diabetes mellitus did not differ between the groups up to 
the follow-up of 11 years (Table 18, Figure 11). 
 
Table 18. Comorbidities recorded at the 11-year visit in both original randomization 
groups 
 
 Randomization group for the first 2 years 
Comorbidities at the 11-year visit, n (%) FIN-RACo 
(n = 68) 
 
SINGLE 
(n = 70) 
Hypertension 23 (34) 26 (37) 
Osteoporosis 14 (21) 12 (17) 
Cardiovascular diseases 10 (15) 9 (13) 
        Ischemic heart disease 6 (9) 6 (9) 
        Cerebral stroke 3 (4) 1 (1) 
        Peripheral vascular disease 0 (0) 1 (1) 
        Cardiomyopathy 1 (1) 1 (1) 
Gastrointestinal events 8 (12)  8 (11)  
Diabetes mellitus 6 (9) 6 (9) 
Pulmonary diseases 5 (7) 3 (4) 
Neurological diseases 0 (0) 2 (3) 
Psychiatric disorders 4 (6) 3 (4) 
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Figure 11. Cumulative incidence of different comorbidities in the 2 original 
treatment groups. P-values are age and sex adjusted. 
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9.4.4 Mortality 
During the whole 11-year follow-up period, a total of 15 patients had died: 6 in 
the original FIN-RACo group (6.2% [95% CI: 2.8 to 13.3]), and 9 in the original 
SINGLE group (9.2% [95% CI: 4.9 to 16.9]). The age- and sex-adjusted hazard ratio 
was 1.54 (95% CI: 0.54 to 4.39) (p = 0.42) between groups. The age- and sex-
standardized mortality ratio in the entire study group was 1.13 (95% CI: 0.64 to 
1.87). The reasons for death patients in the original FIN-RACo group were: 2 acute 
myocardial infarctions, 1 acute arrhythmia (sudden death), 1 dissection of the 
ascending aorta, 1 pneumonia and exacerbation of chronic bronchitis and 
emphysema, and 1 malignancy of the lungs, and in the original SINGLE group: 1 
acute myocardial infarction, 1 rupture of an abdominal aortic aneurysm, 1 
subarachnoid and intracerebral hemorrhage, 2 malignancies of the colon, 1 acute 
myeloid leukemia, and 3 accidental deaths.  
 
10. Results of the Finnish cohort of early rheumatoid arthritis 
10.1 General results 
Information of a total of 14 878 patients was assessed.  Of these, 9314 (62.6%) 
had received their reimbursement decision on grounds of RF positive RA and the 
rest for RF negative disease. The mean (SD) age in the entire patient cohort was 56 
(15) years and 10 117 (68.0%) patients were female. From this cohort, the annual 
incidence of RA in Finland was 44.5/100 000 (95 % CI: 43.8 to 45.2). 
10.2 The use of DMARDs in early rheumatoid arthritis in Finland (III) 
Throughout all time periods (2000-01, 2002-03, 2004-05 and 2006-07), 
methotrexate, sulfasalazine and hydroxychloroquine were the three most prescribed 
DMARDs during the first year of RA; all the other DMARDs had been prescribed 
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to a substantially smaller percentage of patients (Table 19). Sulfasalazine had been 
the most often used DMARD in 2000-01, but after that its use had decreased and 
that of hydroxychloroquine and especially of methotrexate had increased. A total of 
69% of new patients with RA received methotrexate during the first year of drug 
treatment in 2006-07. 
 
Table 19. DMARDs purchased by the Finnish RA patients during the first year after 
diagnosis (III) 
 
The use of methotrexate, sulfasalazine and hydroxychloroquine alone or in 
combinations up until 31 days after the index day, i.e., obviously as the very first 
DMARD or DMARDs (Table 20) was studied. As this very early treatment, the use 
of methotrexate alone or in combinations increased from 23.5% of the patients in 
2000-01 to 56.0% in 2006-07 (p < 0.001) (Figure 12).  Also the use of 
glucocorticoids as a very early treatment of RA increased during the follow-up.  
 
Medication during the first 
12 months 
Years  P for 
linearity 
 2000-01 
N=3739 
N (%) 
2002-03 
N=3880 
N (%) 
2004-05 
N=3631 
N (%) 
2006-07 
N=3628 
N (%) 
  
       
Methotrexate 1639 (43.8) 2079 (53.9) 2330 
(64.2) 
2505 
(69.0) 
 <0.001 
Sulfasalazine 2355 (63.0) 2355 (60.7) 2127 
(58.6) 
1975 
(54.4) 
 <0.001 
Hydroxychloroquine 1879 (50.2) 2045 (52.7) 2056 
(56.6) 
2169 
(59.8) 
 <0.001 
       
Sodium aurothiomalate 333 (8.9) 204 (5.3) 139 (3.8) 86 (2.4)  <0.001 
Auranofin 200 (5.3) 150 (3.9) 76 (2.1) 49 (1.3)  <0.001 
Leflunomide 65 (1.7) 140 (3.6) 184 (5.1) 179 (4.9)  <0.001 
Azathioprine 51 (1.4) 53 (1.4) 49 (1.3) 40 (1.1)  0.34 
Cyclosporine 52 (1.4) 51 (1.3) 43 (1.2) 28 (0.8)  0.012 
Podophyllotoxin 19 (0.5) 17 (0.4) 19 (0.5) 28 (0.8)  0.11 
Penicillamine 2 (0.1) 3 (0.1) 0 (0) 0 (0)  0.12 
Cyclophosphamide 1 (0.0) 7 (0.2) 4 (0.1) 3 (0.1)  0.73 
       
Adalimumab/Etanercept 0 (0) 13 (0.3) 58 (1.6) 38 (1.0)  <0.001 
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Table 20. Treatment with methotrexate (MTX), sulfasalazine (SASP), 
hydroxychloroquine (HCQ) and glucocorticoids GCs during the first month after 
diagnosis in Finnish RA patients (III) 
 
N.A. = not available 
During the first 3 months the treatments were generally further intensified (Table 
21).  Only 6.3 % of all patients had not purchased DMARDs during the first 3 
months and this non-compliance decreased significantly from 2000-01 to 2006-07. 
During the study period the use of early single DMARD strategy decreased and the 
use of early combination DMARD strategy increased (Table 21).  
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Figure 12. The use of methotrexate alone or in combinations during the first month 
after the RA diagnosis in different year cohorts. 
Medication  Years  P for 
linearity 
 2000-01 
N=3739 
N (%) 
2002-03 
N=3880 
N (%) 
2004-05 
N=3631 
N (%) 
2006-07 
N=3628 
N (%) 
  
Single treatment       
   MTX   352 (9.4) 392 (10.1) 464 (12.8) 708 (19.5)  <0.001 
   SASP 1113 (29.8) 1083 (27.9) 789 (21.7) 641 (17.7)  <0.001 
   HCQ 415 (11.1) 368 (9.5) 296 (8.2) 227 (6.3)  <0.001 
       
Combination treatment       
    MTX and HCQ 148 (4.0) 242 (6.2) 312 (8.6) 502 (13.8)  <0.001 
    MTX and SASP 155 (4.1) 137 (3.5) 187 (5.2) 248 (6.8)  <0.001 
    SASP and HCQ 229 (6.1) 259 (6.7) 225 (6.2) 249 (6.9)  0.34 
    MTX, SASP and HCQ 226 (6.0) 324 (8.4) 481 (13.2) 576 (15.9)  <0.001 
       
Glucocorticoids 1379 (36.9) 1591 (41.0) 1637 (45.1) N.A.  <0.001 
103 
 
Table 21. Treatment strategies used during the first 3 months after diagnosis in 
Finnish RA patients (III) 
*Two or more DMARDs 
 
Combination DMARD therapy was prescribed more often to seropositive and to 
younger patients than single DMARD treatment, whereas both genders were treated 
equally (Table 22). 
 
Table 22. Demographic factors of Finnish patients using different treatment 
strategies during the first 3 months after RA diagnosis (III) 
 
Variables No DMARDs 
N=944 
Single therapy 
N=7174 
Combination 
therapy 
N=6760 
 P value 
Female, n (%) 629 (66.6) 4867 (67.8) 4623 (68.4)  0.49 
Age, mean (SD) 54 (15) 58 (16) 55 (14)  <0.001 
Rheumatoid factor 
present, n (%) 
556 (58.9) 4207 (58.6) 4556 (67.4)  <0.001 
 
The use of the FIN-RACo combination (methotrexate, sulfasalazine and 
hydroxychloroquine) as initial treatment increased throughout the study period 
Medication  Years  P for 
linearity 
 2000-01 
N=3739 
N (%) 
2002-03 
N=3880 
N (%) 
2004-05 
N=3631 
N (%) 
2006-07 
N=3628 
N (%) 
 
  
No DMARDs 240 (6.4) 273 (7.0) 245 (6.7) 179 (4.9)  0.0072 
Single therapy 2097 (56.1) 2034 (52.4) 1606 (44.2) 1427 (39.3)  <0.001 
Combination therapy* 1402 (37.5) 1572 (40.5) 1765(48.6) 2006 (55.3)  <0.001 
   
Adalimumab/Etanercept  
      
      only TNF-inhibitor 0 (0.0) 0 (0.0) 3 (0.1) 4 (0.1)  ND 
      and one DMARD 0 (0.0) 1 (0.0) 5 (0.1) 4 (0.1)  ND 
      and DMARD  
      combination 
0 (0.0) 0 (0.0) 7 (0.2) 8 (0.2)  ND 
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(Table 20). During 2006-07 it was prescribed to 20.3 % of the patients with recent-
onset RA within the first 3 months (Figure 13). 
 
Figure 13. The proportion of Finish RA patients using the FIN-RACo combination 
during the first three months after the diagnosis (III) 
 
The use of adalimumab and etanercept during the first 3 months or even during 
the first year of RA therapy remained extremely rare throughout the study period 
(Table 19, Table 21). Reflecting the channelling bias, during the follow-up more of 
the patients who had received a combination of DMARDs during the first 3 months 
started a treatment with adalimumab or etanercept [6.7% (95% CI: 5.8 to 7.7%)] 
than of the patients who had initiated the treatment with a single DMARD [3.4% 
(95% CI: 2.8 to 4.1%)] or no DMARDs [5.7% (95% CI: 3.8 to 8.4%)] (p < 0.001, 
adjusted for age, sex, RF-positivity) (Figure 14). 
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Figure 14. The cumulative introduction of adalimumab or etanercept with regard to 
the initial antirheumatic treatment during the first 3 months. 
 
10.3 The maintenance of working ability in early rheumatoid arthritis in 
Finland (IV) 
A total of 7831 (71% female, 61% RF-positive) working-aged (18-64 years), and 
at index date full-time available to work force RA patients were identified. An 
additional cohort of 137 patients, already part-time retired at the index date, was 
included in the analysis of mean annual WD days. Table 22 presents the 
demographic data. During the follow-up, the use of combination-DMARDs during 
the first 3 months increased, while that of single-DMARD treatment decreased. The 
use of MTX, either alone or in combinations, increased. The admission of 
adalimumab or etanercept for patients remained rare (Table 22).  
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Table 22. Demographic data and initial treatment strategies of the 7831 patients 
with a recent diagnosis of RA, available to labour force at baseline (IV) 
 
Variable  Year cohort   
 
 
2000-01 
(N = 1998) 
N (%) 
2002-2003 
(N = 2043) 
N (%) 
2004-05 
(N = 1871) 
N (%) 
2006-07 
(N = 1919) 
N (%) 
Female (%) 1422 (71) 1462 (72) 1291 (69) 1377 (72) 
Age on index day, mean (SD) 45 (11) 46 (11) 47 (10) 46 (11) 
Rheumatoid factor present (%) 1135 (57) 1235 (60) 1161 (62) 1242 (65) 
     
Initial treatment (≤ 3 months)     
      No DMARDs 149 (7) 171 (8) 145 (8) 113 (6) 
      Single DMARD 1072 (53) 1004 (49) 750 (40) 708 (36) 
            MTX 166 (8) 196 (10) 243 (13) 295 (15) 
      Combination DMARDs 781 (39) 877 (43) 989 (53) 1105 (58) 
            Including MTX 502 (25) 651 (32) 801 (43) 925 (48) 
     
Etanercept or adalimumab initiated at 
any time while available to labour force 
79 (4) 84 (4) 85 (5) 29 (2) 
DMARD = disease modifying anti-rheumatic drug, MTX = methotrexate, SD = standard deviation 
 
During the first year after RA diagnosis, the mean number of annual WD days 
per patient years was similar in all year cohorts, 45-50 days per year. During the 
second year it decreased, and again increased steadily thereafter (Figure 15). During 
the second year the mean number of annual WD days per patient years decreased 
along the year cohorts (p = 0.002 for linearity, adjusted for age, sex and RF).  
When analysing the data of all cohorts during the first two years together, the 
number of the mean annual WD days per patient years was 53 in men, and 37 in 
women [mean ratio between men and women 1.42 (95 % CI: 1.28 to 1.54)], while 
45.6 (95% CI: 43.6 to 47.6) of the men and 48.2 (95% CI: 46.9 to 49.5) of the 
women had no registered WD days during the first 2 years after the RA diagnosis. 
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Figure 15. Mean annual WD days per patient years in the early RA cohorts. The 
values are presented as means with 95% confidence intervals (IV) 
 
The median (IQR) follow-up time was 4.0 (2.2 , 6.3) years.  By 8 years 14.5% 
(95% CI: 13.5 to 15.5) patients of the total patient population had prematurely 
retired due to RA. In the female population the cumulative incidence of RA 
dependent continuous WD was 12.6 % (95 % CI: 11.5 to13.7) and in males 19.2 % 
(95 % CI: 17.1 to 21.4) [age and RF adjusted HR = 0.68 (0.59 to 0.78), p <0.001] 
(Figure 16).  
During the first 2 years after the index day, the incidence of RA related 
continuous WD was 8.9 % (95 % CI: 7.7 to 10.3), 9.4 % (95 % CI: 8.2 to 10.8), 7.2 
% (95 % CI: 6.2 to 8.5), and 4.8 % (95 % CI: 3.9 to 5.9) in the year cohorts 2000-
01, 2002-03, 2004-05, and 2006-07, respectively (age, sex, and RF adjusted p < 
0.001 for linearity). Figure 17 presents the Kaplan-Meier curves for permanent WD 
in different year cohorts during the 8-year follow-up.  
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Figure 16. Kaplan-Meier curves and confidence intervals of the incidence of RA 
related work disability in the male and the female patients after the diagnosis of RA 
(IV)  
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Figure 17. Kaplan-Meier curves of the proportions of patients prematurely retired 
due to RA in different recent RA patient cohorts. In a Cox regression analysis each 
cohort had a lower risk for permanent working disability than the preceding one (p < 
0.001 for linearity) (IV) 
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In a Cox multivariate analysis for the 8-year follow up, the year cohort, higher 
age, and male gender were related to premature retirements (Table 24). In the same 
model, when single non-MTX DMARDS as initial treatment was used as reference, 
undoubtedly due to the confounding effect of indication, all the other active initial 
treatment strategies (but not no-DMARDs) significantly increased the risk of 
premature retirements. However, despite this channelling bias, etanercept and 
adalimumab appeared to protect the patients from premature retirements (Table 24). 
During the follow-up, they were prescribed to 277 patients [70 % female, mean 
(SD) age on index day 41 (12)] while still available to labour force and were started 
on average 2.6 (SD 1.8) years after the index day.  
 
Table 24. Cox multivariate regression analysis on factors predicting premature 
retirement in the Finnish early RA cohort (IV) 
 
 HR (95% CI) p-value 
   
Age 1.08 (1.07 to 1.09) <0.001 
Male 1.50 (1.30 to 1.72) <0.001 
RF present 1.10 (0.96 to 1.27) 0.18 
Year cohort  <0.001* 
  2000-01 1 (reference)  
  2002-03 0.79 (0.68 to 0.93)  
  2004-05 0.52 (0.43 to 0.63)  
  2006-07 0.36 (0.28 to 0.45)  
Medication (first 3 months)  <0.001 
  Single other  1 (reference)  
  Single MTX  1.35 (1.07 to 1.71)  
  Combi other 1.28 (1.02 to 1.62)  
  Combi including MTX 1.53 (1.29 to 1.81)  
  None 1.18 (0.89 to 1.55)  
Etanercept or adalimumab initiated at any 
time while available to labour force  
0.61 (0.39 to 0.96) 0.034 
* p for linearity 
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The incidence of premature work disability pension for any reason in the entire 
working aged Finnish population remained stable; it was 0.7 % in 2000 and 0.8% in 
2008.  When comparing our early RA population to the entire working aged Finnish 
population, the age and sex stratified standardized incidence ratio (SIR) for a 
premature disability pension was 3.16 (95 % CI: 2.97 to 3.35) and it declined along 
the year cohorts; it was 3.69 (95 % CI: 3.35 to 4.04), 3.34 (95 % CI: 2.99 to 3.71), 
2.77 (95 % CI: 2.40 to 3.19), and 2.80 (95 % CI: 2.29 to 3.39) for the year cohorts 
2000-01, 2002-03, 2004-05, and 2006-07, respectively (p for linearity < 0.001) 
(Figure 18).  
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Figure 18. The standardised incidence ratio (SIR) for a premature disability pension 
in the Finnish early RA patients compared to the general Finnish population. The 
values are presented as means with 95% confidence intervals (IV) 
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DISCUSSION 
11. General discussion 
With the perfect, curing, therapy of RA still lacking, the current treatment of RA 
should remove the inflammatory symptoms rapidly and safely, prevent permanent 
damage, and be financially available to all patients. Furthermore, as RA is a chronic, 
lifelong disease, all of these prerequisites should be met even in long-term. The 
studies on long-term (>10 years) clinical outcomes in early RA are, however, few 
and most of them have neither a definite nor an active treatment protocol, thus 
representing the course of conservatively treated RA (Jacoby et al. 1973, Corbett et 
al. 1993, Drossaers-Bakker et al. 1999, Jäntti et al. 2002, Lindqvist et al. 2002). 
Nonetheless, to justify the use of therapies potentially bothersome to the patient and 
burdening to the health care resources, long-term results of patients treated with the 
contemporary, active treatment protocol are of great importance. 
12. The FIN-RACo Trial 11-year follow-up 
12.1 Patient selection and methods 
When estimating the effects of different treatments, it is essential that the patients 
represent the true disease and that the treatment effect may be estimated. The 
patients participating in the FIN-RACo trial had a definite diagnosis of RA as they 
were fulfilling the ACR criteria, which have even been criticised for missing the 
early phases of the disease (Aletaha et al. 2010). Also, at baseline the patients had 
an active RA with a minimum of 3 swollen joints, the mean SJC being 13 in both 
groups, indicating a potentially progressive disease (Welsing et al. 2004). Thus, a 
spontaneous recovery of the symptoms is implausible (Symmons and Silman 2006) 
and the effect of different treatment strategies may reliably be estimated.  
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The baseline clinical and demographic variables were similar in both groups. 
However, for unknown reason the dropout patients in the FIN-RACo group had a 
higher Larsen score at baseline than the patients completing the study, in whom 
there was a trend towards a lower Larsen score at baseline compared to the SINGLE 
group completers. To neutralize the possible bias caused by this trend, the statistical 
analyses on radiographic outcomes were adjusted with the baseline Larsen score. 
Throughout the follow-up the functional ability was assessed with a valid 
method, the HAQ score (Wolfe 2001). For defining remission the ACR criteria 
(Pinals et al. 1981) were used, with the exclusion of the fatigue criterion and with 
the requirement of fulfilment of all the remaining criteria. Thus, a patient in 
remission had practically no signs of the disease, a very strict definition (Mäkinen et 
al. 2005a), seldom fulfilled even by normal elderly people (Sokka et al. 2007a). This 
must be kept in mind when comparing our results to those of others with less strict 
definitions of remission, such as the widely used DAS28 score below 2.6, which 
may still allow significant disease activity (Mäkinen et al. 2005b).  
Larsen score was used for the evaluation of the radiographic damage. On one 
hand, this method has been found to be less sensitive to change than the currently 
widely used Sharp/van der Heijde method (Bruynesteyn et al. 2002, Guillemin et al. 
2005), but, on the other hand, the Larsen method tends to be more specific than the 
Sharp/van der Heijde method (Bruynesteyn et al. 2002). With as long a follow-up as 
11 years, specificity was preferred over sensitivity; it is more important to 
distinguish clinically relevant from unspecific changes than to find subtle joint space 
narrowing. Also, the intraobserver reliability in Larsen score is somewhat better 
than that of the Sharp/van der Heijde method (Sharp et al. 2004, Guillemin et al. 
2005), and having had the same experienced radiologist scoring the radiographs 
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with the Larsen method throughout the follow-up, the use of this method was found 
logical. Further, to our knowledge there are no other valid methods for evaluating 
the radiographic progression in large joints besides the Larsen method.  
The extension of a trial originally planned to continue for 2 years is by no means 
without problems (Landewe 2010).  Different confounders may have affected how 
the patients are treated, as well as which patients continue the follow-up and which 
drop out of it. Thus, it is important to recognize these possible flaws, and when 
possible, try to overcome them by different statistical methods. Still, more important 
than to concentrate on the possible differences between the groups, we should 
emphasize the impact of retarding disease progression in all RA patients. After all, 
the FIN-RACo trial, launched 15 years before the rest of the world’s 
rheumatologists reached a consensus on treating RA to target (Smolen et al. 2010b), 
gives invaluable and accurate information on the results reached by such protocol in 
real life and in long-term.   
12.2 Clinical and radiographic outcomes 
In this study, after the initiation of treatment, most of the patients in both study 
groups had low HAQ scores throughout the follow-up reflecting well-preserved 
functional ability. At 11 years approximately half of the patients had a HAQ score 
of zero, having thus no disability, which is an excellent result, especially when 
keeping in mind that HAQ scores increase with age even in a normal population 
(Sokka et al. 2006). In previous long-term follow-up studies of early, conservatively 
treated RA the HAQ scores have shown an increasing course (Drossaers-Bakker et 
al. 1999, Welsing et al. 2001, Lindqvist et al. 2002). However, contemporary studies 
with shorter follow-up and active treatments with either a single DMARD (Scott 
and Strand 2002), combinations of conventional DMARDs (Boers et al. 1997, 
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Landewe et al. 2002), or biological agents (St Clair et al. 2004, Breedveld et al. 
2006) have shown functional improvement along with the induction of treatment. 
Furthermore, cross-sectional studies comparing recent RA cohorts to earlier ones 
have found a tendency toward better-preserved functional ability during the present 
time (Sokka et al. 2000, Krishnan and Fries 2003) and a predictive role of strict 
remission on protection of functional ability (Scire et al. 2011). Our results thus 
confirm the benefit from continuous active treatment strategy on preserving 
functional ability even in long-term. 
At 11 years, most of the patients in both study groups had low parameters of 
disease activity and approximately half of them achieved remission according to the 
DAS28 criteria (Prevoo et al. 1995). Even though not otherwise comparable, similar 
proportions of early RA patients treated with a combination of a biologic and MTX 
have reached the DAS28 remission in 1-2 years of follow-up (Breedveld et al. 2006, 
Emery et al. 2008).  
However, the main outcome measure of this study was the strict ACR remission, 
which was reached by a substantial proportion of the patients in both study groups at 
some point during the follow-up. The sustainability of remission was, nevertheless, 
more frequent in the FIN-RACo group, whereas never having achieved remission 
was more common in the SINGLE group. Still, even somewhat surprisingly, the 
proportion of patients in strict remission at 11 years was as high as 37 % in the FIN-
RACo group, while it was 19 % in the SINGLE group; quite similar a figure than in 
an earlier Swedish study where the proportion of patients in remission was 18 % 
after 10 years of RA (Lindqvist et al. 2002). Yet, variations between remission and 
no remission were relatively common in both treatment groups, probably because a 
considerable number of patients were near the limit of remission most of the time 
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and, coincidently on either side of the remission limit at the study visits, as 
illustrated by the disease activity parameters. This is logical, since the therapy in 
both groups was aimed at remission and the treatment armament was open. 
Nonetheless, it appears that early and active treatment is especially worthwhile, as 
the remission reached at 6 months predicted the remission in the FIN-RACo group 
even at 11 years in this study.  One more indicator of successful treatment, the 
presence of modified MDA (Wells et al. 2005), was at 11 years achieved by more 
patients in the FIN-RACo group than in the SINGLE group. Also there, the presence 
of modified MDA at 2 years predicted this outcome at the end of the follow-up, 
especially in the FIN-RACo group. 
For radiographic damage, the main finding of the present study was the low 
radiological progression in both groups compared to earlier cohorts. In a Finnish 
cohort from the Heinola Rheumatism Hospital, 103 patients with early RA starting 
from the 1970s were followed up for 20 years (Kaarela and Kautiainen 1997) and 
found to have the steepest radiographic progression during the first 8 years, even 
though it continued throughout the follow-up. In that cohort, the mean ± SD Larsen 
score at 3 years was 27 ± 21, thus comparable to that of our patients at 11 years. In 
another Finnish cohort, treated with the saw-tooth method and starting the treatment 
in 1980s the mean Larsen score was approximately 36 after 10 years and 44 (95% 
CI: 36 to52) after 15 years of RA (Tiippana-Kinnunen et al. 2011). In a Swedish 
cohort from the 1980s, 181 patients with conservatively treated early RA had at 10 
years a median Larsen score of 54 (IQR 28–80) (Lindqvist et al. 2003), thus double 
the Larsen score of our patients at 11 years. Consequently, the findings of our study 
support the analyses of Finckh et al. (2006a) who found that during the past decades 
the radiographic prognosis of RA has improved in parallel with more active 
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treatments. There are other contemporary long-term follow-up studies on 
radiographic progression in patients with early RA treated with conventional 
DMARDs, but as they have utilized the Sharp van der Heijde method, direct 
comparisons with our results are problematic (Drossaers-Bakker et al. 2002, 
Syversen et al. 2008, Hoff et al. 2009, Hafstrom et al. 2011).   
Still, even though the progression of joint damage was moderate in both groups, 
the FIN-RACo patients had significantly lower increase in the median Larsen score 
from baseline to 11 years than the SINGLE patients; and in addition to the presence 
of rheumatoid factor, only the initial SINGLE treatment predicted the radiographic 
progression at 11 years in an ordered logistic regression analysis. The main 
difference between the groups had developed during the first 2 years; after that both 
groups progressed at a similar rate; additionally, remission achieved at 1 year 
predicted a lower rate of radiographic progression in either group. The difference in 
radiographic damage may also explain the differences in the remission rates; 
radiographic damage causes tender joints and thus excludes the fulfilment of the 
remission criteria.  
These findings emphasize the effect of rapid and effective intervention; damage 
once arisen cannot be undone. The BeSt trial has produced comparable conclusions; 
even though the clinical outcomes at 5 years were similar between the 4 treatment 
arms, the radiographic damage was smaller in the 2 combination groups 
(Klarenbeek et al. 2011), in which the induction of low disease activity had 
succeeded more rapidly than in the monotherapy arms (Goekoop-Ruiterman et al. 
2005). The 11-year analysis of the COBRA trial concentrated in safety issues, but 
found also some sustained benefit on radiographs in the COBRA treatment arm (van 
Tuyl et al. 2010b). Nevertheless, the slow progression rate noted in the 
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contemporary studies raises the question of whether the law of diminishing marginal 
utility could be applied even to medicine; is it cost-effective or ethical to 
recommend exceedingly expensive and at least theoretically hazardous biological 
treatments to a large proportion of patients to achieve slightly lower progression 
rates than noted with these protocols (Yazici et al. 2009)? Undeniably, however, 
there is a minority of patients with refractory disease requiring treatment with 
biologics. 
Damage to large joints correlates with decreased functional ability (Drossaers-
Bakker et al. 2000). In the present study 87 % of the FIN-RACo and 72 % of the 
SINGLE patients had no radiographic damage in large joints. This is substantially 
less than in the few earlier long-term studies on large joint damage in early RA. In 
1997, Kuper et al. found radiographic damage in large joints in 20 % of the patients 
after 1 year of RA, and in 50 % after 6 years of RA (Kuper et al. 1997). In a Dutch 
study only 30% of the patients had no radiographic abnormalities in large joints, 54 
% of patients had at least one eroded large joint, and 14 % had at least one total joint 
replacement after 12 years of RA (Drossaers-Bakker et al. 2000). Recently, 
Tiippana-Kinnunen and colleagues published data on 86 Finnish early RA patients 
treated according to the saw-tooth method; 45 % of these patients had damage in 
large joints after 15 years of RA (Tiippana-Kinnunen et al. 2011). In the present 
study the infrequent destruction of large joints was also reflected in the small 
number of total joint replacements in both of our treatment groups compared to 
earlier cohorts (Wolfe and Zwillich 1998).    
12.3 Safety 
The results of the FIN-RACo Trial indicate that even in long-term therapy with 
combinations of conventional DMARDs is safe. No unexpected adverse effects 
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occurred in either group after 2 (Möttönen et al. 1999), 5 (Korpela et al. 2004), or 
now after 11 years of treatment. What is more, the observed mortality rate was equal 
to that in the general population, thus not increased, which is consistent with some 
previous studies (Sokka et al. 1999b, Kroot et al. 2000, van Nies et al. 2010). The 
incidence or prevalence of comorbidities did not differ either between the groups, 
not even that of osteoporosis, hypertension or type 2 diabetes, thus the possible 
adverse events of long-term GC administration. The incidence of hypertension had 
started already before the diagnosis of RA; the other comorbidities emerged after 
the RA diagnosis. The prevalence of osteoporosis, hypertension, or that of type 2 
diabetes is similar to that reported in other cohorts (Briggs et al. 2009). 
12.4 The significance of the treatment strategy 
The differences in treatment strategies between the groups lay in the use of either 
a combination of 3 DMARDs or a single DMARD during the first 2 years. 
Otherwise both groups were treated equally actively with the target in remission, 
with the medications adjusted and intra-articular as well as systemic GCs 
administered accordingly. Prednisolone was part of the initial treatment protocol in 
the FIN-RACo group, and discretionary in the SINGLE group. However, majority 
of the SINGLE group patients used prednisolone from the very beginning, and by 
the end of 2 years initial follow-up, more patients in the SINGLE group were using 
systemic GCs and had a higher cumulative dose of intra-articular GCs than in the 
FIN-RACo group (Möttönen et al. 1999).  
After 2 years the therapies could be modified without restrictions. At 11 years, 
similar treatments were used in both groups. However, partly due to the protocol 
allowing the tapering of only 1 DMARD per year in a FIN-RACo group patient with 
RA in remission, the FIN-RACo group patients used more often combination-
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DMARDs than the SINGLE group patients between 2-11 years. Another possible 
reason for this difference may have been a relative non-compliance in some 
SINGLE group patients having got used to the treatment with a single-DMARD and 
having low disease activity, even though not being in remission. Still, it appears that 
the difference in treatment strategies between 2-11 years had no impact on the 
clinical or radiographic outcomes at 11 years. In fact, in the FIN-RACo group, the 
patients achieving the modified MDA criteria at 11 years had received significantly 
less combination treatments between 2-11 years than the patients not achieving the 
modified MDA criteria at 11 years. In the SINGLE group, the treatment strategy 
between 2-11 years did not affect on the frequency of modified MDA at 11 years. 
Correspondingly, the patients with the least radiological progression after 2 years 
had used the shortest periods of combination DMARDs after 2 years. 
The short-term benefit of combining MTX, SASP, and HCQ was first 
demonstrated in established RA (O'Dell et al. 1996), but subsequently also as initial 
treatment in early disease in the FIN-RACo trial (Möttönen et al. 1999), by 
Calguneri et al. (1999), and later in a real life setting (Proudman et al. 2007). 
However, in a study by Saunders et al. (2008), stepping up to triple combination was 
as effective as initiating with it, when an otherwise active treatment strategy with 
frequent intra-articular GCs was utilized. Still, in that study, the DAS28 remission 
rates at 12 months were 45 % in the step-up group and 33 % in the initial triple-
therapy group, thus somewhat lower compared to the CIMESTRA Trial, which at 2 
years had a DAS remission rate of 50 % (Hetland et al. 2008). Further, the 5-year 
results of the CIMESTRA Trial show a DAS remission rate of 78 %, ACR 
remission rate of 56 %, while 17 % of the patients had been able to withdraw 
treatment due to remission (Hetland et al. 2010). Corresponding results were 
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achieved with the intensified COBRA strategy, having the DAS28 remission rate at 
90% at week 40 (van Tuyl et al. 2008), as well as in the Finnish NEO-RACo Trial 
(Leirisalo-Repo et al. 2008), where 100 early RA patients were treated with 
intensified FIN-RACo protocol and intraarticular GCs, and randomized to receive 
either infliximab or placebo infusions for the first 6 months. The results of this trial 
have thus far only been published in abstract form, but they show that after 2 years 
53 % of the FIN-RACo treated patients were in strict ACR remission and had a 
mean change in Sharp/van der Heijde score from baseline of 1.4. For the patients 
receiving the FIN-RACo treatment plus infliximab for the first 6 months, the 
remission rate was 70 % and the change in Sharp/van der Heijde score -0.2. The 
proportion of patients in DAS28 remission was 82 % in both groups (personal 
communication, M. Leirisalo-Repo). 
The concept of minimising the cumulative inflammation time crystallises the 
ideal contemporary treatment of RA (Kiely et al. 2009a). This approach includes 
initiating the treatment as soon as possible (Möttönen et al. 2002, van der Linden et 
al. 2010, Bosello et al. 2011), treating the disease as effectively as possible, 
monitoring the response and aiming at the lowest possible disease activity (Knevel 
et al. 2010). There is a broad consensus on the importance of these principles; 
however, the real life resources may pose limitations for their execution. Setting the 
diagnosis early is challenging, while an unequivocal diagnostic test is thus far 
lacking, and financial facts restrict the frequency of control visits as well as the 
repertoire of available medications.  
Various single DMARDs have been proven effective in clinical trials; still, in an 
individual patient, the efficacy of a given medicine may not be estimated in advance 
(Hider et al. 2009), but has to proven suitable by trial and error. And when an either 
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poorly tolerated or ineffective initial therapy has to be changed to another, valuable 
time is lost to active inflammation during the therapeutic “window of opportunity” 
in early RA. Therefore, the point of early, initial combination treatment lies in its 
sustainability; even if one DMARD has to be discontinued because of side effects, 
the patient still has another DMARD working, and at best, all the initiated 
DMARDs are tolerated and having additive efficacy. When using tight treatment 
strategy and intra-articular GCs, however, the benefit of initial combination 
treatment is diminished (Hetland et al. 2008, Saunders et al. 2008). Nonetheless, 
monthly visits to all early RA patients are seldom possible, and unfortunately not all 
rheumatologists are enthusiastic about time-consuming intra-articular injections, 
probably due to strict work schedules. The results of the FIN-RACo trial are thus in 
this respect reassuring, suggesting that possibly by utilising the initial combination 
treatment, good results may be achieved without an excess need for intraarticular or 
peroral GCs or treatment adjustments. Therefore, with real-life resources, starting 
the initial FIN-RACo combination appears to pay off, even in the long run, 
especially when the side effects are not more frequent or serious than with a single 
DMARD. Also others (Graudal and Jurgens 2010, Tosh et al. 2011), but not all 
(Katchamart et al. 2009), have settled on recommending initial combination 
treatment in early RA. 
Nevertheless, the importance of combining small-dose GCs to the other treatment 
of early RA is indisputable (Kirwan et al. 2007). Our results, as well as those of the 
COBRA 11-year follow-up (van Tuyl et al. 2010b) prove that the safety profile of 
such an approach is acceptable. However, for minimising the possible adverse 
effects, intra-articular administration of GCs may be recommended. Such strategy 
was very actively utilised in the CIMESTRA trial, which has thus far shown 
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excellent clinical results during up to 5 years of follow-up (Hetland et al. 2010). In 
the CAMERA trial the use of GCs was deliberately avoided, which may explain 
somewhat inferior results; another possible explanation for achieving mediocre 
results with a supposedly active and steered treatment strategy is allowing too high a 
disease activity before adjusting the therapy (Verstappen et al. 2007, Bakker et al. 
2011). True, significant remission and radiographic non-progression are seldom 
achieved by aiming at an improvement less than 100 %, or by targeting “low disease 
activity” measured by DAS28, a method not assessing the feet joints and, at worse, 
allowing several of the assessed joints to be swollen even in “remission” (Mäkinen 
et al. 2005b).  
Today, the FIN-RACO protocol may be criticised for starting the initial single-
DMARD treatment with SASP; possibly different results would have been achieved 
in the SINGLE group had the first DMARD been MTX. However, in 1993, when 
the FIN-RACo Trial begun, the clinical use of MTX in RA was far less common 
than today, and there were no studies showing its superiority compared to other 
DMARDs. Even a recent review (Donahue et al. 2008) found no evidence of the 
superiority of MTX in comparison with other DMARDs in clinical efficacy. More 
importantly, in the FIN-RACo Trial, the SINGLE strategy was not tied to SASP but 
to a strategy of using 1 DMARD at a time. Consequently, during the first 2 years, 52 
% of the SINGLE group patients were switched to MTX, and some of these even 
further to another DMARD (Möttönen et al. 1999).  
13. The Finnish early RA register studies 
13.1 Patient selection and methods 
The great strength of these studies is that practically all Finnish new RA patients 
were included, thus the representativeness of the data does not need to be 
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questioned. The weakness of this register-based study is the lack of clinical and 
radiographic data. Thus the medications prescribed cannot be related to the disease 
activity noted; only to the patient’s age, gender and the presence of RF. However, 
WD is one of the most significant outcomes of RA (Verstappen et al. 2004), and for 
that the current study had highly reliable and representative data. One shortcoming 
of this official registry-data is that data on short (<10 days) sick leaves were not 
available, since they are not registered by the SII. Also, for natural reasons, the 
follow-up time for the latest cohort for the assessment of continuous WD was 
shorter than for other cohorts. This was, however, controlled by statistical methods.  
The incidence of RA was in this study somewhat higher than in an earlier Finnish 
report (Kaipiainen-Seppänen and Kautiainen 2006). Thus, hardly many RA patients 
are left out of this analysis, quite the opposite. The contemporary emphasis on early 
diagnosis of RA (Puolakka et al. 2005b, Finckh et al. 2006b, van Dongen et al. 
2007, Finckh 2009) may have caused that our cohort includes patients who do not 
fulfil the ACR criteria for RA (Arnett et al. 1988), but were, due to typical clinical 
picture, the presence of ACPA, or due to some other feature, judged to represent 
very early RA by a rheumatologist, who considered the introduction of DMARD 
therapy necessary. On the other hand, the incidence of RA may truly be rising 
(Myasoedova et al. 2010). Either way, as the cohorts do not differ in size, nor in 
demographic variables, it appears that the criteria for the drug imbursement 
decisions have remained similar throughout the follow-up, and thus comparing the 
groups is justified. 
The methods of studying and reporting the use of DMARD are varying, making 
the comparison between studies challenging. However, in this study the following 
time points for analysing the DMARDs prescribed were found valid: the initial, first 
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treatment (from one month before to one month after the diagnosis); the probable 
first modification (within the first 3 months after the diagnosis); and the established 
treatment (within the first year after the diagnosis). For analysing the incidence of 
WD, the methods in different studies are also heterogeneous. In the present registry-
based study the scale and evolution of this phenomenon could be assessed with great 
accuracy, even though the reasons behind it could not.  
13.2 The use of DMARDs in Finland 
In the present study it could be found that in Finland, in accordance with national 
guidelines (Current Care Guideline 2009) and with international trends (Sokka et al. 
2008), all the indicators of treatment policy had changed towards more active ones: 
single DMARD as the most often used initial strategy was replaced by combination 
DMARDs, MTX substituted for SASP as the most used DMARD, the use of GCs 
increased somewhat and the proportion of patients not receiving DMARDs within 
the first 3 months decreased. This progression is not overly unexpected since 
Finnish rheumatologists have had a tradition of treating RA aggressively (Albers et 
al. 2001, Sokka et al. 2007b), already from 1970s (Luukkainen et al. 1977), and 
increasingly so after the publication of the favorable results of the FIN-RACo study 
(Möttönen et al. 1999, Möttönen et al. 2002, Korpela et al. 2004, Puolakka et al. 
2005a).  The participation of all the large Finnish rheumatology centers to the FIN-
RACo Trial might also explain the success of the implementation of this strategy to 
everyday practice compared to, for example, what the COBRA strategy has faced in 
the Netherlands (van Tuyl et al. 2007).  
Others, too, have found, that implementing recommendations or positive study 
results to everyday practice is not always self-evident (Kvalvik et al. 2001, 
Schmajuk et al. 2007, Kiely et al. 2009b, Tavares et al. 2011). Therefore, wide 
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feedback of the success of the current recommendations in real-life would be, in a 
sense, an assurance of their quality and, more importantly, a prerequisite for future 
actions.  
Studies from the last millennium give, in this respect, merely a historical 
perspective of the earlier treatment of RA (Berard et al. 2000, Kvalvik et al. 2001, 
Edwards et al. 2005). Of the more recent studies, the ones interviewing 
rheumatologists give an idea of the degree of agreement with the recommendations 
(Jobanputra et al. 2004, Maravic et al. 2004, Fraenkel et al. 2006). However, the 
clinicians may report more idealistic treatment strategies than the ones they actually 
use, and further, not all RA patients are treated by specialists, a fact to be taken into 
account when considering the results of smaller, hospital-based cohorts (Ward 1999, 
Kvalvik et al. 2001, Aletaha and Smolen 2002, Saraux et al. 2002, Sokka and Pincus 
2002, Carli et al. 2006, Yamanaka et al. 2007). Thus, large population based cohorts 
of RA patients would give a more realistic view of the current DMARD policy. In 
many of such studies, however, the patient populations may be heterogeneous in 
terms of disease durations (Edwards et al. 2005, Schmajuk et al. 2007, Ziegler et al. 
2010, Neovius et al. 2011a).  
The results of earlier, large cohort studies have given rather a nihilistic view on 
the treatment of RA; in the 1990s’ only 13 % (Berard et al. 2000) to 50 % (Edwards 
et al. 2005) of the patients with established RA were receiving DMARDs. More 
recent cohorts prove, however, that the situation has improved. In a private US 
clinic, the 5 practicing rheumatologists prescribed MTX as the first DMARD to 82.3 
% of the early RA patients between 1998 and 2001 (Sokka and Pincus 2002). In a 
Swedish study carried out between 1997 and 2001 in 19 different hospital clinics, 
the prescriptions of DMARDs, especially of MTX, increased, and the proportion of 
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patients with early RA not prescribed any DMARDs decreased from 32.2 % to 14.9 
% (Carli et al. 2006). The Norfolk Arthritis Register (NOAR) showed that the 
treatment of early inflammatory polyarthritis has intensified from the 1990s’ to this 
millennium, but even in the last cohort, diagnosed 2000-2004 and followed up for 5 
years, 28.1 % of the patients had never received DMARDs (Scire et al. 2011); on 
the other hand, not all of the patients had RA. In another UK cohort of early RA 
patients between 2002-2007, 97 % of the patients were initially prescribed a 
DMARD; 91 % monotherapy (51 % MTX, 41 % SASP), and 9 % combination 
therapy, and for the 33 % of the patients requiring treatment intensification, 52 % 
were prescribed sequential monotherapy and 48 % step-up combination therapy 
(Kiely et al. 2009b). For patients with established RA, in 2000-2006, in a single-
institute-based Japanese cohort the use of DMARDs increased from 82.2 % to 89.6 
%, and the proportion of MTX users increased from 33.9% to 58.7% (Yamanaka et 
al. 2007). A very large German study on cross-sectional cohorts of altogether 38 723 
patients with established RA between 1997-2007 showed that the proportion of 
patients receiving no DMARDs remained quite stably at 15 %, the proportion of 
patients on DMARD monotherapy decreased from 74.3 % to 61.8 %, and on 
DMARD combinations increased from 7.5 % to 22.3 % (Ziegler et al. 2010). The 
use of MTX was approximately 56 % throughout the follow-up, and approximately 
half of the patients were using GCs, but the proportion of patients using GC only 
increased from 5 to 8 %. Biologics were not available at the beginning of the study, 
but were used by 16 % of the patients in the latest cohort. In an even larger study, 
Neovius et al. analyzed the data of 58 102 prevalent Swedish RA patients, and 
reported that during the preceding 3 years, 76 % of the patients had been treated 
with DMARDs, GCs or biologics; thus 24 % had not received any antirheumatic 
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treatment during that time (Neovius et al. 2011a). The penetration of DMARDs or 
biologics also decreased with age, a finding in accordance with others (Fraenkel et 
al. 2006), and seen also in our results. To conclude, even during the present era 
marked national variations in the treatment of RA exist, but worldwide the strategy 
has unquestionably changed towards a more active one.  
Compared to the above-mentioned results of others, the Finnish rheumatologists 
appear to treat early RA remarkably actively. Especially the use of initial DMARD 
combinations is markedly higher than in any other reports. Thus, it appears that the 
FIN-RACo philosophy to treat the patient early, to use initial DMARD-
combinations and low dose GC, and to target true remission has gained ground 
throughout Finland. Supposedly the good clinical results achieved by this strategy 
have also caused many Finnish rheumatologists (Current Care Guideline 2009) to 
shun the straightforward EULAR recommendation of inducing a biologic to a 
patient failing single MTX (Smolen et al. 2010a), even though the need of biological 
intervention is recognised in a patient failing treatment with a combination of 
DMARDs including MTX (Current Care Guideline 2009).  
13.3 Working ability 
In this study it could be found that the frequency of permanent disability 
pensions due to early RA in Finland has declined during this millennium. At the 
same time the incidence of all disability pensions in the Finnish population has 
remained stable. The reason for this favourable development could not be solved by 
this study, but it has occurred in parallel with increasingly active treatment strategies 
used for early RA, as well as with altered legislation prioritizing vocational 
rehabilitation over permanent WD pension.  
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The rates of permanent WD in earlier cohorts of RA patients have been 
approximately 20 % after 2 years, and 50 % after 5 years of RA (Verstappen et al. 
2004), higher in European studies (Doeglas et al. 1995, Mau et al. 1996, Fex et al. 
1998, van Jaarsveld et al. 1998, Albers et al. 1999, Barrett et al. 2000, Chorus et al. 
2000, Young et al. 2002, Mau et al. 2005, Björk et al. 2009) than in North-American 
ones (Mitchell et al. 1988, Yelin 1992, Wolfe et al. 2007a, Allaire et al. 2008a). In 
Finland the incidence of WD in the 1980s was 40% in the patients after 5 years of 
RA duration, 50 % after 10 years, and 67 % after 15 years of RA (Mäkisara and 
Mäkisara 1982). Younger age, light work, extensive education and vocational 
training significantly protected the patients’ working ability. Nissilä and co-workers 
studied prospectively another Finnish cohort of 107 patients with recent RA, starting 
from the 1970s’ and found that after 3 years’ disease duration 32 % of the patients 
were permanently work disabled due to their disease (Nissilä et al. 1983). In a 
follow-up study of the aforementioned material, Kaarela et al. found that 43 % of 
the patients had retired due to RA by the 8-year follow-up visit, 7 % due to other 
diseases and 8 % had limited work capacity (Kaarela et al. 1987). Strenuous work, 
higher age and severe RA were associated with work disability. Further, on the same 
Heinola Follow-up Survey, Jäntti and colleagues published the 20 year follow-up 
data and found the incidence of work disability by that time to be 80 % (Jäntti et al. 
1999). Sokka et al. studied prospectively a cohort of 86 gainfully employed patients 
with early RA diagnosed during the 1980s (Sokka et al. 1999a). Two years after the 
disease onset 23 % of the patients had retired due to RA, and 10 years after the 
diagnosis 38 % of the patients had become work disabled. The fastest decline in the 
loss of working ability took place during the first 2 years. In the Cox regression 
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analysis, baseline risk factors for later work disability were a physically demanding 
job, higher age and higher number of swollen joints.  
In addition to the disease-dependent factors, the national differences in social 
security systems play an important role in explaining the different rates of WD in 
RA. Chung et al. compared a Finnish cohort of 364 working aged and working RA 
patients to a US cohort of 269 similar RA patients and found the probability to 
continue working 1, 2, 3 and 4 years after the RA diagnosis to be 92 %, 86 %, 84 % 
and 80 % in Finland and 92 %, 89 %, 89 % and 84 % in the US, respectively 
(Chung et al. 2006). The figures were thus lower than in previous studies, but still, 
after adjustment, 2.6-fold higher in Finland than in the US, even though the Finnish 
RA patients had better functional capacity and global status as well as less pain than 
the US patients. In the US, only clearly elevated pain score or patients global 
assessment at baseline and non-Caucasian race were risk factors for work disability, 
while in Finland higher age, non-sedentary work, lower education, use of 
methotrexate or prednisolone, as well as elevated pain, fatigue and global 
assessment scores and MHAQ at follow-up were associated with an increased risk 
for work disability. Similar differences between countries were found in the 
Quantitative Standard Monitoring of Patients with Rheumatoid Arthritis (QUEST-
RA) trial, where the authors collected cross-sectional data of 8039 RA patients from 
32 countries (Sokka et al. 2010). In this study, 37 % of the patients who had been 
working at the time of the first symptoms of RA reported subsequent work disability 
due to RA. When the 1756 patients with the disease onset during this millennium 
were analysed separately, the authors found the probabilities to continue working to 
be 80 % after 2 years of RA and 68 % after 5 years, similarly in high gross domestic 
product (GDP) (>24K US dollars [USD] per capita) and low-GDP (<11K USD per 
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capita) countries. Patients who stopped working had worse clinical status than the 
ones who continued to work, in both the high- and the low-GDP countries, with the 
HAQ-score as the one most important identifier of work disability. Most 
interestingly, the patients who had become work disabled in the high-GDP countries 
had significantly better HAQ and DAS28 scores than the patients who continued to 
work in the low-GDP countries, again stressing the importance of different social 
security systems’ explanatory role.  
In a more recent US study, Allaire and colleagues assessed data of 5384 RA 
patients with a mean disease duration of 14 years form a large national databank 
between 2002-05 (Allaire et al. 2008a). Of these patients 4385 had been employed 
at disease onset. The prevalence of arthritis-attributed work cessation was 13.6 % in 
subjects with 1-3 years of disease duration, increasing to 19.0 %, 28.9 %, 28.3%, 
38.2 % and 42.2 % after a disease duration of 4-6, 9-11, 14-16, 19-21 and ≥25 years, 
respectively. On the other hand, 39 % of the patients who had stopped working at 
some time, returned later to work at least temporarily. Thus, RA still causes a 
notable menace to the patient’s working ability, but the contemporary risk may be 
lower than that in the previous decades.  
In the most recent large Swedish study, Neovius and colleagues described the 
annual sick leave days during four years before and after the diagnosis for a register-
based cohort of 3029 working-aged early RA patients diagnosed 1999-2007, and 
compared them to a matched general population. The authors found that sick leaves 
increased steadily during the preceding year before RA diagnosis peaking to 147 
days/year during the year after the diagnosis. After that the days on sick leave 
decreased while the days on disability pension increased, and a steady 19 % of the 
patients received sickness benefits for 365 days/year 1-4 years after the RA 
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diagnosis. Nevertheless, the annual WD days in these Swedish cohorts were 2-4 
times higher than in the current Finnish cohorts, and the proportion of patients not 
utilizing sick leave was lower than in our cohort. This may partly be explained by 
different criteria for sickness benefits even in the Nordic countries (Hytti 2008, 
Virjo 2008). In the Swedish study patients diagnosed in 1999 and in 2003 had a 
higher increase in days on sick leave or disability pension from the year preceding 
the diagnosis to the year after the diagnosis than the patients diagnosed in 2007; 
however, there was a similar trend in the general population reflecting a possible 
change in the society (Neovius et al. 2011b).    
Further, Ziegler et al. elucidated the trends in treatments and outcomes of 38 723 
German patients with established RA between 1997-2007 (Ziegler et al. 2010). They 
found that throughout the follow-up, in parallel with increasingly active treatments 
and better clinical outcomes, the proportion of patients requiring at least one sick-
leave during the preceding year had decreased from 39 % to 27 %, and at the same 
time the mean duration of sick-leaves had declined from 71 to 33 days. Similarly, 
the proportion of those employed of all working aged patients increased from 37 % 
to 46 % in women and from 47 % to 57 % in men. The age and sex standardised 
increase in the employment rates was 7 %, but during the same follow-up time also 
the employment rate of the general population improved making the interpretation 
of the results somewhat complicated.  
Clearly, compared to the earlier Finnish results (Mäkisara and Mäkisara 1982, 
Nissilä et al. 1983, Kaarela et al. 1987, Jäntti et al. 1999, Sokka et al. 1999a, Chung 
et al. 2006), but even to the most recent European (Ziegler et al. 2010, Neovius et al. 
2011b) and US (Allaire et al. 2008a) ones, the incidence of continuous WD during 
the first 2 years after the diagnosis found in the present study was significantly 
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lower, resembling that found in the FIN-RACo study (Puolakka et al. 2004); as the 
percentage of continuously work disabled patients at 2 years after the diagnosis was 
8.9 % for the first cohort, and as low as 4.8 % for the last cohort. Since the treatment 
strategies during the same time had become increasingly active, it would be 
tempting to claim that the decline in WD could be accredited to the aggressive 
treatments. Nonetheless, undoubtedly due to a channelling bias, the patients with the 
less effective initial treatment, i.e. single non-MTX DMARD, had a lower risk of 
WD than the patients initially treated more actively.  Still, evidently in the scale of 
clinical disease activity in early RA, the patients with a mild RA, and therefore the 
best prognosis to start with, are the ones prescribed the mildest treatments. And the 
patients receiving more aggressive treatments are the ones with an active disease 
and thus an unfavourable consequent working ability scenario (Chung et al. 2006). 
Probably, still, had these patients been treated with less effective strategies, their 
WD rates would be higher.  
Thus far the studies proving a certain traditional DMARD treatment to protect 
the RA patients’ working ability are sparse. In 1991, in a Scandinavian multi-centre 
study Borg et al. showed, that early RA patients treated double-blindly with 
auranofin had by 24 months a higher probability of continuing to work than those 
treated with placebo (Borg et al. 1991). Within the FIN-RACo trial, Puolakka and 
others found that the patients initially treated with the FIN-RACo strategy had less 
sick leave days than the patients treated with the SINGLE strategy and a smaller 
proportion of patients receiving a permanent disability pension by 5 years, even 
though after adjustment the latter difference was not statistically significant 
(Puolakka et al. 2004). However, none of the patients achieving remission at 6 
months became work disabled during 5 years (Puolakka et al. 2005a). In the 2-year 
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analysis of the BeSt study the mean worked hours per week were higher in both of 
the initial combination groups than in the sequential monotherapy or the step-up 
combination therapy groups (van den Hout et al. 2009).  
Regardless of the channelling bias discussed above, in the present study 
adalimumab and etanercept appeared to protect the patients’ working ability. 
Nonetheless, they were used infrequently, and started first after a few years from the 
diagnosis, thus the use of these biologics may, at best, explain but a very small part 
of the total decline of continuous WD in RA. The role of infliximab in this respect is 
unfortunately unclear, as the data of its use is not included in the present analysis. 
However, as all the biologics were, after their introduction, thus during the follow-
up of the present study, first reserved for RA patients with treatment-resistant and 
usually longstanding disease, their use in early RA would have been exceptional and 
thus cannot explain the current declining trend of WD in Finland. From other 
studies the effect of biologics on WD is still unclear in established RA (Yelin et al. 
2003, Wolfe et al. 2007a, Allaire et al. 2008b, Halpern et al. 2009, Augustsson et al. 
2010, Verstappen et al. 2010), as well as in early disease (Smolen et al. 2006, 
Bejarano et al. 2008). 
Another possible explanation for the declining trend in continuous WD is the 
altered legislation (Cooke 2006). In Finland, the legislation was reformed in 2004 
prioritizing vocational rehabilitation over WD pension, and transferring the 
responsibility of its organisation to the pension providers. While this may have 
affected the WD pension rates in RA patients, the rate of WD pensions in the 
general population have remained at a similar level throughout the follow-up, and 
the SIR for a premature disability pension in the early RA patients compared to the 
general Finnish population has declined during the follow-up. The current 3-fold 
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risk of premature early RA dependent disability pension found in this study is also 
remarkably lower than the 4-7-fold risk (van Jaarsveld et al. 1998, Albers et al. 
1999), not to mention the 32-fold risk (Barrett et al. 2000), found in earlier studies.  
Worth noting is, that even though the altered legislation may have prevented 
certain work disabled patients from receiving permanent WD pensions, these same 
patients would still have received temporary rehabilitation allowances, which, if still 
continuing at the end of our follow-up period, were also registered in our data as 
continuous WD. Thus, the diminishing proportion of early RA patients becoming 
work disabled under the recent years appears to represent a factual phenomenon of a 
better preserved working capacity, rather than a consequence of a redefinition of 
WD. During the first year after the diagnosis the great majority of the WD days 
were caused either by short- or by long-term sick-leaves (Puolakka et al. 2006), as, 
according to the Finnish system, persons unable to perform their usual tasks will 
first be paid a sickness allowance for up to 150 working days, then a rehabilitation 
allowance, and after that, at the earliest after one year of sick leave or rehabilitation 
allowance, a permanent disability pension. During the first year after the RA 
diagnosis the mean number of annual WD days was similar in all year cohorts, but 
during the second year after the diagnosis, when the majority of sick-leave days are 
dependent on long-term WD, the latest year cohort had a significantly lower mean 
number of annual WD days per patient years than the preceding year cohorts, a fact 
confirming the accuracy of the difference noted between the cohorts in continuous 
WD.  
The patient dependent factors behind the observed trend in WD could not be 
analyzed, as the data on clinical disease activity and radiographic changes was 
lacking, as well as that on employment and schooling details of the patients. 
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However, earlier studies have shown that the most important patient depending 
factors predicting WD are severe and long-standing RA, reduced functional ability, 
physically demanding work and older age (Verstappen et al. 2004), the latter 
confirmed also in the present study. Interestingly, male patients were found to have 
a clearly higher risk of RA related WD than females. In the FIN-RACo study, after 
5 years females had a slightly higher risk for WD compared to males (Puolakka et 
al. 2006), another study had similar findings (Kaptein et al. 2009). On the other 
hand, another study found a slightly increased risk for arthritis related WD in males 
(Badley and Wang 2001), while others have found no gender-association (Doeglas 
et al. 1995, Albers et al. 1999, Puolakka et al. 2005b, Allaire et al. 2009). According 
to Statistics Finland, 70 % of the Finnish working aged males and 71 % of females 
participated to labour force in 2008, thus a higher engagement to housekeeping and 
lesser to paid employment does not explain the lower risk for disability pensions in 
females compared to males. Nevertheless, it is possible that male workers are more 
often occupied in manual labour than female workers and therefore become more 
often work disabled.  
To conclude, the results of this study demonstrate that it is possible to decrease or 
to postpone long-term WD in patients with early RA. At the same time with this 
development the treatments used in early RA have become increasingly active. 
TNF-inhibitors contribute to preserving the patients’ working ability, but their use 
explains but a minor part of the current favourable outcome. A part of the declining 
incidence of continuous WD in early RA may be explained by legislative changes 
emphasizing vocational rehabilitation, however, these alterations do not appear to 
have affected the incidence of premature permanent WD in the total Finnish 
population and the standardised incidence ratio of RA dependent permanent WD has 
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decreased during this millennium. It is also possible, that the contemporary, active 
possibilities to treat RA towards better outcomes, have changed both the patients’ 
and the physicians’ attitudes towards the more favourable prognosis of the disease. 
Permanent WD has ceased to be a self-evident consequence of RA. 
137 
SUMMARY AND CONCLUSIONS 
 
1. Using tight clinical controls and targeting in remission results in good 
functional and clinical outcomes in most RA patients even in long-term. 
Initial therapy with a combination of DMARDs in early RA results in higher 
rates of patients achieving strict ACR remission even after 11 years of 
disease duration than initial single-DMARD therapy.  
 
2. Aiming at remission and using tight clinical controls and intraarticular GC 
injections results in low long-term radiological progression in the hand and 
feet joints, as well as in the large joints in most RA patients. Patients treated 
initially with a combination of DMARDs have less long-term radiological 
damage than those treated initially with DMARD monotherapy. Early 
remission predicts slow radiographic progression. 
 
3. During the present millennium more and more active drug treatments have 
been taken into practice in Finland. Currently, combination therapy 
including methotrexate is the most commonly prescribed treatment strategy 
for early RA. Less than 5 % of the patients are not using DMARDs within 
the first 3 months after diagnosis. 
 
 
4. In parallel with the increasingly active treatment strategies, continuous work 
disability in early RA has declined in Finland. Other possible explanations 
for this evolution are the changed legislation prioritizing vocational 
rehabilitation over disability pension as well as altered attitudes towards the 
more favourable prognosis of RA due to contemporary active treatment 
strategies. 
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The Good Initial Response to Therapy With
a Combination of Traditional Disease-Modifying
Antirheumatic Drugs Is Sustained Over Time
The Eleven-Year Results of the Finnish Rheumatoid Arthritis
Combination Therapy Trial
Vappu Rantalaiho,1 Markku Korpela,1 Pekka Hannonen,2 Hannu Kautiainen,3
Salme Ja¨rvenpa¨a¨,4 Marjatta Leirisalo-Repo,5 Markku Hakala,6 Kari Puolakka,7
Heikki Julkunen,8 Riitta Luosuja¨rvi,5 and Timo Mo¨tto¨nen,9 for the FIN-RACo Trial Group
Objective. To evaluate the evolution of functional
and clinical outcomes over 11 years in patients with
early rheumatoid arthritis (RA) initially treated with a
combination of 3 disease-modifying antirheumatic
drugs (DMARDs) or with a single DMARD.
Methods. A cohort of 199 patients with early
active RA were initially randomized to receive treatment
with a combination of methotrexate, sulfasalazine, and
hydroxychloroquine with prednisolone or treatment
with a single DMARD (initially, sulfasalazine) with or
without prednisolone. After 2 years, the drug treatment
strategy became unrestricted, but still targeted remis-
sion. At 11 years, function was assessed with the Health
Assessment Questionnaire (HAQ), and clinical out-
comes were assessed with the modified Minimal Disease
Activity (MDA) measure and the American College of
Rheumatology (ACR) criteria for remission.
Results. At 11 years, 138 patients were assessed
(68 in the combination-DMARD group and 70 in the
single-DMARD group). The mean  SD HAQ scores
were 0.34 0.54 in the combination-DMARD group and
0.38  0.58 in the single-DMARD group (P  0.88).
Modified MDA was achieved by 63% (95% confidence
interval [95% CI] 51, 77) and by 43% (95% CI 32, 55)
(P  0.016) of the combination-DMARD group and the
single-DMARD group, respectively, and ACR remission
by 37% (95% CI 26, 49) and by 19% (95% CI 11, 29)
(P  0.017), respectively.
Conclusion. Initial therapy with a combination of
DMARDs in early RA results in higher rates of patients
achieving modified MDA and strict ACR remission even
over the long term than initial single-DMARD therapy.
Targeting remission with tight clinical controls results
in good functional and clinical outcomes in most RA
patients.
Rheumatoid arthritis (RA) influences the pa-
tient’s quality of life and even the patient’s lifespan.
During the early years of RA, active inflammation limits
functional capacity, and later, progressive joint destruc-
tion may cause disability (1). Impaired working capacity
causes expenses both for the individual and for the
society. Furthermore, rates of premature death are
increased in RA patients (2).
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Recent evidence shows that early and aggressive
treatment with traditional disease-modifying antirheu-
matic drugs (DMARDs) (3–5) as well as with biologic
agents, eliminating the activity of tumor necrosis factor
 (6–8), alters the disease course in the short term.
Effective early therapy with combinations of conven-
tional DMARDs has also been shown to retard the
radiologic progression of joint damage in RA patients
and, thus, to reduce the probability of chronic disability
(9,10). However, the effects of the more aggressive
therapy on the long-term prognosis of RA patients are
unknown. Longer followup studies of RA patients re-
ceiving different treatment strategies are therefore
needed. This issue is emphasized when considering the
chronic nature of RA with the potentially high costs of
treatment as well as the considerable indirect costs.
We have previously reported that early RA pa-
tients treated with a combination of DMARDs more
frequently reached clinical remission and had less radio-
graphic progression at 2 years as compared with patients
treated with a single DMARD (4). Furthermore, despite
the change to an unrestricted treatment strategy after 2
years, less radiologic joint destruction was still present at
5 years (4,10). The good clinical response seen at 6
months in those receiving a combination of conventional
DMARDs also translated into better maintenance of
working capacity at 5 years (11,12).
The main purpose of the present study was to
examine whether the treatment strategy used during the
first 2 years had a long-term impact on the outcome of
RA as assessed by self-reported function, by clinical
disease activity determined by various disease activity
measures, as well as by death and other serious adverse
events over 11 years.
PATIENTS AND METHODS
Patients. From April 1993 to May 1995, a total of 199
DMARD-naive patients with RA of recent onset (symptom
duration 2 years; median 6 months) were admitted to this
multicenter, parallel-group, randomized study comparing the
efficacy and tolerability of treatment with either a combination
of DMARDs (methotrexate, sulfasalazine, and hydroxychloro-
quine, with prednisolone) or a single DMARD (initially,
sulfasalazine, with or without prednisolone) (4).
The patient selection criteria were as follows: fulfill-
ment of the American College of Rheumatology (ACR; for-
merly, the American Rheumatism Association) 1987 revised
criteria for RA (13), age 18–65 years, duration of symptoms
2 years, and active disease, with3 swollen joints and at least
3 of the following 4 features: either an erythrocyte sedimenta-
tion rate (ESR) 28 mm/hour or a C-reactive protein level
19 mg/liter, morning stiffness 29 minutes in duration, 5
swollen joints, and 10 tender joints.
Study design during the first 2 years. Combination-
DMARD therapy was started with methotrexate 7.5 mg/week,
sulfasalazine 500 mg twice daily, and hydroxychloroquine 300
mg/day, with prednisolone 5 mg/day, but the dosages could be
adjusted to achieve remission. The highest dosages allowed
were 15 mg/week for methotrexate, 2 gm/day for sulfasalazine,
and 10 mg/day for prednisolone. If any of the components of
the drug combination had to be discontinued for any reason, a
combination of 3 DMARDs was restarted by replacing the
discontinued DMARD with a different DMARD, as described
in detail previously (4).
Single-DMARD treatment was initiated according to
the “sawtooth” strategy (14), using sulfasalazine (2 gm/day) as
the initial drug for all patients. The dosage was allowed to be
increased to 3 gm/day, and the simultaneous use of pred-
nisolone up to 10 mg/day was allowed. If an adverse event
occurred or if the clinical response was insufficient, sulfasala-
zine was replaced with methotrexate or, after that, with a
different single DMARD.
Treatment was targeted toward remission in all pa-
tients. Intraarticular injections of glucocorticoids into inflamed
joints were allowed, based on the judgment of the attending
rheumatologist.
Study design from year 2 to year 5. After 2 years,
treatment was still aimed at achieving or maintaining remis-
sion, but the choice and use of DMARDs was unrestricted.
Thus, regardless of the original randomization group, patients
who had an insufficient response could be treated liberally with
increased dosages of DMARDs (e.g., methotrexate up to 25
mg/week orally or parenterally, sulfasalazine up to 3 gm/day)
and with DMARD combinations when clinically indicated and
tolerated. During long-term remission, however, the protocol
required drug dosages to be reduced and eventually tapered
off. The first drug to be tapered off was prednisolone. If it
could be discontinued without losing remission, other
DMARDs could be tapered down, 1 DMARD per year, by
gradually reducing the dosage. If the RA was reactivated, the
last medication and dosage at which remission was maintained
was reinstituted (10).
Study design after 5 years. After 5 years, most of the
patients were followed up at the original participating centers
by the same rheumatologist and were treated according to his
or her clinical judgment. The treatment was still targeted
toward remission. As a consequence, depending on the clinical
situation, the drug therapies of the study patients could vary
from no DMARDs or prednisolone to a combination of
DMARDs as well as to biologic agents. All patients who had
participated in the 5-year followup survey were invited to
participate in the 11-year followup visit.
Clinical assessments. All clinical assessments were
performed by the treating rheumatologist. Outcome measures
included the patient’s self report of physical functioning and
assessment of RA clinical activity, as well as the indices of
disease activity required to determine the frequency of remis-
sions. The medications used by the patients were recorded at
each study visit. DMARD strategies used between year 2 and
year 11 were carefully elucidated based on the patient’s self
report and his or her medical records. Serious adverse events,
including death, malignant disorders, any life-threatening
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event, and any event that necessitated hospital admission,
among the patients participating in the 11-year followup were
recorded. The vital status of all patients in whom the study
medication was initiated was determined by inquiry from the
Local Register Office. Death certificates for all deceased
patients were obtained from the office of Statistics Finland.
Functional capacity was assessed with the Health As-
sessment Questionnaire (HAQ) (15). Clinical activity of RA
was assessed with the Disease Activity Score 28-joint assess-
ment (DAS28) (16), which was calculated with the following
formula:
DAS28 
0.56  TJC28  0.28  SJC28  0.70 
lnESR  0.014  GH
where TJC28 represents the tender joint count in 28 joints,
SJC28 represents the swollen joint count in 28 joints, and GH
represents general health.
Criteria for the modified Minimal Disease Activity
(MDA) (17) were no swollen joints, no tender joints, and an
ESR 10 mm/hour or fulfillment of at least 5 of the following
7 criteria: swollen joint count 1 (range 0–52), tender joint
count 1 (range 0–52), HAQ score 0.5 (range 0–3), visual
analog scale (0–100-mm scale) score for pain 20, for the
patient’s global assessment of disease activity 20, and for the
physician’s global assessment of disease activity 15, and an
ESR 20 mm/hour. Use of a 52-joint count of tender and
swollen joints instead of the 28-joint count used in the original
analysis (17) made our modified criteria more stringent.
Remission was defined as fulfillment of 5 of the ACR
criteria (18), excluding fatigue and duration of remission.
Thus, a patient whose RA was designated as being in remission
could not have any tender or painful joints, no swollen joints or
tendon sheaths, no elevation of the ESR (normal 30 mm/
hour in women and 20 mm/hour in men), and a duration of
morning stiffness of 15 minutes. Remission according to the
DAS28 was defined as score of 2.6 (19).
Ethical considerations. The study was performed ac-
cording to the principles of the Declaration of Helsinki. The
protocol was approved by the national health authorities and
ethics committees of all 18 participating hospitals. All patients
gave written informed consent.
Statistical analysis. Results are presented as the
mean SD, the median with the interquartile range (IQR), or
counts with percentages. The 95% confidence intervals (95%
CIs) are given for the most important outcomes. Statistical
comparison between groups was performed with the t-test,
permutation test, chi-square test, or Fisher’s exact test, as
appropriate. Repeated measures for continuous and binary
outcomes were analyzed using generalized estimating equation
(GEE) models with the exchangeable correlation structure.
GEE models do not require complete data and can be fit even
when individuals do not have observations at all time points.
The Cox proportional hazards model was used to estimate age-
and sex-adjusted risk of death between groups. The standard-
ized mortality ratio (i.e., the ratio of observed to expected
deaths) was calculated using the subject-years method with
95% CIs, assuming a Poisson distribution. Probabilities of
survival in an age- and sex-matched sample of the general
population between 1993 and 2006 were calculated from data
from the Official Statistics of Finland.
RESULTS
A flow chart of the study patients is shown in
Figure 1. Of the 199 patients originally randomized to
the study, 195 started treatment, 97 in the combination-
DMARD therapy group and 98 in the single-DMARD
therapy group (starting with sulfasalazine). In each
Figure 1. Flow chart showing the distribution of the rheumatoid arthritis
study patients from initial screening to the 11-year followup visit. Patients
were randomized at baseline to receive a combination (combi) of 3
disease-modifying antirheumatic drugs (DMARDs), consisting of meth-
otrexate, sulfasalazine, and hydroxychloroquine, with prednisolone, or to
receive a single DMARD, consisting of sulfasalazine, with or without
prednisolone. After year 2 of study, the choice of DMARDs was
unrestricted (see Patients and Methods for details).
1224 RANTALAIHO ET AL
group, 2 patients withdrew consent before receiving the
first dosage of study medication. The 2-year followup
was completed by 178 patients (4) and the 5-year
followup by 160 patients (10). Between years 5 and 11, 6
patients in the combination therapy group and 7 in the
single therapy group had changed residence, were reluc-
tant to continue the followup, or had been enrolled at a
center that did not participate in the study after 5 years
(Figure 1). During the entire 11-year followup period, a
total of 6 patients in the combination therapy group and
9 in the single therapy group had died.
Thus, a total of 138 patients were assessed at the
11-year visit, 68 in the combination therapy group and 70
in the single therapy group. The baseline demographic
and clinical characteristics of the patients were compa-
rable (Table 1). These data were comparable at baseline
and at 2 years both between the participants and the
dropouts in both study arms. Likewise, the data were
comparable between the dropouts of both study groups
(data not shown). At 2, 5, and 11 years, data for the
measured parameters were available in 96–100% of the
patients.
Self-reported physical functioning. The changes
in mean HAQ scores in the single and combination
therapy groups during the followup period are shown in
Figure 2A. The decrease in HAQ scores from baseline
to 2 years was statistically significant in both groups (P 
0.001), with a decrease of –0.56 (95% CI –0.70, –0.42) in
the combination therapy group and –0.61 (95% CI
–0.74, –0.47) in the single therapy group. The age-, sex-,
and baseline DAS28–adjusted treatment effect over
time was not significant (P  0.90). At 11 years, 56% of
the combination therapy group and 43% of the single
therapy group had a HAQ score of 0. On the other hand,
HAQ scores 1 were present in 10% and 9% of the
groups, respectively. The distributions of the HAQ
scores at the 11-year visit are shown in Figure 2B.
Disease activity according to the modified MDA
and the DAS28 and frequency of remissions according
to the DAS28 and the ACR criteria. The clinical char-
acteristics of the patients at the 11-year followup visit are
shown in Table 1. Clinical disease activity was low in
both treatment groups. The only statistically significant
difference between the groups was in the physician’s
Table 1. Demographic features at baseline and clinical characteristics at baseline and at 11 years in the 138 RA patients who participated in the
11-year followup visit, by initial randomization group*
Characteristic
Randomization group for the first 2 years
Combination-DMARD
group (n  68)
Single-DMARD
group (n  70)
Demographics at baseline
Female, no. (%) 42 (62) 48 (69)
Age, mean  SD years 46 9 47  11
Duration of RA, median (IQR) months 6 (4–9) 7 (4–12)
Rheumatoid factor, no. (%) 49 (72) 46 (66)
Measures of disease activity at baseline
DAS28, mean  SD 5.39  0.86 5.65  1.13
Erythrocyte sedimentation rate, median (IQR) mm/hour 27 (16–48) 33 (22–54)
No. of swollen joints, median (IQR) 13 (9–16) 13 (10–16)
No. of tender joints, median (IQR) 16 (12–22) 16 (13–24)
Patient’s global assessment of disease activity, by VAS, median (IQR) mm 48 (29–65) 47 (30–61)
Pain, by VAS, median (IQR) mm 47 (27–63) 48 (26–61)
Physician’s global assessment of disease activity, by VAS, median (IQR) mm 38 (31–54) 43 (30–59)
Physical function, by HAQ, mean  SD score 0.82  0.53 0.90  0.63
Measures of disease activity at 11 years
DAS28, mean  SD 2.48  1.22 2.73  1.23
Erythrocyte sedimentation rate, median (IQR) mm/hour 10 (6–21) 13 (6–20)
No. of swollen joints, median (IQR) 0 (0–3) 2 (0–4)
No. of tender joints, median (IQR) 1 (0–5) 2 (0–5)
Patient’s global assessment of disease activity, by VAS, median (IQR) mm 16 (3–35) 19 (5–36)
Pain, by VAS, median (IQR) mm 15 (3–30) 16 (5–34)
Physician’s global assessment of disease activity, by VAS, median (IQR) mm 5 (1–14) 12 (3–19)†
Physical function, by HAQ, mean  SD score 0.34 0.54 0.38  0.58
* After the first 2 years of study, the choice of disease-modifying antirheumatic drugs (DMARDs) was unrestricted (see Patients and Methods for
details). RA  rheumatoid arthritis; IQR  interquartile range; DAS28  Disease Activity Score 28-joint assessment; VAS  visual analog scale
(range 0–100 mm); HAQ  Health Assessment Questionnaire (range 0–3).
† P  0.016 versus the combination-DMARD group.
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global assessment of disease activity, which favored the
combination therapy group. However, the modified
MDA criteria were met by 63% (95% CI 51, 77) of the
patients in the original combination therapy group and
by 43% (95% CI 32, 55) of those in the original single
therapy group at 11 years (P  0.016).
The mean DAS28 scores are shown in Figure 3A.
The treatment effect over time was a significant advan-
tage in the original combination therapy group (P 
0.0022). At 2, 5, and 11 years, the mean DAS28 score in
patients randomized to combination-DMARD therapy
was below the reported DAS28 remission limit (2.6),
while in those randomized to single-DMARD therapy,
DAS28 scores remained in the area of low disease
activity. DAS28 remission at 11 years was reached by
57% (95% CI 45, 69) of the combination therapy group
and by 49% (95% CI 37, 60) of the single therapy group
(P  0.30).
Moreover, the strict ACR remission criteria were
met by 37% (95% CI 26, 49) of the combination therapy
group and by 19% (95% CI 11, 29) of the single therapy
group (P  0.017) at 11 years (Figure 3B). The age-,
sex-, and baseline DAS28–adjusted treatment effect
over time was also significant (P  0.0015). With regard
to the ACR remission rates at 2, 5, and 11 years, 13% of
the patients in the combination therapy group were in
remission at all 3 time points, 54% at 1–2 time points,
and 32% at no time points. In the single therapy group,
these percentages were 3%, 37%, and 60%, respectively.
The difference between the groups was significant (P 
0.006, adjusted for age, sex, and baseline DAS28).
Drug treatment and serious adverse events. At
11 years, methotrexate was the most commonly used
DMARD, followed by hydroxychloroquine and sul-
fasalazine. The DMARDs in use at the 11-year visit are
shown in Table 2. At the 11-year visit, 32 (47%) of the
combination therapy group and 32 (46%) of the single
therapy group were taking various combinations of
traditional DMARDs. A single DMARD was taken by
15 (22%) and 23 (33%) of the patients in the original
combination therapy and single therapy groups, respec-
tively, and no DMARDs by 13 (19%) and 10 (14%)
patients, respectively. A biologic agent was taken by 8
(12%) of the patients in the original combination ther-
apy group; in 3 patients, this was taken with a combina-
tion of DMARDs and in 5 with a single DMARD. In the
original single therapy group, 5 (7%) of the patients
were taking a biologic agent; in 2 patients, this was taken
with a combination of DMARDs and in 3 with a single
DMARD.
Figure 2. Health Assessment Questionnaire (HAQ) scores in the rheumatoid arthritis study patients. A, HAQ scores at baseline and
at 2, 5, and 11 years in patients randomized to receive a combination (Combi) of disease-modifying antirheumatic drugs (DMARDs)
or a single DMARD. HAQ scores were adjusted for age, sex, and baseline Disease Activity Score 28-joint assessment. Values are the
mean and 95% confidence interval. B, Distribution of HAQ scores at the 11-year followup visit. Values are the percentages of patients
without disability (HAQ score 0) and the percentages with mild, moderate, or severe disability.
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At some time between the 2-year and the 11-year
visits, a combination-DMARD strategy had been used
by 62 (91%) of the patients in the original combination
therapy group and by 56 (80%) of the patients in the
original single therapy group (P 0.062). The respective
figures for single-DMARD strategy were 39 (57%) of
those in the original combination therapy group and 56
(80%) of those in the original single therapy group.
Twenty-two (32%) of the patients in the combination
group and 27 (39%) of those in the single group had
been able to discontinue all DMARDs, at least tempo-
rarily, during the followup period from year 2 to year 11.
The median percentage of time receiving the
combination-DMARD strategy between year 2 and year
11 was 79% (IQR 43–100) in the original combination
therapy group and 54% (IQR 3–94) in the original single
therapy group (P  0.0043). The respective median
percentages for receiving the single-DMARD strategy
were 5% (IQR 0–30) and 35% (IQR 3–67) (P  0.001),
and the respective median percentages for receiving the
no-DMARD strategy were 0% (IQR 0–6) and 0% (IQR
0–8) (P not significant).
The more frequent use of the combination-
DMARD strategy between 2 and 11 years in the original
combination therapy group, however, had no impact on
the frequency of those who met the modified MDA
criteria at 11 years. Patients in the original combination
Figure 3. Scores on the Disease Activity Score 28-joint assessment (DAS28) and percentages of patients whose rheumatoid arthritis (RA)
was in remission according to the American College of Rheumatology (ACR) criteria. A, DAS28 scores at baseline and at 2, 5, and 11 years
in patients randomized to receive a combination (Combi) of disease-modifying antirheumatic drugs (DMARDs) or a single DMARD.
Values are the mean and 95% confidence interval. Values under the lower broken line (score of 2.6) represent DAS28 remission; values
under the upper broken line (score of 3.2) represent low disease activity. B, Proportions of patients randomized to receive combination
therapy or single therapy whose RA was in strict remission according to the ACR criteria at 2, 5, and 11 years, as well as the proportion of
patients whose RA was in strict remission at any of these visits. Values are the mean and 95% confidence interval.
Table 2. Medications in the 138 rheumatoid arthritis patients who
participated in the 11-year followup visit, by initial randomization
group*
Medications at
the 11-year visit
Randomization group for the first 2 years
Combination-DMARD
group (n  68)
Single-DMARD
group (n  70)
Methotrexate 39 (57) 42 (60)
Hydroxychloroquine 36 (53) 26 (37)
Sulfasalazine 29 (43) 23 (33)
Leflunomide 2 (3) 7 (10)
Aurothiomalate 2 (3) 4 (6)
Cyclosporine 1 (2) 5 (7)
Auranofin 1 (2) 2 (3)
Podophyllotoxin
(CPH 82)
1 (2) 2 (3)
Azathioprine 0 (0) 1 (1)
TNF inhibitors 8 (12) 4 (6)
Rituximab 0 (0) 1 (1)
Prednisolone 22 (32) 33 (47)
* After the first 2 years of study, the choice of disease-modifying
antirheumatic drugs (DMARDs) was unrestricted (see Patients and
Methods for details). TNF  tumor necrosis factor.
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therapy group who met the modified MDA criteria at 11
years and those who did not had received the
combination-DMARD strategy (after 2 years) for a
median of 54 months (95% CI 46, 62) and 108 months
(95% CI 101, 115), respectively (P 0.001). For patients
in the original single therapy group, the median times
were 51 months (95% CI 11, 91) and 61 months (95% CI
26, 96) (P  0.71), respectively.
The number of serious adverse events between
year 5 and year 11 did not differ between the patients in
the original combination therapy group and those in the
original single therapy group. There were 3 serious
infections in the combination therapy group and 4 in the
single therapy group. Cardiovascular events occurred in
9 and 7 patients, respectively, and other serious adverse
events occurred in 3 and 5 patients, respectively. The
number of all malignancies during the 11 years was
similar in the 2 study groups, with 6 in the original
combination therapy group and 4 in the original single
therapy group.
Mortality rates. During the 11-year followup
period, a total of 6 patients in the original combination
therapy group (6.2% [95% CI 2.8, 13.3]) died: 2 of acute
myocardial infarction, 1 of acute arrhythmia (sudden
death), 1 of dissection of the ascending aorta, 1 of
pneumonia and exacerbation of chronic bronchitis and
emphysema, and 1 of malignancy of the lungs. During
the same time period, a total of 9 patients in the original
single therapy group (9.2% [95% CI 4.9, 16.9]) died: 1 of
acute myocardial infarction, 1 of rupture of an abdom-
inal aortic aneurysm, 1 of subarachnoid and intracere-
bral hemorrhage, 2 of malignancy of the colon, 1 of
acute myeloid leukemia, and 3 died in accidents. The
age- and sex-adjusted hazard ratio was 1.54 (95% CI
0.54, 4.39) (P  0.42) between groups. The age- and
sex-standardized mortality ratio in the entire study
group was 1.13 (95% CI 0.64, 1.87).
DISCUSSION
The present followup study shows that in patients
with clinically active early RA, initial therapy with a
combination of traditional DMARDs as compared with
a single DMARD translates into improved long-term
outcomes in terms of clinical disease activity and remis-
sions. Furthermore, tight clinical control with adjust-
ments in the active DMARDs and injections of intraar-
ticular corticosteroids preserves function in most of these
patients irrespective of the initial DMARD strategy.
The ideal therapy for RA would cure or induce
permanent remission of the disease. Currently, the treat-
ment of RA should reduce acute symptoms effectively
and safely, have positive effects on the long-term prog-
nosis, and be affordable. There are few truly long-term
(10 years) followup studies on early RA that include
clinical outcomes. Most of these studies have neither a
definite nor an active treatment protocol, and the results
can be considered to represent the course of conserva-
tively treated RA (20–24).
The management of RA should consist of more
than choosing between various DMARDs. It should be
targeted toward remission (as in the treatment of malig-
nancies) and should be guided by tight control (as in the
treatment of diabetes mellitus). In the present study, we
compared the effects of 2 different initial treatment
strategies, both of which were targeted toward remission
at all time points. The same rheumatologists provided
followup care over the course of the study, made prede-
termined treatment adjustments, and gave intraarticular
glucocorticoid injections whenever needed. This treat-
ment policy likely resulted in the observed excellent
outcome in the HAQ scores of most of the patients in
both study groups.
Other studies of early RA with long-term fol-
lowup but with more conservative treatment strategies
have shown a constantly deteriorating course of the
HAQ scores (22,24). However, studies with shorter
followup periods and active strategies using a single
DMARD (25), combinations of conventional DMARDs
(3,9), or biologic agents (6,7) have actually shown func-
tional improvement. In addition, cross-sectional studies
comparing earlier and more recent cohorts of RA
patients have found a tendency toward better function
during the present era, when active DMARD treatment
is prevalent (26,27). In our study, the HAQ score
decreased after the initiation of DMARD treatment and
remained low throughout the entire followup period in
both study groups. We emphasize that after 11 years of
RA, half of our patients had no disability according to
the HAQ score, a finding that is in notable contrast with
previously described cohorts (22,24).
After 11 years of RA, the parameters reflecting
clinical disease activity also remained low in most of the
patients in both study groups. The differences between
the patients in the single-DMARD group and those in
the combination-DMARD group were small when each
parameter was examined separately. Taken together,
however, more patients in the combination therapy
group than in the single therapy group achieved the
modified MDA criteria. For our modification of the
MDA criteria, we used a method that applied a 52-joint
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count instead of the 28-joint count used in the original
analysis (17), which makes our criteria even more strin-
gent than the original MDA criteria. The proportions of
patients who achieved remission according to the
DAS28 criteria were also rather high in both study
groups, although patients in the combination therapy
group had more favorable DAS28 scores over time than
did those in the single therapy group.
Our requirement for strict adherence to the ACR
remission criteria allowed for practically no signs of
disease (28). A substantial proportion of the patients in
both study groups reached this rigorous target at some
point in the study. However, in contrast to the 5-year
results, the proportion of patients whose RA was in
remission at 11 years was significantly higher in the
combination therapy group than in the single therapy
group. The sustainability of remission was more fre-
quent in the combination therapy group, whereas never
having achieved remission according to the ACR criteria
was more characteristic of the single therapy group.
Nevertheless, fluctuations between remission and no
remission were rather common in both treatment
groups. The most plausible explanation for this fluctua-
tion is the fact that a substantial number of patients were
near the limit of remission most of the time and, by
chance, either above or below the remission limit at the
study visits, as shown by DAS28 values as well as the
individual parameters reflecting disease activity. How-
ever, the odds of being in remission at the followup visits
were in favor of the combination treatment group.
The use of DMARDs between year 2 and year 11
differed between groups, with combination treatments
used more often in the original combination therapy
group. This difference is due, on the one hand, to the
protocol, which allowed the tapering of only 1 DMARD
per year in a combination group patient whose RA was
in remission. On the other hand, the investigators may
not have intensified the medications in a noncompliant
single-DMARD group patient who was “doing fine,” but
whose RA was not in remission. However, this had no
impact on the clinical outcome at 11 years. In fact, in the
combination therapy group, the patients who had met
the modified MDA criteria at 11 years had received
significantly less combination treatments between 2
years and 11 years than the patients who did not meet
the modified MDA criteria at 11 years. In the single-
DMARD group, the treatment strategy between 2 and
11 years had no impact on the number of patients who
met the modified MDA criteria at 11 years. At the end
of the followup, comparable antirheumatic drugs were
used irrespective of the initial group allocation. Hence,
the most plausible explanation for the higher remission
rate during years 2–11 in the combination therapy group
is the more intensive initial drug treatment and not the
current medication.
This study illuminates the long-term outcome of
early RA when starting the initial single-DMARD treat-
ment with sulfasalazine. It can be hypothesized that
different results would have been achieved in the single-
DMARD group had the first DMARD been methotrex-
ate. In 1993, when this study was begun, the clinical use
of methotrexate in RA was far rarer than today, and
there were no studies showing its superiority compared
with other DMARDs. Even a recent review (29) found
no evidence of the superiority of methotrexate in com-
parison with other DMARDs in terms of clinical effi-
cacy. In our study, the single-DMARD strategy was not
tied to sulfasalazine but to a strategy of using 1 DMARD
at a time. During the first 2 years, 52% of patients in the
single-DMARD group were switched to methotrexate,
and some of these patients were further switched to
another DMARD (4).
Thus, it seems to us that the superiority of the
initial combination treatment may be explained by its
sustainability. In the combination therapy group, even if
1 DMARD had to be stopped because of side effects,
the patient still had at least 1 other DMARD working.
This strategy guaranteed continuing treatment during
the therapeutic window of opportunity in early RA.
The present study indicates that even long-term
therapy with combinations of conventional DMARDs is
safe. No unexpected adverse effects were found in either
group after 2 (4), 5 (10), or 11 years of treatment. Also,
the observed mortality rate was equal to that in the
general population. This finding is consistent with those
of some previous studies (30,31).
Our results highlight the concept of a window of
opportunity for treatment in RA (32). The short-term
advantages of early, tight control of RA have been
demonstrated by Scottish (33) and Danish (34,35) stud-
ies. The present study shows that the consequences of
effective initial treatment extend from sustained low
levels of disease activity and preserved functional capac-
ity to normal life expectancy.
The FIN-RACo (Finnish Rheumatoid Arthritis
Combination Therapy) trial is the first published con-
trolled study of a treatment strategy for RA in which
remission was the primary target. Furthermore, the
definition of remission we applied allowed for no signs
of disease activity. More recently, probably due to the
increased options of biologic agents in the treatment of
RA, remission as the treatment goal has been widely
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accepted. Early strict remission predicts preserved work-
ing capacity (12), but the value of more liberal remission
levels and the value of strict remission during late
disease remain to be proven.
In summary, the natural course of RA can be
altered with active DMARD treatment. When the ther-
apy is targeted toward remission and the disease is kept
under tight control, which means adjustments to active
treatment and intraarticular injections of glucocorticoids
when needed, even by starting drug therapy with a single
DMARD, the prognosis is better than that in patients
described in previous cohorts. However, it is difficult to
see why rheumatologists and RA patients should settle
for single-DMARD therapy, when by starting with a
combination of DMARDs, superior results are achieved
without an increase in the number of adverse events.
The combination of methotrexate, sulfasalazine, and
hydroxychloroquine along with low-dose prednisolone,
however, is not the ultimate, perfect treatment of early
RA, since it does not cure the disease or produce
sustained remission in all patients. Still, in real life, this
combination is satisfactory for most patients and, even
more importantly, is economically available for a large
number of patients worldwide (36). The ideal treatment
strategy for the patients in whom this protocol fails
remains to be determined by other studies.
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Abstract
Introduction: Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage 
for a period of up to 5 years. The aim of this study was to evaluate the radiologic progression beyond that time in 
patients with early RA initially treated with a combination of three disease-modifying antirheumatic drugs (DMARDs) or 
a single DMARD.
Methods: A cohort of 199 patients with early active RA were initially randomized to receive treatment with a 
combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone (FIN-RACo), or treatment with 
a single DMARD (initially, sulfasalazine) with or without prednisolone (SINGLE). After 2 years, the drug-treatment 
strategy became unrestricted, but still targeted remission. The radiographs of hands and feet were analyzed by using 
the Larsen score at baseline, 2, 5, and 11 years, and the radiographs of large joints, at 11 years.
Results: Sixty-five patients in the FIN-RACo and 65 in the SINGLE group had radiographs of hands and feet available at 
baseline and at 11 years. The mean change from baseline to 11 years in Larsen score was 17 (95% CI, 12 to 26) in the 
FIN-RACo group and 27 (95% CI, 22 to 33) in the SINGLE group (P = 0.037). In total, 87% (95% CI, 74 to 94) and 72% (95% 
CI, 58 to 84) of the patients in the FIN-RACo and the SINGLE treatment arms, respectively, had no erosive changes in 
large joints at 11 years.
Conclusions: Targeting to remission with tight clinical controls results in low radiologic progression in most RA 
patients. Patients treated initially with a combination of DMARDs have less long-term radiologic damage than do those 
treated initially with DMARD monotherapy.
 Trial registration : Current Controlled Trials ISRCTN18445519.
Introduction
Conservatively treated cohorts of rheumatoid arthritis
(RA) patients have shown a constant deterioration of
joint integrity [1,2]. However, treatment with traditional
disease-modifying antirheumatic drugs (DMARDs) alone
or in combinations [3,4] with glucocorticoids [5] as well
as with biologic agents [6-9] has been shown to retard the
progression of joint damage. Early therapy with combina-
tions of conventional DMARDs has been shown to retard
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years [4,10], but the effects of initial aggressive DMARD
therapy on radiologic prognosis after that are unknown.
We previously demonstrated that early RA patients
treated with a combination of DMARDs (methotrexate,
sulfasalazine, and hydroxychloroquine with predniso-
lone) reached, at 2 years, more often clinical remission [3]
and had less radiographic progression at 2 years [3] and at
5 years [10] than did patients initially treated with a single
DMARD. We also reported that, at 11 years, most
patients in both treatment groups had low disease activity
and well-preserved function, but the combination
DMARD-group patients reached remission more often
than did those treated initially with a single DMARD [11].
In this study, we explored the effects of initial treatment
strategy on the long-term radiographic findings at 11
years.
Materials and methods
Patients
From April 1993 to May 1995, 199 DMARD-naïve
patients with recent-onset RA were admitted to this ran-
domized study comparing the efficacy and tolerability of
treatment with either a combination of DMARDs (start-
ing with methotrexate, sulfasalazine, and hydroxychloro-
quine with prednisolone; FIN-RACo strategy) or a single
DMARD (initially sulfasalazine with or without predniso-
lone; SINGLE strategy). The treatment was targeted
toward remission in all patients. After 2 years, the treat-
ment of RA was unrestricted, but still aiming at remis-
sion. Thus, regardless of the original randomization
group, the patients could be treated liberally with
DMARDs, biologic agents, glucocorticoids, and with
their combinations, as clinically indicated and tolerated.
Conversely, in long-term remission the protocol required
drug doses to be reduced and eventually tapered off. The
patient-selection criteria and the study design were
described in detail earlier [3,10,11].
Radiologic assessment
Hands and feet of all patients were radiographed at base-
line and at 2, 5, and 11 years. Hip, knee, elbow, and shoul-
der joints of the patients were radiographed at 11 years in
13 study centers; in two study centers, only clinically
symptomatic large joints were radiographed. Total joint
replacements were counted from the radiographs as well
as from the patients' medical records. The radiographs
were assessed by the same experienced radiologist (LL),
who was blinded to the clinical data but aware of the
order of the radiographs. The radiographs of hands and
feet were scored according to the method of Larsen et al.
[12], with a range from 0 to 200. The large joints were also
scored according to the method of Larsen [12], and a
score of ≥2 was considered to indicate erosive disease.
Clinical assessments were performed by the treating
rheumatologist. DMARD strategies used between years 2
and 11 were carefully elucidated based on the patient's
self-report and his or her medical records [11].
Ethical considerations
The study was performed according to the principles of
the Declaration of Helsinki. The protocol was approved
by the national health authorities and ethics committees
in all 18 participating hospitals. All patients gave written
informed consent.
Statistical methods
The data are presented as means with standard devia-
tions (SDs), medians with interquartile ranges (IQRs), or
counts with percentages. Statistical comparison between
groups was made by t test, permutation test, χ2 test, or the
Fisher Exact test, when appropriate. The 95% confidence
intervals (95% CIs) for the Larsen score are obtained by
bias-corrected bootstrapping due to the skewed distribu-
tion. The difference in crude changes in Larsen score
between the groups was tested by a permutation test. A
random coefficient model with bootstrapped standard
errors was adapted to analyze the progression of the Lar-
sen score during 11 years and to compare the groups in
time. An ordered logistic regression analysis was used to
estimate the prediction of achieving radiologic progres-
sion. The adjusted risk ratio (RR) between the groups for
having no erosive changes in large joints was estimated by
a generalized linear model (log link), with presence of
erosion in hands or feet at baseline as covariate. A time-
to-event analysis based on the product-limit estimate of
the cumulative "survival" function (Kaplan-Meier) was
used to describe the time to the first total joint replace-
ment. A log-rank test was used to identify any survival
difference between the groups.
Results
Of the 199 patients originally randomized to the study,
195 started treatment, 97 in the FIN-RACo group, and
98, in the SINGLE group. At the 11-year visit, 68 patients
were assessed in the FIN-RACo group, and 70, in the
SINGLE group; the patients' baseline demographic and
clinical characteristics were comparable [11]. In total, 130
patients had radiographs of hands and feet available at
baseline and at 11 years, 65 cases in each group.
A trend toward a higher mean (range) Larsen score at
baseline was found in the SINGLE group compared with
the FIN-RACo group: 5 (0 to 30) versus 3 (0 to 25) (P =
0.069). Furthermore, the dropout cases in the FIN-RACo
group had a higher mean ± SD Larsen score at baseline
than did the completers: 6 ± 9 versus 3 ± 6 (P = 0.037). In
the SINGLE group, the baseline Larsen scores did not dif-
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5 ± 7 (P = 0.22).
The cumulative percentages of Larsen scores in both
groups are shown in Figure 1. One outlier in the FIN-
RACo group had progressed to almost a maximum score
after 11 years. Despite active combination DMARD treat-
ment, this patient had had high disease activity and HAQ
score throughout the follow-up, and by 11 years, also had
damage in large joints as well as one total joint replace-
ment.
The mean Larsen scores of hands and feet at baseline
and at 2, 5, and 11 years in both groups are shown in Fig-
ure 2. The crude mean change from baseline to 11 years
in Larsen score was 17 (95% CI, 12 to 26) in the FIN-
RACo group and 27 (95% CI, 22 to 33) in the SINGLE
group (P = 0.037). When using all time points (0, 2, 5, and
11 years) and adjusting for Larsen score at baseline, the
progression of Larsen score differed statistically signifi-
cantly between the groups (P = 0.021, for Time-by-Group
interaction effect), with the FIN-RACo group having on
average lower progression (P < 0.001, for Group-Effect)
(Figure 2a). In an ordered logistic regression analysis, the
extent of joint-damage progression in hands and feet at
11 years was predicted by the presence of serum rheuma-
toid factor at baseline and by the single-treatment strat-
egy for the first 2 years (Table 1).
The crude mean change from baseline to 11 years in
Larsen score was 10 (95% CI, 6 to 16) in patients who had
been in remission at 1 year and 25 (95% CI, 21 to 31) in
patients who had not been in remission at 1 year (P =
0.001). When using all time points (0, 2, 5, and 11 years)
and adjusting for Larsen score at baseline, the progres-
sion of Larsen score differed statistically significantly
between the patients in remission and not in remission at
1 year (P < 0.001, for Time-by-Group interaction effect),
with the patients in remission at 1 year having on average
lower progression (P < 0.001, for Group-Effect) (Figure
3).
At 11 years, 52 and 54 patients in FIN-RACo and in
SINGLE groups, respectively, had all the large joints
radiographed. In FIN-RACo and SINGLE groups, 87%
(95% CI, 74 to 94) and 72% (95% CI, 58 to 84), respec-
tively, of these patients had no erosive changes in large
joints at 11 years (RR, 1.22 (95% CI, 0.99 to 1.50)). The
number of damaged large joints (Larsen score, ≥2) did
not differ between the groups (Table 2).
Nine patients (four in the FIN-RACo and five in the
SINGLE group) had altogether 12 total joint replace-
ments (six knees and six hips). Of these, two arthro-
plasties had been performed because of primary
osteoarthrosis of the knee, and one, because of hip frac-
ture. The occurrence of total joint replacements did not
differ between the FIN-RACo and the SINGLE treatment
groups: 6% (95% CI, 2 to 16) versus 8% (95% CI, 3 to 18)
(P = 0.73) during the follow-up.
Treatment strategies used between 2 to 11 years were
reported previously [11]. In both groups, the patients in
the tertile of the lowest radiologic progression in hands
and feet from year 2 to year 11 (change in Larsen score, 0
to 1) had received significantly shorter periods of combi-
nation-DMARD treatments between years 2 and 11 than
did the patients with intermediate (change in Larsen
score, 2 to 17) or high (change in Larsen score, ≥18) pro-
gression rates (P = 0.001 for linearity in both treatment
groups) (Figure 4). A similar trend was found for biologic
treatments in the entire study population; 14 patients
(11%) had received TNF-inhibitors; of these, one had low;
five, intermediate; and eight, high radiographic progres-
sion between years 2 and 11.
Discussion
The main finding of the present study is that targeting to
remission with traditional DMARDs and tight clinical
controls results in low radiologic progression in most RA
patients. Still, patients treated initially with the FIN-
RACo strategy during the first 2 years have less radio-
graphic damage in small joints, even in long term than
did those treated initially with DMARD monotherapy.
Less radiographic damage is found in RA patients at
present than during previous decades [13]. In our study,
both treatment arms had excellent radiologic small-joint
outcome compared with historic cohorts. In a previous
Finnish cohort of 103 patients with early RA, beginning
in the 1970 s, the radiologic progression was steepest
Figure 1 The cumulative percentage of increase in Larsen score 
from baseline to 11 years in patients initially randomized to re-
ceive a combination (FIN-RACo) of disease-modifying antirheu-
matic drugs (DMARDs) or a single DMARD (SINGLE).
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Figure 2 The crude mean Larsen scores of hands and feet at baseline and at 2, 5, and 11 years in patients initially randomized to receive a 
combination (FIN-RACo) of disease-modifying antirheumatic drugs (DMARDs) or a single DMARD (SINGLE). (a) Included are the subjects 
scored at 11 years (two patients in each group did not have scores at 5 years). Values are expressed as the mean and 95% confidence interval. (b) The 
mean changes in Larsen score during years 0 to 2, 2 to 5, and 5 to 11, according to the initial treatment groups.
Table 1: Ordered logistic regression analysis for radiologic progression at 11 years
Variable at baseline Odds ratio (95% CI) P value
Female sex 1.74 (0.84 to 3.60) 0.13
Age, years 0.99 (0.96 to 1.02) 0.60
Disease duration before diagnosis, months 1.02 (0.94 to 1.10) 0.68
Rheumatoid factor positivity 3.17 (1.45 to 6.92) 0.004
Erythrocyte sedimentation rate 1.01 (0.99 to 1.02) 0.33
Larsen score 0.99 (0.94 to 1.05) 0.77
Initial randomization group 0.016
FIN-RACo 1.00 (reference)
SINGLE 2.39 (1.78 to 4.84)
Radiologic progression in hands and feet was determined according to the tertiles of Larsen score changes (categories 0 to 1, 2 to 17, and 
≥18). FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially 
methotrexate, sulfasalazine, and hydroxychloroquine, with prednisolone; SINGLE, study group treated for the first 2 years with one disease-
modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.
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low-up of 20 years [1]. In that cohort, the mean ± SD Lar-
sen score at 3 years was 27 ± 21, and at 15 years, 78 ± 49.
Thus, after 3 years of RA, the historic patients had com-
parable amounts of radiographic damage to the patients
of the present study at 11 years. In a Swedish cohort start-
ing in 1985, 181 patients with conservatively treated early
RA had, at 10 years, a median Larsen score of 54 (IQR, 28
to 80) [2], thus double the Larsen score of our patients at
11 years. These findings are in accordance with those of
Finckh et al. [13], who found that the radiographic prog-
nosis of RA has improved during the past decades parallel
to more active treatments.
Even though most patients had excellent radiographic
results at 11 years, the patients treated with the FIN-
RACo strategy had significantly lower increases in the
median Larsen score from baseline to 11 years than did
the SINGLE patients, and besides the presence of rheu-
matoid factor, only the initial SINGLE treatment pre-
dicted the radiographic progression at 11 years in the
ordered logistic regression analysis. The main difference
between the groups had developed during the first 2
years; after that, both groups progressed similarly. For
unknown reasons, the dropout patients in the FIN-RACo
group had a higher Larsen score at baseline than did
those cases who completed the study. Thus, in the com-
pleters of the FIN-RACo group, a trend toward a lower
Larsen score at baseline was seen compared with the
SINGLE group completers. At worst, this fact may bias
the study. However, in the statistical analysis adjusted
with baseline Larsen score, a highly significant difference
in radiologic progression was found between the groups.
Therefore, we find it justified to conclude that the
observed difference between the groups represents rather
the results of a more-effective initial DMARD treatment
strategy than a biologic bias.
For evaluating the radiographic damage, we used the
Larsen score, which has been found to be less sensitive to
change than the Sharp/van der Heijde method [14,15].
Conversely, the Larsen method tends to be more specific
than the Sharp/van der Heijde method [14], and when the
follow up is as long as 11 years, we prefer specificity over
sensitivity; it is more important to distinguish clinically
relevant from unspecific changes than to find subtle
joint-space narrowing. Also, the intraobserver reliability
in Larsen score is somewhat better than that of the
Sharp/van der Heijde method [15,16], and because we
have had the same experienced radiologist scoring the
radiographs with the Larsen method throughout the fol-
low-up, we find this method logical. To our knowledge,
no other methods exist for evaluating the radiographic
progression in large joints besides the Larsen method.
Only 13% of the FIN-RACo and 28% of the SINGLE
patients had some radiographic damage in large joints.
Few long-term studies of early RA assess large-joint dam-
age, and none of them have a definite treatment protocol.
One study, published in 1997, found radiographic damage
in large joints in 50% of the patients after 6 years of RA
[17]. In a Dutch study, 54% of patients had at least one
eroded large joint after 12 years of RA [18]. In the present
study, the infrequent destruction of large joints was also
reflected in the small number of total joint replacements
in both of our treatment groups compared with earlier
cohorts [19], even though the follow-up of 11 years is too
short to evaluate the final incidence of total joint replace-
ments.
Probably the most important precondition to our excel-
lent results in most patients was the active treatment pol-
icy aiming at remission at all time points. Even though
recent reports showed that radiologic progression may
occur even while the patient appears to be in remission
[20], most damage still emerges in clinically inflamed
joints [21]. Our results emphasize the importance of early
remission for the long-term outcome of the patients. In
the present study, the patients who had been in strict
remission at 1 year had significantly less radiologic pro-
Figure 3 The crude mean Larsen scores of hands and feet at base-
line, and at 2, 5, and 11 years in patients who had been in remis-
sion at 1 year and in patients who had not been in remission at 1 
year. Included are the subjects scored at 11 years (two patients in each 
group did not have scores at 5 years). Values are expressed as the mean 
and 95% confidence interval.
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who had not reached remission at 1 year. Remissions
were reached more often by the FIN-RACo arm patients
than by the SINGLE patients at 2 years [3], as well as at 11
years [11], but patients in both treatment arms had
mainly low disease activity and well-preserved function
throughout the follow-up [11]. This clinical profile fits
the radiologic profile of our study groups well; compared
with less aggressively treated patients, both groups were
doing well, but the FIN-RACo patients even better.
We earlier reported that during the liberal treatment
phase between years 2 and 11, the use of DMARDs dif-
fered between groups, with combination treatments used
more often in the original FIN-RACo group [11]. This
difference had, however, no impact on the clinical out-
come at 11 years. In the FIN-RACo group, the patients
who had low disease activity at 11 years had received sig-
nificantly shorter periods of combination DMARDs
between 2 and 11 years than had the patients who had
high disease activity at 11 years [11]. Similarly, in the
present study, the patients with the least radiologic pro-
gression after year 2 had received the shortest periods of
combination DMARD strategy after 2 years. These
results are in agreement with the fact that in longitudinal
observational studies, the cases treated most intensively
are the most likely ones to have the most severe disease
[22]. And yet, aggressive treatments in established disease
do not seem to gain as much effect as they do in early dis-
ease. This emphasizes the importance of early, effective
treatment and tight control of therapeutic response. Late
strengthening of DMARD treatment is not able to reverse
the damage already arisen. Nevertheless, it is probable
that radiologic progression would have been even steeper
had the treatments during the liberal phase been less
aggressive.
Glucocorticoids were a part of the FIN-RACo strategy
and were allowed in the SINGLE strategy to reach remis-
Table 2: Number (percentage) of RA patients with damage to any or to multiple large joints as well as with uni- or bilateral 
erosive (Larsen score ≥2) large joints after 11 years of follow-up, by initial randomization group
Original randomization group
FIN-RACo (n = 52) SINGLE (n = 54)
Damage to any large joint 7 (13%) 15 (28%)
Damage to multiple (two to three) large joints 5 (10%) 10 (19%)
Radiographed joint Unilateral damage Bilateral damage Unilateral damage Bilateral damage
Shoulder 0 2 (4%) 4 (7%) 7 (13%)
Elbow 1 (2%) 0 1 (2%) 1 (2%)
Hip 3 (6%) 2 (4%) 4 (7%) 1 (2%)
Knee 3 (6%) 1 (2%) 2 (4%) 0
FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially methotrexate, 
sulfasalazine, and hydroxychloroquine, with prednisolone; RA, rheumatoid arthritis; SINGLE, study group treated for the first 2 years with one 
disease-modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.
Figure 4 Percentage of treatment time using combination 
DMARD strategy between year 2 and year 11 in patients of the 
original randomization groups divided into tertiles, according to 
change in Larsen score of hands and feet from year 2 to year 11. 
Values are expressed as median and interquartile range.
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Page 7 of 8sion. Because glucocorticoids have been shown to retard
radiologic progression [5], it could be hypothesized that
their use would explain the difference in Larsen score
between the groups. However, the patients treated with
the FIN-RACo strategy needed fewer intraarticular glu-
cocorticoid injections and had a smaller cumulative dose
of glucocorticoids during the first 2 years than did the
SINGLE strategy group [3]. Thus, the better radiologic
outcome in the FIN-RACo arm does not seem to depend
on the use of glucocorticoids, but rather on the more
effective and rapidly working DMARDs during the criti-
cal "window of opportunity." Whether the difference
between the groups would have been smaller, had the
first DMARD in the SINGLE strategy been methotrexate,
cannot be answered by this study. However, the SINGLE
strategy was not tied to sulfasalazine but to a strategy of
using one DMARD at a time, and, during the first 2 years,
52% of patients in the SINGLE group were switched to
methotrexate [3].
Conclusions
We conclude that treating RA from the very beginning
actively and aggressively with DMARDs, including tight
clinical control and aiming for remission, pays off, even in
the long run. Further, the patients treated initially with
the FIN-RACo strategy manage better than the cases
treated actively with the SINGLE strategy. Both small and
large peripheral joints are spared. Consequently, the need
for joint-replacement operations decreases. Clinical dis-
ease activity remains low, functional capacity well pre-
served, and life expectancy normal [11]. Further studies
will reveal whether all this is reflected in the maintenance
of working capacity.
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Abstract 
Objectives. To determine disease modifying antirheumatic drugs (DMARDs) currently used 
by Finnish rheumatologists to treat early rheumatoid arthritis (RA). 
Methods. Information on sex, date of birth, and date of special medicine reimbursement 
decision for all new RA patients was collected from a nationwide register maintained by the Social 
Insurance Institution (SII) during the time period from 1.1.2000 to 31.12.2007. Patient cohorts were 
registered in 2-year time periods (2000-01, 2002-03, 2004-05, 2006-07) and disease modifying 
antirheumatic drugs (DMARDs) purchased by the patient cohorts during the first year after the date 
of reimbursement decision for RA were registered. The frequencies of early drug treatment 
strategies (combination of DMARDs, single DMARD or no DMARD) were evaluated. 
Results. A total of 14 878 (68.0% female, 62.6% RF-positive) patients were identified. 
Between years 2000-01 the most commonly used treatment strategy for early RA during the first 3 
months was single DMARD treatment (56.1%) and the most commonly used DMARD during the 
first year was sulfasalazine (63.0%), while between years 2006-07 the respective treatments were 
combination DMARDs (55.3%) and methotrexate (69.0%). The change in treatment strategies as 
well as in DMARDs used was highly significant (P <0.001 for linearity). At the end of the study 
period only 4.9% of the patients with early RA were not receiving DMARDs during the first three 
months.  
Conclusions. Currently, combination therapy including methotrexate is the most commonly 
prescribed treatment strategy for early RA in Finland. During the present millennium more and 
more active drug treatments have been taken into practice.  
 
Introduction 
When untreated, rheumatoid arthritis (RA) causes continuing destruction of the joints in most 
patients. Impaired function leads to need for hospitalizations and to decreased working capacity, 
both of which cause expenses for the individual and for the society. Diseases modifying 
antirheumatic drugs (DMARDs) reduce inflammation, prevent structural damage and thus improve 
function in RA. Early and aggressive therapy with tight clinical controls aiming at the lowest 
possible disease activity has been shown to be effective in reaching these goals.(1-3)  
Several national recommendations have been given on the treatment of RA(4-8) but whether 
clinical practice is in line with these guidelines, is unknown. The Finnish Current Care guideline(4) 
recommends as the first medication in active early RA either methotrexate or a combination of 
methotrexate, sulfasalazine, hydroxychloroquine, and low dose glucocorticoids (the FIN-RACo 
combination).(9) Other DMARDs may be used according to individual judgment. Biological 
treatments are indicated if the arthritis continues active (swollen joints ≥ 6 and tender joints ≥ 6 and 
either an ESR ≥ 30 mm/h or a CRP ≥ 28 mg/l or morning stiffness ≥ 45 minutes) in spite of a 
DMARD combination, which has included methotrexate.  
In this nation-wide register-study we wanted to assess which DMARDs and treatment 
strategies are currently used to treat early RA in Finland and whether the guidelines are followed. 
 
Methods       
Finland has a general sickness insurance covering the entire population, and all permanent 
residents are issued a personal health insurance card. The costs of medicines prescribed by a doctor 
for the treatment of an illness are more or less reimbursed by the Social Insurance Institution (SII). 
The basic medicine reimbursement rate is 42% of the price but patients with certain chronic and 
severe diseases are entitled to a special reimbursement of medications if their condition meets 
predefined criteria. The patients with chronic inflammatory rheumatic disorders can be granted the 
special reimbursement of 72% for antirheumatic drugs. To establish entitlement, the patient must 
submit to the SII a medical certificate based on examinations performed by a specialist-level health 
care unit or issued by a specialist. The medical certificate must include information on proper 
diagnostic procedures, an ICD-10 diagnosis, and a treatment plan according to a good clinical 
practice. The certificates are reviewed by an insurance physician of SII before the special 
reimbursement can be granted. The administrative process usually takes a couple of weeks. Up to 
three months’ supply of medicines can be reimbursed at one transaction. Practically all Finnish 
patients with antirheumatic medications receive the reimbursement decision since it is economically 
very much in the patients’ interest and in the rare occasions when the reimbursement decision does 
not exist, the pharmacists generally encourage the patients to request it. 
Patient cohort. All medicine reimbursement decisions are gathered in a nationwide register 
maintained by the SII. From that register we assessed data gathered from 1.1.2000 to 31.12.2007, 
and collected information of patients who, for the first time in their life, had been granted a special 
reimbursement of medications for rheumatoid factor (RF) -positive (ICD-10 diagnosis M05) or RF-
negative RA (M06). The information included sex, date of birth, and the date of reimbursement 
decision (index day).  
The SII maintains a prescription register on the drugs purchased from pharmacies and 
reimbursed either according to the basic or the special rate. In the register, drugs are classified 
according to the Anatomical Therapeutic Chemical (ATC) classification (10). The register includes 
also the amount of the drug as well as the date of purchase. From this register, we gathered the data 
on the drugs purchased by the patient cohort for 31 days before the index day (to include 
medication possibly purchased before the reimbursement decision) and for 31 days, for 91 days, and 
for one year after the index day. The first-month and first-year treatments were analyzed in 2-year 
time periods (2000-01, 2002-03, 2004-05, 2006-07) and any change in drugs over this time 
recorded.  The purchase of initial glucocorticoids was assessed only between years 2000 and 2005 
since prednisolone 5 mg tablets were not reimbursed in Finland between 1.1.2006 and 30.11.2007.  
Further, we investigated the early drug treatment strategy up to 3 months from the index day - no 
DMARD, single conventional DMARD, combination of conventional DMARDs, or treatment 
including TNF-inhibitors – and the change in strategy over time. The intravenous drugs given and 
reimbursed by hospitals and outpatient clinics are not registered by the SII. Consequently, our study 
does not include infliximab or other infusion-based biologic therapies.  
Ethical considerations. There was no legal requirement for approval by an ethics committee, 
since only unidentifiable register data were used and patients were not contacted. 
Statistical methods. Statistical comparisons between groups were made by using analysis of 
variance (ANOVA) and chi-square test. Statistical significance for hypotheses of linearity was 
evaluated by Cochran-Armitage test.  
 
Results 
Information of a total of 14 878 patients was assessed.  Of these, 9314 (62.6%) had received 
their reimbursement decision on grounds of RF positive RA and the rest for RF negative disease. 
The mean (SD) age in the entire patient cohort was 56 (15) years and 10 117 (68.0%) patients were 
female. 
Throughout all time periods (2000-01, 2002-03, 2004-05 and 2006-07), methotrexate, 
sulfasalazine and hydroxychloroquine were the three most prescribed DMARDs during the first 
year of RA; all the other DMARDs had been prescribed to a substantially smaller percentage of 
patients (Table 1). Sulfasalazine had been the most often used DMARD in 2000-01, but after that its 
use had decreased and that of hydroxychloroquine and especially of methotrexate had increased 
(Table 1). A total of 69% of new patients with RA received methotrexate during the first year of 
drug treatment in 2006-07. 
  
Table 1. Proportions of patients using various antirheumatic drugs during the first year of drug 
treatment. 
 
We then studied the use of methotrexate, sulfasalazine and hydroxychloroquine alone or in 
combinations up until 31 days after the index day, i.e., obviously as the very first DMARD or 
DMARDs (Table 2). As this very early treatment, the use of methotrexate alone or in combinations 
increased from 23.5% of the patients in 2000-01 to 56.0% in 2006-07 (p<0.001).  Also the use of 
glucocorticoids as a very early treatment of RA increased during the follow-up (Table 2).  
Medication Years  P for 
linearity 
 2000-01 
N=3739 
N (%) 
2002-03 
N=3880 
N (%) 
2004-05 
N=3631 
N (%) 
2006-07 
N=3628 
N (%) 
  
Medication during the first 
12 months 
      
   Methotrexate 1639 (43.8) 2079 (53.9) 2330 (64.2) 2505 (69.0)  <0.001 
   Sulfasalazine 2355 (63.0) 2355 (60.7) 2127 (58.6) 1975 (54.4)  <0.001 
   Hydroxychloroquine 1879 (50.2) 2045 (52.7) 2056 (56.6) 2169 (59.8)  <0.001 
       
   Sodium aurothiomalate 333 (8.9) 204 (5.3) 139 (3.8) 86 (2.4)  <0.001 
   Auranofin 200 (5.3) 150 (3.9) 76 (2.1) 49 (1.3)  <0.001 
   Leflunomide 65 (1.7) 140 (3.6) 184 (5.1) 179 (4.9)  <0.001 
   Azathioprine 51 (1.4) 53 (1.4) 49 (1.3) 40 (1.1)  0.34 
   Ciclosporin 52 (1.4) 51 (1.3) 43 (1.2) 28 (0.8)  0.012 
   Podophyllotoxin 19 (0.5) 17 (0.4) 19 (0.5) 28 (0.8)  0.11 
   Penicillamine 2 (0.1) 3 (0.1) 0 (0) 0 (0)  0.12 
   Cyclophosphamide 1 (0.0) 7 (0.2) 4 (0.1) 3 (0.1)  0.73 
       
   Adalimumab/Etanercpt 0 (0) 13 (0.3) 58 (1.6) 38 (1.0)  <0.001 
  
Table 2. Proportions of the most commonly used antirheumatic medications (methotrexate, 
sulfasalazine, hydroxychloroquine) in single and combination strategies and the proportion of 
patients with glucocorticoids during the first month of drug treatment. The use of glucocorticoids 
could not be assessed after year 2005 because of change in drug reimbursement policy. 
 
 During the first 3 months the treatments were generally further intensified (Table 3).  Only 
6.3 % of all patients had not purchased DMARDs during the first 3 months and this non-compliance 
decreased significantly from 2000-01 to 2006-07 (Table 3). During the study period the use of early 
single DMARD strategy decreased and the use of early combination DMARD strategy increased 
(Table 3). Combination strategy was prescribed more often to seropositive and to younger patients 
than single DMARD strategy, whereas both genders were treated equally (Table 4).  
Medication  Years  P for 
linearity 
 2000-01 
N=3739 
N (%) 
2002-03 
N=3880 
N (%) 
2004-05 
N=3631 
N (%) 
2006-07 
N=3628 
N (%) 
  
Single treatment       
    Methotrexate   352 (9.4) 392 (10.1) 464 (12.8) 708 (19.5)  <0.001 
    Sulfasalazine 1113 (29.8) 1083 (27.9) 789 (21.7) 641 (17.7)  <0.001 
    Hydroxychloroquine 415 (11.1) 368 (9.5) 296 (8.2) 227 (6.3)  <0.001 
       
Combination treatment       
    Methotrexate and 
    hydroxychloroquine 
148 (4.0) 242 (6.2) 312 (8.6) 502 (13.8)  <0.001 
    Methotrexate and  
    sulfasalazine 
155 (4.1) 137 (3.5) 187 (5.2) 248 (6.8)  <0.001 
    Sulfasalazine and  
    hydroxychloroquine 
229 (6.1) 259 (6.7) 225 (6.2) 249 (6.9)  0.34 
    Methotrexate,  
    sulfasalazine and  
    hydroxychloroquine 
226 (6.0) 324 (8.4) 481 (13.2) 576 (15.9)  <0.001 
       
Glucocorticoids 1379 (36.9) 1591 (41.0) 1637 (45.1) N.A.  <0.001 
 *Two or more DMARDs 
 
Table 3. Proportions of treatment strategies during the first 3 months of RA treatment. 
 
 
Variables No DMARDs 
N=944 
Single therapy 
N=7174 
Combination 
therapy 
N=6760 
 P value 
Female, n (%) 629 (66.6) 4867 (67.8) 4623 (68.4)  0.49 
Age, mean (SD) 54 (15) 58 (16) 55 (14)  <0.001 
Rheumatoid factor 
present, n (%) 
556 (58.9) 4207 (58.6) 4556 (67.4)  <0.001 
 
Table 4. Association of gender, age and rheumatoid factor with the early (up to 3 months) drug 
treatment strategy 
 
The use of the FIN-RACo combination (methotrexate, sulfasalazine and hydroxychloroquine) 
as initial treatment increased throughout the study period (Table 2). During 2006-07 it was 
prescribed to 20.3 % of the patients with recent-onset RA within the first 3 months (Figure 1). 
The use of adalimumab and etanercept during the first 3 months or even during the first year 
of RA therapy remained extremely rare throughout the study period (Table 1, Table 3). 
 
Medication  Years  P for 
linearity 
 2000-01 
N=3739 
N (%) 
2002-03 
N=3880 
N (%) 
2004-05 
N=3631 
N (%) 
2006-07 
N=3628 
N (%) 
  
   No DMARDs 240 (6.4) 273 (7.0) 245 (6.7) 179 (4.9)  0.0072 
   Single therapy 2097 (56.1) 2034 (52.4) 1606 (44.2) 1427 (39.3)  <0.001 
   Combination therapy* 1402 (37.5) 1572 (40.5) 1765 (48.6) 2006 (55.3)  <0.001 
   Adalimumab/Etanercept        
      only TNF-inhibitor 0 (0.0) 0 (0.0) 3 (0.1) 4 (0.1)  ND 
      and one DMARD 0 (0.0) 1 (0.0) 5 (0.1) 4 (0.1)  ND 
      and DMARD  
      combination 
0 (0.0) 0 (0.0) 7 (0.2) 8 (0.2)  ND 
 
 
 
Discussion 
In this national register study of practically all Finnish patients with a recent diagnosis of RA 
between years 2000 and 2007, we found that almost all patients were prescribed a DMARD during 
the first 3 months after diagnosis. In the beginning of the study period less than 7 percent of the 
patients were receiving no DMARDs during the first 3 months and by the end of the study this 
proportion had decreased to less than 5%. Single DMARD was the most often used initial strategy 
in the beginning of the study period but during the follow up it gave way to combination DMARDs 
with especially the FIN-RACo combination gaining increasing support. Methotrexate substituted 
for sulfasalazine as the most used DMARD. Also the use of glucocorticoids early in RA increased 
somewhat. All these features of active treatment policy are in accordance with national 
guidelines(4) and with international trends.(11)  
Worldwide, the treatment of RA has changed enormously during the past decades.(11) 
Despite the new medications made available during the recent years, the most revolutionary change 
has occurred in the rheumatologists’ way of thinking; the importance of starting treatments early 
and of aiming at the lowest possible disease activity has been acknowledged. National guidelines 
for the treatment of early RA have been published at least in the Netherlands,(5) France,(6) UK,(8) 
US(7) and Finland.(4) However, implementing recommendations or positive study results to 
everyday practice is not always self-evident,(12-15) thus studies on current DMARD strategies are 
needed. 
Different methods can be used to assess the use of DMARDs. Interviewing rheumatologists 
has some disadvantages.(16-19) The respond rate is seldom high and it is possible that physicians 
report more idealistic treatment strategies than the ones they actually use. When studying cohorts of 
RA patients the results may be somewhat misleading since the patients are treated by specialists and 
thus in many countries represent only a minority of RA patients.(12, 20-25) Large register based 
cohorts of patients give a more realistic view to the current DMARD policy; even though the patient 
populations may be heterogeneous in terms of disease durations.(13, 26, 27) So far the results of 
register studies have illustrated rather a nihilistic view; the use of DMARDs has been surprisingly 
sparse, only 13%(26) to 50%(27) of the RA patients were receiving DMARDs. This may partly be 
explained by the fact that these studies were carried out in an earlier era and that the majority of 
patients were treated by non-rheumatologists.  
When comparing our results with those from other countries, the studies not extending to this 
millennium have merely a historical relevance. The results of the more recent studies show that the 
majority of rheumatologists prefer methotrexate(19, 22) or either methotrexate or sulfasalazine(16) 
as the first DMARD in early RA, which is in line with our findings, as is the finding that more 
aggressive strategies are applied to younger than to older RA patients.(18) In a large register study 
between years 1987 and 2002, 34 364 patients with RA of various duration were identified from the 
UK national database (General Practice Research Database, GRRD) and DMARDs prescribed to 
them were assessed. Only 50% of the patients were prescribed at least one DMARD during the 
study period, most often sulfasalazine (46.3%) or methotrexate (31.4%), the use of the latter having 
increased 17-fold during the study period while the use of intramuscular gold had decreased.(27) A 
single-institute-based Japanese cohort of 7512 patients with established RA from October 2000 to 
April 2006 showed that the use of DMARDs increased from 82.18% to 89.60%, the frequency of 
methotrexate users increased from 33.9% to 58.7% and that the average dosage of methotrexate also 
increased.(25) In a more recent Swedish study, register data of disease characteristics and DMARD 
prescriptions were collected from 2584 patients with early RA at 19 hospitals between 1997 and 
2001. Prescriptions of DMARDs, especially of methotrexate, increased during the study period, 
more in university or county hospitals than in district hospitals. The proportion of patients with 
early RA not prescribed any DMARDs decreased from 32.2% to 14.9% during the follow up.(20) 
Between 2002 and 2007 in the UK, a cohort of 691 patients with early RA was collected and 
followed up for at least 3 months. Initially 97 % of the patients were prescribed a DMARD; 91 % of 
these received monotherapy, mainly methotrexate (51 %) or sulfasalazine (41 %), and 9 % received 
combination therapy. Treatment intensification was required in 33 % of the patients of whom 52 % 
got sequential monotherapy and 48 % step-up combination therapy.(15) Thus, there are marked 
national variations in the tradition of treating RA, but worldwide, the strategy has changed towards 
a more active one.  
Naturally, our results can not be generalized to other countries. However, they show that 
treating early RA according to the modern guidelines is possible despite the nihilistic view given by 
earlier cohort studies.(13, 26, 27) Finnish rheumatologists have traditionally treated RA 
aggressively;(28, 29) the active strategy having it’s roots in the 1970s.(30) Prescribing DMARD 
combinations has gained increasing national support after the publication of the favorable results of 
the FIN-RACo study,(2, 9, 31, 32) which all the large rheumatology centers in Finland participated 
in. That might also explain why the implementation of this strategy to everyday practice has not 
faced such problems as the COBRA strategy has in Holland.(14) Moreover, as the doctor’s 
certificate for medicine reimbursement decision needs to be done by a specialist, the vast majority 
of patients are seen by rheumatologists who initiate the treatment and also, according to the national 
guideline, follow the patient up for at least one year. Even though some local variation in the 
availability of rheumatology services exists, so far Finland has had enough rheumatologists to 
handle this task.  
Thus, a prerequisite for inclusion to our cohort was RA diagnosis made by a rheumatologist. 
We have, however, no data about the fulfillment of the ACR classification criteria for RA. 
Therefore it is possible that that some patients did not fulfill the ACR criteria for RA,(33) but were 
assumed by a rheumatologist to represent very early RA because of anti-cyclic citrullinated peptides 
or some other features and institution of DMARDs was deemed necessary. In RA, ample evidence 
shows the importance of early institution of remission-targeted drug treatment for prevention of 
disease’s adverse consequences(2, 34) and recent data suggest that treatment of early arthritis with 
DMARDs is beneficial even before the fulfillment of the ACR classification criteria for RA.(35, 36)  
We have no information on the patients’ disease activity or functional ability. Obviously, the 
patients with active disease are more likely to be prescribed aggressive treatments than the ones 
with mild disease,(17) in which also the evidence base for aggressive treatment is far flimsier than 
in active RA. On the other hand, different medications may be contraindicated for various – good – 
reasons. Especially older patients are more likely to have comorbidities and to be more prone to 
side effects than younger patients, thus the age of the patient is likely to affect the choice of  the 
treatment strategy in RA.(18) Inevitably these real life variables have affected also our results; this 
could be seen for example from the fact that combination treatments were more often given to 
seropositive and to younger patients. Still, despite this “natural” restriction of the treatment choices, 
the vast majority of Finnish patients with early RA were treated actively.  
To summarize, we found that almost all Finnish patients with early RA received DMARDs – 
most of them methotrexate - within the first 3 months of treatment. Presumably the results of the 
FIN-RACo study have encouraged Finnish rheumatologists to increasing use of DMARD 
combinations as the initial treatment. Whether this active strategy is reflected to better maintenance 
of functional and working capacity, decreased need of reconstructive surgery and reduction in pre-
term mortality will be revealed by further studies.  
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Abstract 
Objectives. To study whether the work disability (WD) rates in early rheumatoid arthritis (RA) 
have changed in Finland, where the treatment of RA has long been active, but has, during this 
millennium, further intensified.  
Methods. From a nationwide register maintained by The Finnish Social Insurance Institution 
(SII) we identified all incident, not-retired, working aged (18-64y) RA patients 1.1.2000-
31.12.2007. Patient cohorts were analyzed in 2-year time periods (2000-01, 2002-03, 2004-05, 
2006-07) and initial disease modifying antirheumatic drugs (DMARDs) were elucidated from the 
drug purchase register. The incidence of continuous work disability (WD) in the RA cohorts, as 
well as in the entire Finnish population up to 31.12.2008 was clarified. 
Results. A total of 7 831 (71% female, 61% RF-positive) patients were identified. Throughout 
the follow-up, the use of methotrexate and combination-DMARDs increased as the initial treatment 
of early RA. During the first 2 years the incidence of RA related continuous WD was 8.9%, 9.4%, 
7.2%, and 4.8% in the year cohorts, respectively, (p < 0.001 for linearity). Compared to the entire 
Finnish population, the age and sex stratified standardized incidence ratio of WD pension due to 
any cause was 3.69, 3.34, 2.77, and 2.80, in the year cohorts, respectively (p<0.001 for linearity).  
Conclusions. During the present millennium, the frequency of continuous WD in early RA has 
declined in Finland. The present data allows no explanatory analysis, but at the same time 
increasingly active treatment strategies have been introduced. 
 
Introduction  
In clinical studies, the actively treated rheumatoid arthritis (RA) patients have had lower disease 
activity, more frequent remissions, and less radiographic progression than the conservatively treated 
ones.[1-5] These findings have led to specific treatment recommendations, and clinical practice 
appears to have changed accordingly.[6, 7]  
Work disability (WD) is one of the hard outcomes of RA. Depending on study populations and 
on national differences in social security systems, 20-40% of the previously employed RA patients 
had become permanently work disabled within 2 years after the diagnosis and 40-80% 5-20 years 
after the diagnosis.[8] Some studies have shown that early remissions predict better maintenance of 
working capacity,[9] but how these study results translate into real life, is not evident. Biologic 
agents have shown promising results on clinical outcomes and their use has significantly increased 
during this millennium, but thus far their effect on the maintenance of RA patients’ working 
capacity is ambiguous.[10-14] 
Furthermore, there is a great national variance between the rates of permanent WD; in some 
countries RA patients with low disease activity become work disabled, while in others patients with 
severe disease activity continue working.[15, 16] Therefore the most reliable research method for 
trends in WD is to study them longitudinally in a same setting.  
We have previously shown that in Finland the treatment of early RA has been active, and has 
recently further intensified.[7] In this study we wanted to elucidate whether this modern era has 
brought any changes in the trends in RA related WD in Finland. 
 
Methods 
Finland has a general sickness insurance covering the entire population, and all permanent 
residents are issued a personal health insurance. The Social Insurance Institution (SII) grants the 
patients with chronic inflammatory rheumatic disorders a special reimbursement of 72% for 
antirheumatic drugs, and practically every Finnish patient with antirheumatic medications receives 
it. All medicine reimbursement decisions are gathered in a nationwide register maintained by the 
SII. Furthermore, the SII maintains a prescription register on the drugs purchased from pharmacies 
and reimbursed according to special rate.[7]  
If Finnish residents aged 16-67 years become unable to perform their regular or corresponding 
jobs, they are entitled to a sickness allowance as a compensation for lost income. All 16-64 year-old 
persons who have lived in Finland for at least 3 years and who have an illness, injury or defect that 
prevents them from earning a reasonable living, stated by a doctor’s certificate, can, after 150 
working days of WD, and must, after 300 days of WD, apply either for a temporary rehabilitation 
allowance or a permanent disability pension. Permanent disability pensions are usually antedated by 
rehabilitation allowances of varying durations, and granted, at the earliest, after one year’s WD, for 
persons over 60 years on somewhat easier terms. The SII and the Finnish Centre for Pensions 
maintain a register on sick leaves, rehabilitation allowances and permanent disability pension. 
Patient cohort. From the nationwide register maintained by the SII we collected data of 18-64 
year-old patients who were available for workforce when they, for the first time in their life, had 
been granted a special reimbursement of medications for rheumatoid factor (RF) positive (ICD-10 
diagnosis M05) or RF-negative RA (M06) 1.1.2000-31.12.2007. The data included sex, birth date, 
and the date of reimbursement decision (index day, equalling RA diagnosis). No other clinical data 
were available. According to the index day, we analysed the patient data in 2-year cohorts (2000-01, 
2002-03, 2004-05, 2006-07).  
For these cohorts, from the registers of the SII and of the Finnish Centre for Pensions, we 
collected data of annual WD days, in 365 day cycles from the index date, including all periods of 
sickness allowance, temporary rehabilitation allowance, partial disability pensions (the number of 
the days divided by 2), and of permanent disability pension from one year before the index day up 
to the end of follow-up, 31.12.2008. However, sick leaves ≤10 days could not be assessed, as they 
are not compensated by the SII. The annual WD days per patient years for any reason were counted. 
In this analysis also the patients already on partial pensions on index date were included.  
During the same period the incidence of continuous WD was assessed by elucidating all 
permanent disability pensions and long-term rehabilitation allowances still continuing at the end of 
our follow-up, including continuous WD for any reason and that exclusively due to RA. The 
follow-up of the patients ended when they retired because of other reasons than RA, became 65 
years old, or died, whichever the first. From the same institutes we received the incidence data of 
WD pensions of all 18-64 year-old Finnish citizens. 
Further, from the reimbursement drug register, we gathered data on the drugs purchased by these 
patient cohorts from 31 days before to 91 days after the index day and investigated the early drug 
treatment strategies: no DMARD, any single DMARD, single methotrexate (MTX), any 
combination of DMARDs, or combination of DMARDs including MTX. The commencement of 
adalimumab or etanercept any time throughout the follow-up was elucidated. The intravenous drugs 
are given and paid by hospitals and outpatient clinics and not registered by the SII. Consequently, 
our study does not include infliximab or other infusion-based biologic therapies. 
Ethical considerations. There was no legal requirement for approval by an ethics committee, 
since only unidentifiable register data were used and the patients were not contacted. 
Statistical methods. Results are expressed as means with standard deviation (SD) and as 
medians with interquartile range (IQR). Statistical significance for hypotheses of linearity was 
evaluated by analysis of variance (ANOVA) or Cochran-Armitage test. Incidence of RA for each 
2-year cohort with 95% confidence intervals (CIs) was calculated assuming a Poisson 
distribution using the 18-64 year old Finnish population (from Statistics Finland) as 
reference. The 95% CIs for annual WD days were obtained by bias-corrected bootstrapping and 
the linearity across year-cohorts was tested by bootstrap type analysis of covariance with an 
appropriate contrast. The cumulative incidence of continuous WD was estimated and illustrated by 
Kaplan-Meier method. In order to adjust for confounding factors, the differences between the 
groups and the hypothesis of linearity were tested by using Cox’s regression models with a contrast, 
when appropriate.  Cox’s multivariate regression model was also used to analyse factors associated 
to continuous WD. The patients with RA and the population at risk were stratified by gender, age 
(in 5 year categories), and calendar years, and incidence rates with 95% CIs were calculated. The 
ratio between observed and expected numbers, Standardized Incidence Ratio (SIR), was calculated 
with 95% CIs, assuming a Poisson distribution; significance for hypotheses of linearity was 
evaluated by Poisson regression models. 
   
Results  
We identified a total of 7831 (71% female, 61% RF-positive) working-aged (18-64 years) RA 
patients who, at the index date were available to work force full-time. Further, a cohort of 137 
patients, already part-time retired at the index date, was included in the analysis of mean annual 
WD days. The demographic data is presented in Table 1. During the follow-up, the use of single-
DMARD treatment during the first 3 months decreased, while that of combination-DMARDs 
increased. The use of MTX, either alone or in combinations, increased. The admission of 
adalimumab or etanercept for patients remained rare (Table 1).  
Table 1. Demographic data and initial treatment strategies of the 7831 patients with a recent 
diagnosis of RA, available to workforce at baseline 
 
* age and sex adjusted 
 
One year preceding the index date, the median (IQR) duration of >10 days WD periods was 0 (0 
, 4) days per year in all cohorts. During the first year after index date, the mean number of annual 
WD days per patient years was similar in all year cohorts, 45-50 days per year.  It decreased during 
the second year, increasing steadily thereafter (Figure 1). The mean number of annual WD days per 
patient years during the second year decreased along the year cohorts (p = 0.002 for linearity, 
adjusted for age, sex and RF). When the data of all cohorts during the first two years were analysed 
together, the number of the mean annual WD days per patient years was 53 in men, and 37 in 
women [mean ratio between men and women 1.42 (95% CI 1.28 to 1.54)], while 45.6% (95% CI 
Variable  Year cohort    
 
 
2000-01 
(N = 1998) 
N (%) 
2002-2003 
(N = 2043) 
N (%) 
2004-05 
(N = 1871) 
N (%) 
2006-07 
(N = 1919) 
N (%) 
p for 
linearity 
Female (%) 1422 (71) 1462 (72) 1291 (69) 1377 (72) 0.86 
Age on index day, mean (SD) 45 (11) 46 (11) 47 (10) 46 (11) <0.001 
Rheumatoid factor present (%) 1135 (57) 1235 (60) 1161 (62) 1242 (65) <0.001 
Incidence of RA in the 18-64 year 
old population  /100 000 per year 
(95% CI) 
39 (37 to 40) 39 (38 to 41) 36 (35 to 38) 36 (35 to 38) <0.001* 
      
Initial treatment (≤ 3 months)      
    No DMARDs 149 (7) 171 (8) 145 (8) 113 (6) 0.045 
    Any single DMARD 1072 (53) 1004 (49) 750 (40) 708 (36) <0.001 
           Single MTX 166 (8) 196 (10) 243 (13) 295 (15)  
    Any combination DMARDs 781 (39) 877 (43) 989 (53) 1105 (58) <0.001 
          Combination including MTX 502 (25) 651 (32) 801 (43) 925 (48)  
      
Adalimumab or etanercept initiated 
at any time while available to 
workforce 
79 (4) 84 (4) 85 (5) 29 (2) NA 
43.6 to 47.6%) of the men and 48.2% (95% CI 46.9 to 49.5%) of the women had no registered WD 
days during the first 2 years after the RA diagnosis. 
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Figure 1. Mean annual WD days due to any cause per patient years in the early RA cohorts. The 
age and sex adjusted p-values show the statistical significance between the groups at years 1 and 2, 
during which all groups are followed up. 
 
 
The median (IQR) follow-up time was 4.0 (2.2 , 6.3) years.  By 8 years 14.5% (95% CI: 13.5 to 
15.5) patients of the total patient population had retired due to RA. In women the cumulative 
incidence of RA dependent continuous WD was 12.6% (95% CI: 11.5-13.7) and in men 19.2% (95 
% CI: 17.1 to 21.4) [age and RF adjusted HR = 0.68 (0.59 to 0.78), p <0.001] (Figure 2).  
During the first 2 years after the diagnosis, the incidence of RA related continuous WD was 
8.9% (95% CI 7.7 to 10.3), 9.4% (95% CI 8.2 to 10.8), 7.2% (95% CI 6.2 to 8.5), and 4.8% (95% 
CI 3.9 to 5.9) in the year cohorts 2000-01, 2002-03, 2004-05, and 2006-07, respectively (age, sex, 
and RF adjusted p < 0.001 for linearity). Figure 3 presents the Kaplan-Meier curves for continuous 
WD in different year cohorts during the 8-year follow-up.  
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Figure 2. Kaplan-Meier curves with confidence intervals of the incidence of A) RA related 
continuous WD, and B) all-cause continuous WD in the male and the female patients after the 
diagnosis of RA. Under the x-axis are shown the numbers of male and female patients at risk at 0, 2, 
4, 6, and 8 years on whom the estimates are based, and, in parenthesis, the numbers of events during 
the preceding period. 
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Figure 3.  Kaplan-Meier curves of the incidence of continuous WD due to RA in different early RA 
patient cohorts.  The dotted line describes the estimated cumulative incidence of WD pension due to 
any cause in general population. 
In a Cox multivariate analysis for the total follow-up time, the year cohort, age, and sex were 
related to continuous WD (Table 2). In the same model, when single non-MTX DMARDS as an 
initial treatment was used as reference, all other active treatment strategies (but not no-DMARDs) 
significantly increased the risk of continuous WD. However, adalimumab and etanercept appeared 
to protect the patients from continuous WD (Table 2). Nevertheless, their use was rare, during the 
follow-up these TNF-inhibitors were prescribed to 277 patients [70% female, mean (SD) age on 
index day 41 (12)] (Table 1), and were started on average 2.6 (SD 1.8) years after the index day.  
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Figure 4. The standardised incidence ratio (SIR) for a premature disability pension due to any cause 
in the Finnish early RA patients compared to the general Finnish population. The Finnish legislation 
was reformed in 2004; prioritizing vocational rehabilitation over WD pensions.   
 
Table 2. Cox multivariate regression analysis on factors predicting continuous, RA related WD in 
patients with a recent diagnosis of RA  
 
 HR (95% CI)  p-value 
    
Age 1.08 (1.07 to 1.09)  <0.001 
Male 1.50 (1.31 to 1.72)  <0.001 
RF present 1.12 (0.97 to 1.30)  0.11 
Year cohort   <0.001* 
  2000-01 1 (reference)   
  2002-03 0.79 (0.67 to 0.93)   
  2004-05 0.51 (0.42 to 0.61)   
  2006-07 0.35 (0.27 to 0.44)   
Medication (first 3 months)   <0.001 
  Single other  1 (reference)   
  Single MTX  1.33 (1.05 to 1.69)   
  Combi other 1.28 (1.02 to 1.62)   
  Combi including MTX 1.52 (1.29 to 1.79)   
  None 1.17 (0.89 to 1.54)   
Adalimumab or etanercept initiated 
at any time while available to 
workforce  
0.61 (0.39 to 0.97)  0.036 
The number of WD days the year 
before the index day, 
corresponding to one month’s 
change 
1.12 (1.06 to 1.18)  <0.001 
* p for linearity 
 
In the whole working aged Finnish population the incidence of preterm WD pension for any 
reason remained stable; it was 0.7% in 2000 and 0.8% in 2008. Compared to the Finnish 
population, the age and sex stratified incidence ratio (SIR) for WD pension in our early RA 
population was 3.16 (95% CI 2.97 to 3.35) and it declined along the year cohorts (Figure 4).  
 
Discussion 
This study shows that in Finland the frequency of continuous WD in early RA is declining, while 
the incidence of all disability pensions in the Finnish population has remained stable. This 
favourable development has occurred in parallel with increasingly active treatment strategies used 
for early RA, even though we failed to confirm a direct protective relationship between traditional 
DMARD treatments and WD.  
The first year after the diagnosis of RA the majority of WD days are due to temporary sick 
leaves, thereafter mainly to permanent disability pensions, as shown by the FIN-RACo study.[17] 
The rates of permanent WD in earlier cohorts of RA patients have been around 20 % after 2 years, 
and 50 % after 5 years of RA.[8] Especially in European studies the WD has occurred quite early 
after the diagnosis of RA,[18, 19] whereas in the US, presumably due to differences in the sickness 
benefit systems, permanent WD has increased only later in the disease course.[20] Compared to 
earlier European and Scandinavian, even earlier Finnish reports,[21-25] the novel Finnish WD rates 
in early RA appear clearly lower, with their incidence further decreasing. A recent large Swedish 
study found a similar trend of decreasing number of annual WD days in the latest early RA cohort 
compared to earlier cohorts.[26] However, the annual WD days in these Swedish cohorts were 2-4 
times higher than in the current Finnish cohorts, and the proportion of patients not utilizing sick 
leave was lower than in our cohorts.  
There are some possible explanations for the declining trend in RA depended WD. Firstly, 
legislative changes could affect the permanent WD pension rates, and indeed, in Finland, the 
legislation was reformed in 2004; prioritizing vocational rehabilitation over WD pension, and 
transferring the responsibility of organising it to the pension providers. While it is possible that this 
has affected the WD pension rates in RA patients, the rate of WD pensions in the general population 
remained at a similar level throughout the follow-up.  
The earlier data comparing the incidence of permanent WD between early RA patients and 
general population are sparse. Two studies from The Netherlands found a 4-7-fold risk for WD in 
early RA compared to general population,[19, 27] and an UK study even a 32-fold risk.[28] 
Compared to them, the 3-fold risk caused by early RA found in this study is remarkably lower but 
presents still a considerable menace, giving an informative estimate for the patients and for the 
authorities of the current threat that RA causes to the patients’ working ability.  
The second possible explanation for the decline of continuous WD in early RA is the 
contemporary change in treatment strategies, aiming at early diagnosis and treatment, targeting 
remission or low disease activity. We too found a shift towards more active treatment strategies in 
early RA during our follow-up.[7] Still, undoubtedly due to a channelling bias, the patients with the 
mildest initial treatment, i.e. single non-MTX DMARD had a lower risk of WD than the patients 
initially treated more actively.  However, it is evident that in the continuum of clinical disease 
activity in early RA, the patients with a mild RA, and therefore the best prognosis to start with, are 
the ones prescribed the mildest treatments. And the patients receiving more aggressive treatments 
are the ones with an active disease and thus an unfavourable consequent working ability scenario. 
Most probably, still, had any of these patients been treated with less effective strategies, their WD 
rates would be much higher.  
Regardless of the channelling bias discussed above, TNF-inhibitors (adalimumab and etanercept) 
protected the patients’ working ability. Nevertheless, their use was uncommon, and they were 
started firstly after a few years from the diagnosis, thus the use of biologics cannot explain but a 
very small part of the total decline of RA disability pensions. Our data on biologics is unfortunately 
limited, as we have no data on hospital-based medications such as infliximab, which are not 
reimbursed by the SII but funded by hospitals. Infliximab was the first TNF-inhibitor to become 
available in Finland in 1999.  Etanercept became available in 2002, and adalimumab in 2003, and 
the other biologics only after the end of our study period. After their introduction, the SII-
reimbursed etanercept and adalimumab often displaced infliximab as the first biologic for financial 
reasons. All of the biologics were first reserved for RA patients with treatment-resistant and 
therefore often longstanding disease and their use in early RA was exceptional.[29] Therefore, more 
evidence is needed about the role of early biologic treatment on maintaining working ability.  
The third potential explanation for the decline in disability pensions are both the patients’ and the 
physicians’ altered attitudes towards the prognosis of RA; with new possibilities to treat RA 
towards better outcomes permanent inability to work has ceased to be a self-evident consequence of 
RA. Furthermore, the authorities giving their expert opinion on whether a patient is qualified for a 
disability pension may have adopted a similar change in attitude. 
The great strength of our study is that it is unbiased, including all Finnish early RA patients, not 
only particular, in various ways selected, populations. Moreover, we have highly reliable and 
extensive register data on WD as well as on RA medications. Also the comparison to general 
population is reliable, as all Finnish citizens available to work force are included in the control 
material.  
A limitation of our register-based study is the patient inclusion on grounds of the drug 
reimbursement decision, which, however, practically all Finnish RA patients receive.[7] Further, the 
incidence of RA in the present population[30] is not lower than in earlier reports from Finland[31] 
or from other countries,[32] indicating comprehensive patient inclusion. 
Other limitations of our study are that we have no data on short (<10 days) sick leaves, since 
they are not registered by the SII, making our results an underestimate, and more importantly, the 
lack of clinical and radiographic data and on details of employment and schooling of the patients, 
which forbids us from analyzing the patient dependent factors behind the observed trend in WD 
pensions. However, ample evidence has shown that amongst the main patient depending factors 
predicting WD are severe and long-standing RA, reduced functional ability, physically demanding 
work and older age.[8] Of these, we confirmed higher age to be a significant risk factor for 
premature WD in early RA. Interestingly, we also found male patients to have a clearly higher risk 
of RA related WD than females. One earlier study showed a slightly increased risk for arthritis 
related WD in males,[33] some have found an increased risk in females;[16, 26, 34] and others no 
gender-association.[18, 19, 35, 36] Further, different risk factors predispose males and females to 
WD.[37] Nonetheless, comparing our results with those of others is difficult as we lack the clinical 
and socioeconomic data, and as some studies include patients with self-announced arthritis of any 
type.[33, 34] Also, defining WD according to the patient’s own announcement of not being 
employed might produce nebulous results, [35] especially in countries where women are not as 
active a component of workforce as in Finland, where the participation to workforce is similar in 
working aged males and females; 70 % and 71 % respectively in 2008 according to Statistics 
Finland. Thus, higher engagement to housekeeping and lesser to paid employment does not explain 
the lower risk for WD in females. Nevertheless, male workers being possibly more often occupied 
in manual labour than female workers could partially explain our finding.  
To conclude, our results demonstrate that it is possible to decrease or to postpone long-term WD 
in patients with early RA. This development has occurred in parallel with increasingly active 
treatments with conventional DMARDs, possibly altered attitudes towards the prognosis of RA, and 
legislative changes emphasizing vocational rehabilitation. The use of TNF-inhibitors contributes to 
preserving the patients’ working ability, but their use explains but a minor part of this favourable 
outcome, at least in Finland. 
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